Benzazepine compound

ABSTRACT

Provided is a compound which is useful as an agent for treating or preventing 5-HT 2C  receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. The present inventors have investigated compounds having a 5-HT 2C  receptor agonist activity and have found that the benzazepine compounds of the present invention have an excellent 5-HT 2C  receptor agonist activity, thereby completing the present invention. That is, the benzazepine compounds of the present invention have a 5-HT 2C  receptor agonist activity and can be used as an agent for treating or preventing 5-HT 2C  receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

TECHNICAL FIELD

The present invention relates to a benzazepine compound which is useful as an active ingredient of a pharmaceutical composition, particularly a pharmaceutical composition for treating or preventing 5-HT_(2C) receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

BACKGROUND ART

A serotonin 2C (5-HT_(2C)) receptor is one of the receptors for serotonin, a transmitter related to various physiological functions in the biological body. Its expression has been recognized mainly in the central nervous system (brain/spinal cord).

An anorectic action is known as a physiological function of the central 5-HT_(2C) receptor, and the lowering action of various 5-HT_(2C) receptor agonists on food intake has been reported in rats (Non-Patent Documents 1 and 2). Further, it has been confirmed that an anti-obesity action in humans is exhibited due to the anorectic action of the 5-HT_(2C) receptor agonist (Non-Patent Document 3).

The central 5-HT_(2C) receptor is involved in the control of peripheral nerve functions and it has been reported that the rat penile erection is induced by a 5-HT_(2C) receptor agonist (Non-Patent Document 4) and that the time taken from insertion to ejaculation in the experiment for mating behavior of monkeys is prolonged (Non-Patent Document 5). Moreover, it has been reported that a 5-HT_(2C) receptor agonist increases the urethral resistance when the abdominal pressure is increased in rats (Non-Patent Document 6). In addition, it has been reported that in disease models with neuropathic/inflammatory pain in rats, efficacy is exhibited by intraspinal administration of a 5-HT_(2C) receptor agonist (Non-Patent Documents 7 and 8). Various clinical applications are considered for 5-HT_(2C) receptor agonists, particularly as anti-obesity drugs, drugs for treating male erectile dysfunction, drugs for treating premature ejaculation, drugs for treating stress urinary incontinence, drugs for treating neuropathic/inflammatory pain, or the like.

As the 5-HT_(2C) receptor agonist, a benzazepine derivative has been reported, and as a tricyclic benzazepine derivative, for example, Compound A (Patent Document 1) and Compound B (Patent Document 2) are known.

As other 5-HT_(2C) receptor agonists, bicyclic benzazepine derivatives have been reported (Patent Document 3, Patent Document 4, and Patent Document 5).

As a 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline derivative or a 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine derivative, which is a tricyclic benzazepine derivative, a compound of the formula (AA) is known to be a Dopamine D3 modulator and be useful for central drug abuse and drug dependence (Patent Document 6).

In addition, in this document, the following compounds are disclosed as a synthetic intermediate for the formula (AA).

Furthermore, there is a report on the structure-activity relationship of a specific compound of the formula (AA) (Non-Patent Document 9), and in this report, it is described that the following compound was used in the preparation of the compound of the formula (AA).

Moreover, there is a report on a 5-HT₆ receptor antagonist (Non-Patent Document 10), and it is disclosed that for the compound below, potency on the 5-HT₆ receptor is lost by changing a ring condensed with benzazepine from a 5-membered ring to a 6-membered ring.

However, in the documents which disclose such tricyclic benzazepine derivatives, there is no disclosure on the 5-HT_(2C) receptor agonist activity of the 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline derivative or the 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine derivative.

PRIOR ART DOCUMENT Patent Document

-   [Patent Document 1] WO 2002/074746 -   [Patent Document 2] WO 2003/086306 -   [Patent Document 3] WO 2005/042490 -   [Patent Document 4] WO 2005/042491 -   [Patent Document 5] WO 2005/003096 -   [Patent Document 6] WO 2005/118549

Non-Patent Document

-   [Non-Patent Document 1] Obesity, 2008, vol. 17, pp. 494-503 -   [Non-Patent Document 2] Progress in Neuro-Psychopharmacology and     Biological Psychiatry, 2002, vol. 26, pp. 441-449 -   [Non-Patent Document 3] Journal of Pharmacology and Experimental     Therapeutics, 2008, vol. 325, pp. 577-587 -   [Non-Patent Document 4] European Journal of Pharmacology, 2004, vol.     483, pp. 37-43 -   [Non-Patent Document 5] Psychopharmacology, 1993, vol. 111, pp.     47-54 -   [Non-Patent Document 6] American Journal of Physiology: Renal     Physiology, 2009, vol. 297, pp. 1024-1031 -   [Non-Patent Document 7] Pain, 2004, vol. 108, pp. 163-169 -   [Non-Patent Document 8] Anesthesia and Analgesia, 2003, vol. 96, pp.     1072-1078 -   [Non-Patent Document 9] Bioorganic & Medicinal Chemistry Letters,     2008, vol. 18, pp. 901-907 -   [Non-Patent Document 10] Bioorganic & Medicinal Chemistry Letters,     2008, vol. 18, pp. 5698-5700

SUMMARY OF THE INVENTION Problems to be Solved by the Invention

A benzazepine compound which is useful as an active ingredient for a pharmaceutical composition, particularly a pharmaceutical composition for treating or preventing 5-HT_(2C) receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like is provided.

Means for Solving the Problem

The present inventors have extensively studied compounds having a 5-HT_(2C) receptor agonist activity, and as a result, they have found that the benzazepine compound of the present invention has a 5-HT_(2C) receptor agonist activity, thereby completing the present invention.

That is, the present invention relates to a pharmaceutical composition including the compound of the formula (I) or a salt thereof and a pharmaceutically acceptable excipient.

(wherein

R^(1a) and R^(1b) are the same or different and each represents —H or C₁₋₆ alkyl, or are combined to form oxo,

R^(2a) and R^(2b) are the same or different and each represents —H or C₁₋₆ alkyl which may be substituted with —O—C₁₋₆ alkyl,

R³ represents —H, C₁₋₆ alkyl which may be substituted, C₃₋₈ cycloalkyl, aryl which may be substituted, —SO₂—C₁₋₆ alkyl, or a hetero ring which may be substituted,

R⁴ represents —H, halogen, cyano, C₁₋₆ alkyl which may be substituted, C₂₋₆ alkenyl, aryl which may be substituted, C₃₋₈ cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,

R⁵ represents —H, halogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or an aromatic hetero ring,

R⁶ and R⁷ are the same or different and each represents —H or C₁₋₆ alkyl,

X represents —C(R^(A))(R^(B))— or —O—, and

R^(A) and R^(B) are the same or different and each represents —H or C₁₋₆ alkyl.)

Furthermore, the present invention relates to a compound of the formula (II) or a salt thereof.

(wherein R^(11a) and R^(11b) are the same or different and each represents —H or C₁₋₆ alkyl, or are combined to form oxo,

R^(21a) and R^(21b) are the same or different and each represents —H or C₁₋₆ alkyl which may be substituted with —O—C₁₋₆ alkyl,

R³¹ represents —H, C₁₋₆ alkyl which may be substituted, C₃₋₈ cycloalkyl, aryl which may be substituted, —SO₂—C₁₋₆ alkyl, or a hetero ring which may be substituted,

R⁴¹ represents —H, halogen, cyano, C₁₋₆ alkyl which may be substituted, C₂₋₆ alkenyl, aryl which may be substituted, C₃₋₈ cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring,

R⁵¹ represents —H, halogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or an aromatic hetero ring,

R⁶¹ and R⁷¹ are the same or different and each represents —H or C₁₋₆ alkyl,

X¹ represents —C(R^(A1))(R^(B1))— or —O—, and

R^(A1) and R^(B1) are the same or different and each represents —H or C₁₋₆ alkyl,

provided that

(i) in the case where R^(11a), R^(11b), R^(21a), R^(21b), R⁴¹, R⁵¹, R⁶¹, and R⁷¹ are respectively —H and X¹ is —O—, R³¹ is a group other than —H, —CO-methyl, or —SO₂-methyl, and

(ii) in the case where R^(11a) and R^(11b) are combined to form oxo, R^(21a), R^(21b), R⁴¹, R⁵¹, R⁶¹, and R⁷¹ are respectively —H, and X¹ is —O—, R³¹ is a group other than —H or methyl.)

Furthermore, in the case where the symbols in any of the formulas in the present specification are also used in other formulas, the same symbols denote the same meanings, unless specifically described otherwise.

Furthermore, the present invention relates to a pharmaceutical composition for preventing or treating 5-HT_(2C) receptor-related diseases, including the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof. In this connection, the pharmaceutical composition includes an agent for preventing or treating 5-HT_(2C) receptor-related diseases, including the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof.

Moreover, the present invention relates to use of the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof for preparation of a pharmaceutical composition for preventing or treating 5-HT_(2C) receptor-related diseases; the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof for prevention or treatment of 5-HT_(2C) receptor-related diseases; and a method for preventing or treating 5-HT_(2C) receptor-related diseases, including administering to a subject an effective amount of the compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof. In addition, the “subject” is human or other animals in need of the prevention or treatment, and in a certain embodiment, human in need of the prevention or treatment.

In addition, the compound of the formula (II) or a salt thereof is included in the compound of the formula (I) or a salt thereof. Accordingly, in the present specification, the explanation of the compound of the formula (I) includes that of the compound of the formula (II).

Effects of the Invention

The compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof has a 5-HT_(2C) receptor agonist activity and can be used as an agent for preventing or treating 5-HT_(2C) receptor-related diseases.

Here, examples of the 5-HT_(2C) receptor-related diseases include incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like.

EMBODIMENTS FOR CARRYING OUT THE INVENTION

Hereinafter, the present invention will be described in detail.

In the present specification, the “alkyl” includes straight alkyl and branched alkyl. Accordingly, the “C₁₋₆ alkyl” is a straight or branched alkyl having 1 to 6 carbon atoms, and specific examples thereof include methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl, and the like, in another embodiment, methyl, ethyl, propyl, isopropyl, in a further embodiment, methyl, ethyl, in a still further embodiment, methyl, and in a still further embodiment, ethyl.

The “alkylene” is a divalent group formed by the removal of any one hydrogen atom of the “alkyl” above. Accordingly, the “C₁₋₆ alkylene” is straight or branched alkylene having 1 to 6 carbon atoms, and specific examples thereof include methylene, ethylene, trimethylene, tetramethylene, pentamethylene, hexamethylene, methylmethylene, dimethylmethylene, ethylmethylene, methylethylene, dimethylethylene, ethylethylene, and the like, in another embodiment, methylene, ethylene, and in a further embodiment methylene.

The “aryl” is a monocyclic to tricyclic aromatic hydrocarbon ring group having 6 to 14 carbon atoms. Specific examples thereof include phenyl and naphthyl, in another embodiment, phenyl, and in a further embodiment, naphthyl.

The “cycloalkyl” is a saturated hydrocarbon ring group, the cycloalkyl may have a bridge and may be condensed with a benzene ring, and a part of the bonds may be unsaturated. Accordingly, specific examples of the “C₃₋₈ cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, cycloheptyl, cyclooctyl, cyclooctadienyl, norbornyl, bicyclo[2.2.2]octyl, indanyl, indenyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and the like.

The “hetero ring” is a monovalent group of a 3- to 15-membered, in another embodiment, a 5- to 10-membered, monocyclic to tricyclic heterocyclic group containing 1 to 4 hetero atoms selected from oxygen, sulfur, and nitrogen, and includes a saturated ring, an aromatic ring, and a partially hydrogenated ring group thereof. The ring atom, sulfur or nitrogen, may be oxidized to form an oxide or a dioxide. Specific examples thereof include monocyclic aromatic hetero rings such as pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, and the like, bicyclic aromatic hetero rings such as indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl, benzothiadiazolyl, and the like, tricyclic aromatic hetero rings such as carbazolyl, dibenzo[b,d]furanyl, dibenzo[b,d]thienyl, and the like, monocyclic non-aromatic hetero rings such as azetidinyl, pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, morpholinyl, thiomorpholinyl, tetrahydropyridinyl, oxetanyl, tetrahydrofuranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, tetrahydrothiopyranyl, and the like, bicyclic non-aromatic hetero rings such as indolinyl, tetrahydroquinolyl, tetrahydroisoquinolyl, dihydrobenzimidazolyl, tetrahydrobenzimidazolyl, tetrahydroquinoxalinyl, dihydroquinoxalinyl, dihydrobenzoxazolyl, dihydrobenzoxazinyl, dihydrobenzofuryl, chromanyl, chromenyl, methylenedioxyphenyl, ethylenedioxyphenyl, and the like, bridged hetero rings such as quinuclidinyl and the like, in another embodiment, a 5- to 10-membered monocyclic to bicyclic hetero ring, in a further embodiment, a 5- to 6-membered monocyclic hetero ring, and in a still further embodiment, a 5- to 6-membered monocyclic aromatic hetero ring.

The “aromatic hetero ring” is a 5- to 10-membered monocyclic to bicyclic aromatic hetero ring among the “hetero rings” above, and specific examples thereof include pyrrolyl, furyl, thienyl, pyrazolyl, imidazolyl, oxazolyl, thiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, indolyl, isoindolyl, benzofuranyl, benzothienyl, indazolyl, benzimidazolyl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, quinolyl, isoquinolyl, quinoxalinyl, quinazolinyl, phthalazinyl, and the like, and in another embodiment, furyl, thienyl, pyrazolyl, thiazolyl, pyridyl, pyrimidinyl, and pyrazyl.

The “cyclic amino” is a 5- to 7-membered non-aromatic hetero ring having a binding position at a nitrogen atom among the “hetero rings” above, and specific examples thereof include pyrrolidinyl, piperidyl, piperazinyl, azepanyl, diazepanyl, morpholinyl, and thiomorpholinyl.

The “oxygen-containing hetero ring” is a monovalent group of a non-aromatic 5- to 6-membered ring which may be condensed with a benzene ring having one or two oxygen atoms as ring-constituting atoms. Specific examples thereof include tetrahydrofuranyl, tetrahydropyranyl, dioxolanyl, dioxanyl, dihydrobenzofuranyl, dihydrochromenyl, benzodioxolyl, benzodioxinyl, dihydrodioxinyl, dihydrobenzodioxinyl, dihydropyranyl, dioxinyl, chromenyl, and benzodioxinyl.

The “halogen” means —F, —Cl, —Br, or —I, and in another embodiment, —F, —Cl, or —Br.

The “halogeno-C₁₋₆ alkyl” is C₁₋₆ alkyl substituted with one or more halogen atoms, and specific examples thereof include fluoromethyl, difluoromethyl, trifluoromethyl, trifluoroethyl, fluoroethyl, chloroethyl, bromoethyl, fluoropropyl, dichloropropyl, fluorochloropropyl, and the like, and in another embodiment, difluoromethyl, trifluoromethyl, difluoroethyl, trifluoroethyl, and fluoropropyl.

In the present specification, the expression “which may be substituted” means unsubstituted or substituted with 1 to 5 substituents. Further, if it has a plurality of substituents, the substituents may be the same as or different from each other.

Specific examples of the substituent for the “C₁₋₆ alkyl which may be substituted”, “C₁₋₆ alkylene which may be substituted”, “(C₃₋₈) cycloalkyl which may be substituted”, “aryl which may be substituted”, or “hetero ring which may be substituted” of R³ and R⁴ include amino, nitro, cyano, halogen, C₁₋₆ alkyl, halogeno-C₁₋₆ alkyl, —OH, —C₁₋₆ alkylene-OH, —O—C₁₋₆ alkyl, —C₁₋₆ alkylene-O—C₁₋₆ alkyl, —C₁₋₆ alkylene-cycloalkyl, —C₁₋₆ alkylene-aryl, —C₁₋₆ alkylene-hetero ring, —CO—C₁₋₆ alkyl, —CO—C₁₋₆ alkylene-O—C₁₋₆ alkyl, —CO-cycloalkyl, —CO-aryl, —CO—NR⁸R⁹, —CO—O—C₁₋₆ alkyl, —CO—O—C₁₋₆ alkylene-aryl, —SO₂—C₁₋₆ alkyl, aryl, a hetero ring, and the like.

Here, R⁸ and R⁹ are the same or different and each represents —H or C₁₋₆ alkyl.

In another embodiment, examples of the substituent for “C₁₋₆ alkyl which may be substituted” in R³ include:

(1) halogen,

(2) oxo, —OH, and —O—R^(Z),

(3) —O-(phenyl which may be substituted with one or more groups selected from the group consisting of R^(Z), —O—R^(Z), halogen, and cyano),

(4) —O-aromatic hetero ring,

(5) amino which may be substituted with one or two R^(Z),

(6) phenyl which may be substituted with one or more groups selected from the group consisting of R^(Z), —O—R^(Z), halogen, and cyano,

(7) C₃₋₈ cycloalkyl which may be substituted with R^(Z),

(8) an oxygen-containing hetero ring which may be substituted with halogen,

(9) a cyclic amino which may be substituted with R^(Z), and

(10) an aromatic hetero ring,

in which the C₁₋₆ alkyl may be substituted with one or more substituents.

Furthermore, R^(Z) herein represents C₁₋₆ alkyl which may be substituted with one or more groups selected from the group consisting of halogen, —O—C₁₋₆ alkyl, C₃₋₈ cycloalkyl, and phenyl (in which the phenyl may be substituted with one or more groups selected from the group consisting of halogen and —O—C₁₋₆ alkyl).

In another embodiment, examples of the substituent for the “aryl which may be substituted” in R³ include halogen, and the aryl may be substituted with one or more substituents.

In a further embodiment, examples of the substituent for the “C₁₋₆ alkyl which may be substituted” in R⁴ include halogen and aryl, and the C₁₋₆ alkyl may be substituted with one or more substituents.

In a still further embodiment, examples of the substituent of the “aryl which may be substituted” in R⁴ include halogen, C₁₋₆ alkyl, and —O—C₁₋₆ alkyl, and the aryl may be substituted with one or more substituents.

Some embodiments of the compound of the formula (I) or a salt thereof are presented below.

(1) The compound or a salt thereof, wherein R^(1a) and R^(1b) are the same or different and each represents —H or methyl. In another embodiment, the compound or a salt thereof, wherein R^(1a) and R^(1b) are respectively —H. In a further embodiment, the compound or a salt thereof, wherein R^(1a) is —H and R^(1b) is methyl. In a still further embodiment, the compound or a salt thereof, wherein R^(1a) and R^(1b) are combined to form oxo.

(2) The compound or a salt thereof, wherein R^(2a) is —H and R^(2b) is —H or C₁₋₆ alkyl. In another embodiment, the compound or a salt thereof, wherein R^(2a) is —H and R^(2b) is —H or methyl. In a further embodiment, the compound or a salt thereof, wherein R^(2a) and R^(2b) are respectively —H.

(3) The compound or a salt thereof, wherein R³ is C₁₋₆ alkyl which may be substituted with one or more groups selected from the group consisting of (a) to (e) below:

(a) halogen, (b) —O—C₁₋₆ alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C₁₋₆ alkyl which may be substituted with —O—C₁₋₆ alkyl, halogen, and —O—C₁₋₆ alkyl.

In another embodiment, the compound or a salt thereof, wherein R³ is C₁₋₆ alkyl which may be substituted with one or more groups selected from the group consisting of (f) to (j) below:

(f) fluoro, (g) methoxy, ethoxy, (h) phenoxy which may be substituted with one or more groups selected from the group consisting of fluoro and cyano, (i) tetrahydrofuranyl, tetrahydropyranyl, or dihydrobenzodioxinyl, and (j) phenyl which may be substituted with one or more groups selected from the group consisting of fluoro, chloro, methyl, and methoxymethyl.

In another embodiment, the compound or a salt thereof, wherein R³ is isobutyl. In another embodiment, the compound or a salt thereof, wherein R³ is ethyl or propyl, which respectively is substituted with one or more groups selected from the group consisting of fluoro, methoxy, and ethoxy. In a further embodiment, the compound or a salt thereof, wherein R³ is ethyl substituted with phenoxy which may be substituted with one or more groups selected from the group consisting of fluoro and cyano. In a still further embodiment, the compound or a salt thereof, wherein R³ is methyl substituted with a group selected from the group consisting of tetrahydrofuranyl, tetrahydropyranyl and dihydrobenzodioxinyl. In a still further embodiment, the compound or a salt thereof, wherein R³ is methyl substituted with phenyl which may be substituted with one or more groups selected from the group consisting of fluoro, chloro, methyl, and methoxymethyl.

(4) The compound or a salt thereof, wherein R⁴ is —H, halogen, or C₃₋₈ cycloalkyl. In another embodiment, the compound or a salt thereof, wherein R⁴ is —H, bromo, or cyclopropyl. In a further embodiment, the compound or a salt thereof, wherein R⁴ is —H. In a further embodiment, the compound or a salt thereof, wherein R⁴ is bromo. In a still further embodiment, the compound or a salt thereof, wherein R⁴ is cyclopropyl.

(5) The compound or a salt thereof, wherein R⁵ is —H or C₁₋₆ alkyl. In another embodiment, the compound or a salt thereof, wherein R⁵ is —H or methyl. In a further embodiment, the compound or a salt thereof, wherein R⁵ is —H.

(6) The compound or a salt thereof, wherein R⁶ and R⁷ are the same or different and each represents —H or methyl. In another embodiment, the compound or a salt thereof, wherein R⁶ is methyl and R⁷ is —H. In a further embodiment, the compound or a salt thereof, wherein R⁶ is —H and R⁷ is methyl. In a still further embodiment, the compound or a salt thereof, wherein R⁶ and R⁷ are respectively —H.

(7) The compound or a salt thereof, wherein X is —CH₂— or —O—. In another embodiment, the compound or a salt thereof, wherein X is —CH₂—. In a further embodiment, the compound or a salt thereof, wherein X is —O—.

(8) The compound or a salt thereof, which is a combination of two or more of (1) to (7) as described above.

The compound or a salt thereof as described above in (8), which is a combination of two or more of (1) to (7) as described above, is included in the present invention, and the following embodiments including the specific examples thereof can be exemplified as below.

(9) The compound or a salt thereof, wherein R³ is —H, C₁₋₆ alkyl which may be substituted, C₃₋₈ cycloalkyl, aryl which may be substituted, —SO₂—C₁₋₆ alkyl, or an oxygen-containing hetero ring, and R⁴ is —H, halogen, cyano, C₁₋₆ alkyl which may be substituted, C₂₋₆ alkenyl, aryl which may be substituted, C₃₋₈ cycloalkyl, an aromatic hetero ring, or an oxygen-containing hetero ring.

(10) The compound or a salt thereof as described in (9), wherein R³ is a group other than —H, methyl, —CO-methyl, or —SO₂-methyl.

(11) The compound or a salt thereof as described in (10), wherein R^(1a) is —H or methyl, and R^(1b), R^(2a), R^(2b), R⁵, R⁶, and R⁷ are respectively —H.

(12) The compound or a salt thereof as described in (11), wherein R⁴ is —H, halogen, or C₃₋₈ cycloalkyl.

(13) The compound or a salt thereof as described in (12), wherein R⁴ is cyclopropyl.

(14) The compound or a salt thereof as described in (13), wherein R³ is C₁₋₆ alkyl which may be substituted with one or more groups selected from the group consisting of (a) halogen, (b) —O—C₁₋₆ alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C₁₋₆ alkyl which may be substituted with —O—C₁₋₆ alkyl, halogen, and —O—C₁₋₆ alkyl.

(15) The compound or a salt thereof as described in any one of (1) to (14), wherein X is —CH₂— or —O—. In another embodiment, the compound or a salt thereof as described in any one of (1) to (14), wherein X is —O—. In a still further embodiment, the compound or a salt thereof as described in any one of (1) to (14), wherein X is —CH₂—.

Examples of the specific compounds included in the compound of the formula (I) or a salt thereof include:

-   11-cyclopropyl-1-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline, -   4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(2-ethoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(3-fluoropropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline, -   5-bromo-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-[(2S)-tetrahydrofuran-2-ylmethyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-[(2R)-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(2-fluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-[(2S)-3-fluoro-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   4-(3-chlorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(tetrahydro-2H-pyran-3-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(2-phenoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(2-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(3-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(2,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-[3-(methoxymethyl)benzyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   4-(5-chloro-2-fluorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   (3S)-5-cyclopropyl-4-(2-methoxyethyl)-3-methyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   4-[2-(5-cyclopropyl-2,3,7,8,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepin-4(6H)-yl)ethoxy]-3,5-difluorobenzonitrile, -   5-cyclopropyl-4-(3-methoxybenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, -   5-cyclopropyl-4-(3,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,     and -   5-cyclopropyl-4-[(2R)-2-ethoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine,     and salts thereof.

The compound of the formula (I) may exist in the form of tautomers or geometrical isomers depending on the kind of substituents. In the present specification, the compound of the formula (I) shall be described in only one form of isomer, yet the present invention includes other isomer, such as an isolated forms of the isomers, or a mixture thereof.

In addition, the compound of the formula (I) may have asymmetric carbon atoms or axial asymmetry in some cases, and correspondingly, it may exist in the form of optical isomers. The present invention includes both an isolated form of the optical isomers of the compound of the formula (I) or a mixture thereof.

Moreover, the present invention also includes a pharmaceutically acceptable prodrug of the compound of the formula (I). The pharmaceutically acceptable prodrug is a compound having a group that can be converted into an amino group, a hydroxyl group, a carboxyl group, or the like through solvolysis or under physiological conditions. Examples of the group forming the prodrug include the groups described in Prog. Med., 5, 2157-2161 (1985) and Pharmaceutical Research and Development, Drug Design, Hirokawa Publishing Company (1990), vol. 7, 163-198.

Moreover, the salt of the compound of the formula (I) is a pharmaceutically acceptable salt of the compound of the formula (I) and may form an acid addition salt or a salt with a base depending on the kind of substituents. Specific examples thereof include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, and the like, and with organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, mandelic acid, tartaric acid, dibenzoyltartaric acid, ditoluoyltartaric acid, citric acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, aspartic acid, glutamic acid, and the like, and salts with inorganic bases such as sodium, potassium, magnesium, calcium, aluminum, and the like or organic bases such as methylamine, ethylamine, ethanolamine, lysine, ornithine, and the like, salts with various amino acids or amino acid derivatives such as acetylleucine and the like, ammonium salts, etc.

In addition, the present invention also includes various hydrates or solvates, and polymorphic crystal substances of the compound of the formula (I) and a salt thereof. In addition, the present invention also includes compounds labeled with various radioactive or non-radioactive isotopes.

(Preparation Methods)

The compound of the formula (I) and a salt thereof can be prepared using the characteristics based on the basic structure or the type of substituents thereof and by applying various known synthesis methods. During the preparation, replacing the relevant functional group with a suitable protective group (a group that can be easily converted into the functional group) at the stage from starting material to an intermediate may be effective depending on the type of the functional group in production technology in some cases. The protective group for such a functional group may include, for example, the protective groups described in “Greene's Protective Groups in Organic Synthesis (4^(th) Ed., 2006)” written by P. G. M. Wuts and T. W. Greene, and one of these may be selected and used as necessary depending on the reaction conditions. In this kind of method, a desired compound can be obtained by introducing the protective group, by carrying out the reaction and by eliminating the protective group as necessary.

In addition, the prodrug of the compound of the formula (I) can be produced by introducing a specific group or by carrying out the reaction using the obtained compound of the formula (I) at the stage from a starting material to an intermediate, just as in the case of the above-mentioned protective group. The reaction can be carried out using methods known to those skilled in the art, such as ordinary esterification, amidation, dehydration, and the like.

Hereinbelow, the representative preparation methods for the compound of the formula (I) will be described. Each of the production processes may also be carried out with reference to the References appended in the present description. Further, the preparation methods of the present invention are not limited to the examples as shown below.

The compound of the formula (I) can be obtained by removing P which is a protective group for an amino group. The protective group for P may be any protective group for an amino group which is usually used by a person skilled in the art, and carbonyl such as trifluoroacetyl and the like; oxycarbonyl such as t-butylcarboxyl, ethylcarboxyl, benzylcarboxyl, and the like; or sulfonyl such as methanesulfonyl, p-toluenesulfonyl, trifluoromethanesulfonyl, p-nitrophenylsulfonyl, 2,4-dinitrophenylsulfonyl, and the like is suitably used.

For the deprotection in the present step, the conditions for deprotection usually used by a person skilled in the art can be employed. For example, preparation can be performed by acid treatment, hydrolysis, hydrogenolysis, or the like. For acid treatment, for example, trifluoroacetic acid, hydrochloric acid gas, sulfuric acid, or the like can be used. In the case of alkali hydrolysis, inorganic bases (for example NaOH, KOH, NaHCO₃, Cs₂CO₃, and the like) can be used. In the case of acid hydrolysis, hydrochloric acid and the like can be used. For any reaction temperature, the reaction can be performed under the condition from under ice-cooling to under refluxing and under the condition which does not allow the substrate to be decomposed. As the solvent, dioxane, tetrahydrofuran, dichloromethane, chloroform, ethyl acetate, alcohols (MeOH, EtOH, and the like), N,N-dimethylformamide (DMF), dimethylsulfoxide (DMSO), water, or a mixed solvent thereof, and the like may be used, but are not limited thereto. In the case of hydrogenolysis, the reaction can usually be performed under a hydrogen atmosphere in the presence of a palladium catalyst. Usually, the reaction can be performed under the condition of from room temperature to under refluxing and under the condition which does not allow the substrate to be decomposed. As the solvent, DMF or alcohols (MeOH, EtOH, and the like) may be used, but are not limited thereto. Further, the conditions for the de-carboxamide reaction, the de-carbamate reaction, the de-sulfonamide reaction described in “Greene's Protective Groups in Organic Synthesis (4^(th) Ed., 2006)” above can be employed.

Various substituents defined as the groups in the compound of the formula (I), R^(1a), R^(1b), R^(2a), R^(2b), R³, R⁴, R⁵, R⁶, and R⁷ can be easily converted to other functional groups by using the compound of the formula (I) as a starting material or using the synthetic intermediate of the compound of the formula (I) as a starting material by means of the reaction described in Examples as described later, the reaction apparent to a person skilled in the art, or modified methods thereof. For example, the step that can be usually employed by a person skilled in the art, such as O-alkylation, N-alkylation, reduction, hydrolysis, amidation, and the like can be arbitrarily combined and performed.

(Preparation of Starting Compound)

The starting compound in the preparation method above can be prepared by, for example, the following method, the method described in Preparation Examples as described later, known methods, or modified methods thereof.

(Starting Material Synthesis 1)

A compound represented by the general formula (1) which is a starting material for synthesizing a compound of the general formula (2) is commercially available or prepared by a means known to a person skilled in the art. Then, the compound of the general formula (2) can be prepared by nitrating the compound of the general formula (1). For example, a number of known nitration reactions can be used, examples of which include a method using nitric acid, fumed nitric acid, potassium nitrate, or the like in an acid solvent, a method using nitronium tetrafluoroborate, and the like. Then, the compound of the general formula (3) can be prepared by reducing a nitro group of the compound of the general formula (2) to an amino group. For example, a number of known reduction methods can be used, examples of which include a method using metal hydrides such as lithium aluminum hydride and the like, a method using reduced iron or the like, and the like. Further, catalytic hydrogenation using noble metal catalysts such as Raney nickel, palladium, ruthenium, rhodium, platinum, and the like can also be used.

(Starting Material Synthesis 2)

(wherein R^(Xa) is C₁₋₆ alkyl).

A compound of the general formula (4) can be prepared by halogenating the compound of the general formula (3). For example, a number of known halogenation reactions can be used, examples of which include a method using N-bromosuccinimide or N-chlorosuccinimide, and the like. Then, the compound of the general formula (5) can be prepared from the compound of the general formula (4) by a coupling reaction using a transition metal catalyst. Examples of the coupling reaction include a Heck reaction. The reaction conditions for the Heck reaction vary depending on the starting materials, solvents, and transition metal catalysts used, and techniques known to a person skilled in the art can be used. Examples of the preferred solvent include acetonitrile, tetrahydrofuran, 1,4-dioxane or DMF, and the like, but are not limited thereto. The transition metal catalyst is preferably a palladium complex, and more preferably known palladium complexes such as palladium(II) acetate, dichlorobis(triphenylphosphine)palladium(II), tetrakis(triphenylphosphine)palladium(0), and the like. Further, for the present reaction, a phosphorous ligand (preferably, triphenylphosphine, tri-o-tolylphosphine, tri-tert-butylphosphine, 2-(di-tert-butylphosphino)biphenyl, or the like) may be added in order to obtain excellent results. Also, the present reaction can yield preferable results in the presence of a base, and the base used herein is not particularly limited as long as it is used for the coupling reaction of the present reaction, but it is preferably triethylamine, N,N-diisopropylethylamine, or the like.

(Starting Material Synthesis 3)

The compound of the general formula (IIIa) can be obtained by allowing an intramolecular amide condensation cyclization reaction to proceed by carrying out a hydrogenation reaction of the double bond of the α,β-unsaturated esters of the compound of the general formula (5). In this reaction, the compound of the general formula (5) is stirred in the presence of a metal catalyst, usually for 1 hour to 5 days, in a solvent inert to the reaction, under a hydrogen atmosphere. This reaction is usually carried out in the range from cooling to heating, preferably at room temperature. Examples of the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, 2-propanol, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, water, ethyl acetate, DMF, DMSO and a mixture thereof. As the metal catalyst, palladium catalysts such as palladium on carbon, palladium black, palladium hydroxide, and the like, platinum catalysts such as a platinum plate, platinum oxide, and the like, nickel catalysts such as reduced nickel, Raney nickel, and the like, rhodium catalysts such as tetrakistriphenylphosphine chlororhodium, and the like, iron catalysts such as reduced iron and the like, etc. are preferably used. Instead of hydrogen gas, formic acid or ammonium formate in an equivalent amount or in an excess amount to the compound of the general formula (5) can be used as a hydrogen source.

Furthermore, for the compound in which R^(2b) is other than —H, an R^(2b) group other than —H can be introduced to a desired position by using an electrophilic substitution reaction to the α-position of carbonyl by the use of a base or by a method which can be usually employed by a person skilled in the art for the compound (IIIa).

REFERENCES

-   “Reductions in Organic Chemistry, 2^(nd) Ed. (ACS Monograph: 188)”     written by M. Hudlicky, ACS, 1996

(Starting Material Synthesis 4)

A compound of the general formula (IIIb) can be obtained by carrying out reduction of a carbonyl group of the compound of the general formula (IIIa). This reaction is usually carried out in the presence of a reducing agent in a solvent. Examples of the solvent used herein are not particularly limited, but include ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, and aromatic hydrocarbons such as benzene, toluene, xylene, and the like. Examples of the reducing agent include aluminum hydride compounds such as lithium aluminum hydride, sodium bis(2-methoxyethoxy)aluminum hydride, and the like, and borohydride compounds such as sodium borohydride, diborane, a borane-tetrahydrofuran complex, and the like.

(Starting Material Synthesis 5)

(wherein R^(4a) represents C₁₋₆ alkyl, halogeno-C₁₋₆ alkyl, cycloalkyl which may be substituted, or aryl which may be substituted, and Hal represents halogen).

A compound of the general formula (IIId) can be obtained by a coupling reaction of a compound of the general formula (IIIc). For example, the Suzuki coupling described in the following references, the Heck reaction described for the Starting Material Synthesis 2 above, or the like can be employed.

REFERENCES

-   Chemical Reviews, vol. 95, No. 7, p. 2457 (1995), Journal of     American Chemical Society, vol. 127, p. 4685 (2005), Synlett, No.     13, p. 2327 (2004), Tetrahedron letters, No. 41, p. 4363 (2000), or     Tetrahedron letters, No. 43, p. 2695 (2002)

The compound of the general formula (IIId) can also be obtained by the method described in Examples as described later.

(Starting Material Synthesis 6)

(wherein R^(1a) represents a group other than —H among the groups defined as R³).

A compound of the general formula (IIIe) can be obtained by alkylation, acylation, or the like of the compound of the general formula (IIIb). For the specific reaction conditions, the conditions described in the following references can be employed.

REFERENCES

-   “Organic Functional Group Preparations” written by S. R. Sandler     and W. Karo, 2″ Ed., vol. 1, Academic Press Inc., 1991 -   “Courses in Experimental Chemistry (5^(th) Ed.)”, edited by The     Chemical Society of Japan, vol. 14 (2005) (Maruzen)

The compound of the general formula (IIIe) can also be obtained by the method described in the Examples as described later and the method described for the Starting Material Synthesis 4 above.

(Starting Material Synthesis 7)

A compound of the general formula (8) can be obtained by the reaction of a compound of the general formula (6) with a compound of the general formula (7). In this regard, examples of the leaving group of L¹ include halogen, methanesulfonyloxy, p-toluenesulfonyloxy groups, and the like.

In this reaction, the compound of the general formula (6) and the compound of the general formula (7) are used in equivalent amounts, or with either one of them in an excess amount, and a mixture thereof is stirred under a temperature condition from cooling to heating and refluxing, preferably at 0° C. to 80° C., usually for 0.1 hours to 5 days, in a solvent inert to the reaction in the presence of a base. Examples of the solvent used herein are not particularly limited, but include aromatic hydrocarbons such as benzene, toluene, xylene, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, halogenated hydrocarbons such as dichloromethane, 1,2-dichloroethane, chloroform, and the like, DMF, DMSO, ethyl acetate, acetonitrile, and a mixture thereof. Examples of the base include organic bases such as triethylamine, N,N-diisopropylethylamine, 1,8-diazabicyclo[5.4.0]-7-undecene, n-butyllithium, and the like, and inorganic bases such as sodium carbonate, potassium carbonate, sodium hydride, potassium tert-butoxide, and the like. It may be advantageous to carry out a reaction in the presence of a phase transfer catalyst such as tetra-n-butylammonium chloride and the like in some cases.

A compound of the general formula (IIIf) can be obtained by the method described in the Starting Material Synthesis 3 above and a compound of the general formula (Mg) can be obtained by the method described in the Starting Material Synthesis 4 above.

REFERENCES

-   “Organic Functional Group Preparations” written by S. R. Sandler     and W. Karo, 2^(nd) Ed., vol. 1, Academic Press Inc., 1991 -   “Courses in Experimental Chemistry (5^(th) Ed.)”, edited by The     Chemical Society of Japan, vol. 14 (2005) (Maruzen)

(Starting Material Synthesis 8)

(wherein R^(3b) represents C₁₋₆ alkyl which may be substituted, C₃₋₈ cycloalkyl, aryl which may be substituted, or a hetero ring which may be substituted, among the groups defined as R³. Further, among the C₁₋₆ alkyl which may be substituted, one having oxo substituted on a carbon atom directly bonded to a nitrogen atom connected with R^(3b) is excluded).

The compound of the general formula (10) can be obtained by using the compound of the general formula (9) and a suitable aldehyde or ketone compound in equivalent amounts, and stirring a mixture thereof under a temperature condition from −45° C. to heating and refluxing, preferably at 0° C. to room temperature, usually for 0.1 hours to 5 days, in a solvent inert to the reaction in the presence of a reducing agent. Examples of the solvent used herein are not particularly limited, but include alcohols such as methanol, ethanol, and the like, ethers such as diethylether, tetrahydrofuran, dioxane, dimethoxyethane, and the like, and a mixture thereof. Examples of the reducing agent include sodium cyanoborohydride, sodium triacetoxyborohydride, sodium borohydride, and the like. It is preferable in some cases to carry out the reaction in the presence of a dehydrating agent such as molecular sieves, and the like or an acid such as acetic acid, hydrochloric acid, a titanium(IV) isopropoxide complex, and the like. Further, the reaction can be carried out in a solvent such as methanol, ethanol, ethyl acetate, and the like, in the presence or absence of an acid such as acetic acid, hydrochloric acid, and the like, using a reduction catalyst (for example, palladium on carbon, Raney nickel, and the like), instead of treatment with the reducing agent. In this case, it is preferable to carry out the reaction under a hydrogen atmosphere from normal pressure to 50 atmospheres under a temperature condition ranging from cooling to heating.

A compound of the general formula (IIIh) can be obtained by using the compound of the general formula (10) and a suitable halogenocarboxylic ester and reacting them in the presence of a base.

The compound of the general formula (IIIi) can be obtained by using the method described in the Starting Material Synthesis 4 above and carrying out reduction of a carbonyl group of the compound of the general formula (IIIh).

REFERENCES

-   “Comprehensive Organic Functional Group Transformations II” written     by A. R. Katritzky and R. J. K. Taylor, vol. 2, Elsevier Pergamon,     2005 -   “Courses in Experimental Chemistry (5^(th) Ed.)”, edited by The     Chemical Society of Japan, vol. 14 (2005) (Maruzen)

The compounds of the formula (I) can be isolated and purified as their free compounds, salts, hydrates, solvates, or polymorphic crystal substances thereof. The salts of the compound of the formula (I) can be prepared by carrying out the treatment of a conventional salt forming reaction.

Isolation and purification are carried out by employing ordinary scientific operations such as extraction, fractional crystallization, various types of fractional chromatography, and the like.

Various isomers can be prepared by selecting an appropriate starting compound or separated by using the difference in the physicochemical properties between the isomers. For example, the optical isomers can be obtained by means of a general method for designing optical resolution of racemic products (for example, fractional crystallization for inducing diastereomer salts with optically active bases or acids, chromatography using a chiral column or the like, and others), and further, the isomers can also be prepared from an appropriate optically active starting material.

The pharmacological activity of the compound of the formula (I) was confirmed by the tests shown below.

Test Example 1 Evaluation of 5-HT_(2C) Receptor Agonist Activity

The agonist activity of the compound of the formula (I) on the 5-HT_(2C) receptor was confirmed by the method shown below.

The human 5-HT_(2C) receptor agonist activity was evaluated by measuring the increase of the ligand-dependent intracellular calcium concentration. CHO cells which stably expressing a human 5-HT_(2C) receptor were used. The receptor-expressing cells were prepared by transfecting the genes of the human 5-HT_(2C) receptor (Accession numbers: AF498983 (5-HT_(2C))) into CHO cells (dihydrofolic acid-deficient strain, DS Pharma Biomedical Co., Ltd.)) using a pEF-BOS vector (Nucleic Acids Research, vol. 18, No. 17). After transcription, the 5-HT_(2C) is known to be subjected to RNA editing to cause differences in three kinds of amino acids, resulting in fourteen receptor isoforms. Among them, cells stably expressing an INI type of 5-HT_(2C) receptor which had not been subjected to editing were used. Cells used for evaluation were cultured in a 10% fetal bovine serum (FBS)-containing medium (trade name: α-MEM, Invitrogen) at 37° C. and 5% carbon dioxide. On the day before the evaluation, the cells were suspended in a serum-free medium (trade name: CD-CHO, Invitrogen) containing 8 mM L-glutamine (trade name: L-glutamine 200 mM, Invitrogen, added to the medium at a final concentration of 8 mM) and dispensed into a 96-well poly-D-lysine-coated plate (trade name: Biocoat PDL96W Black/Clear, Japan Becton, Dickinson and Company)) at 4×104 cells/well and cultured at 37° C. and 5% carbon dioxide overnight. A solution including a washing solution (mixture of Hank's Balanced Salt Solution (HBSS)-sodium hydroxide (NaOH), 20 mM 2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid (HEPES)-sodium hydroxide (NaOH), 2.5 mM probenecid, and 0.1% bovine serum albumin (BSA)), and a 4 μM fluorescent reagent (trade name: Fluo-4-AM, Dojindo Co., Ltd.) was used as a loading buffer and the medium of the 96-well plate which had been cultured overnight was replaced with a loading buffer. After leaving to stand (with light-shielding) at room temperature for 3 hours, the cells were washed with a plate washer (trade name: ELx405, BioTek Instruments, Inc.) in which a washing solution had been set up. The plates of the washed cells were set up in a system for measuring a calcium (Ca) concentration in a cell (trade name: FLIPR, Molecular Devices, Inc.). In this device, a test compound that had been dissolved in dimethyl sulfoxide and diluted in the washing solution at a predetermined concentration was added and set up to measure a change in the Ca concentrations in a cell. The difference between a maximum value and a minimum value in the change of the intracellular Ca concentration was determined and kept as measurement data.

Taking the maximum reaction of the 5-HT (agonist action with addition of 5-HT 10 μM) as 100% and the reaction of a solvent alone as 0%, efficacy (Emax (%)) of the present invention compound to the maximum reaction of the 5-HT was obtained and potency (EC50 (nM)) was calculated with a logistic regression method, as the agonist activity.

The results of several compounds are shown in Table 1. In the Table, Ex represents Example Compound No. below.

TABLE 1 5-HT_(2C) agonist activity Ex EC50 (nM) Emax (%) 2 0.64 99 16 1.5 109 21 0.81 101 33 32.9 94 35 0.42 100 36 12 97 38 2.1 94 42 1.9 97 45 3.9 107 50 68 98 56 3.2 112 58 4.0 117 59 7.1 108 76 1.9 116 78 36 98 81 0.84 114 88 1.1 105 90 8.3 113 92 79 84 98 4.4 107 104 1.1 107 105 8.0 111 106 1.1 112 108 5.9 106 135 2.9 112 141 0.36 100 215 10. 96 243 0.53 96 258 1.9 97 263 2.8 96 265 1.3 97 267 0.51 99 268 0.92 99 276 6.4 104 277 2.3 95 283 1.7 90 287 1.0 97 288 0.64 90 290 3.8 93 291 1.2 93 292 0.65 93 297 0.71 96 299 1.0 98 313 4.2 97 315 2.8 108

Test Example 2 Measurement of External Urethral Sphincter Electromyography

The activating action of the compound of the formula (I) on the urethral sphincter electromyography was confirmed with the method shown below.

Hartley female guinea pigs with a body weight of 250 to 350 g were anesthetized with urethane (Sigma). The guinea pigs were fixed in a supine position and catheters (PE-50; Clay Adams) for administration of test compounds were inserted into the jugular vein. Further, a catheters (PE-160; Clay Adams), for an infusion of physiological saline into bladder and measurement of the intravesical pressure, were inserted through an incision into the dome of the bladder. Further, in order to measure the external urethral sphincter electromyography, two electrodes were inserted into both the left and right sides of the urethral opening to the urethral sphincter. The electrodes for measuring base voltages were placed under the skin of the hind part. The bladder catheter was branched over a three-way stopcock, and one was connected with a 50 mL syringe (Terumo) fixed to an infusion pump (Terumo). The other was connected to a pressure transducer (DX-100; Nihon Kohden Corporation) to transfer the signal of the transducer through an amplifier (AP-630G; Nihon Kohden Corporation) and a data acquisition system (PowerLab; AD Instruments) to a computer and record on a hard disk. The electrodes for electromyography measurement were connected to a control unit (JB-101J; Nihon Kohden Corporation) to transfer the signal through an amplifier (AP-651J; Nihon Kohden Corporation) and a data acquisition system (PowerLab; AD Instruments) to a computer and record on a hard disk. Further, the data were analyzed on the computer using a software (Chart; AD Instruments). Physiological saline was continuously injected into the bladder using an infusion pump at a rate of 18 mL/hour and it was confirmed that a micturition reflexes were stably induced. The electromyography activity was analyzed by taking the lowest potential amplitude as a standard during the stabilization period and using the firing frequency over the standard amplitude as an indicator. At internvals between the respective urinations (urine filling phase), the activity of the urethral sphincter electromyography was analyzed and its average value was calculated. After the stabilization period, the solvent and the test compound were administered at an increased dose at an interval of 40 minutes through the catheter placed into the jugular vein. The urethral sphincter electromyography activity after the administration of the solvent was taken as 100% and the urethral sphincter electromyography activity after the administration of the test compound was denoted as a percentage (%) of the electromyography activity after the administration of the solvent.

As a result, the compounds of Example 81, Example 59, Example 88, Example 104, Example 106, Example 141, Example 38, Example 135, Example 215, Example 243, Example 265, Example 287, Example 258, Example 263, Example 267, Example 268, Example 276, Example 277, Example 283, Example 288, Example 290, Example 291, Example 292, Example 297, Example 299, Example 313, and Example 315 as shown later showed an external urethral sphincter electromyography activity of 200% or more with intravenous administration at 3 mg/kg.

As a result of each test above, it was confirmed that the compound of the formula (I) has a 5-HT_(2C) receptor agonist activity, and the compound of the formula (I) can be used for treatment or prevention of 5-HT_(2C) receptor-related diseases, particularly incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like as a pharmaceutical.

According to the results obtained by the tests above, it is considered that the compound has a 5-HT_(2C) receptor agonist activity and thus has substantially the same or a higher activity value than Lorcaserin under development as an anti-obesity drug (The Journal of Pharmacology and Experimental Therapeutics vol. 325, No. 2 p. 577-587 (2008)).

A pharmaceutical composition containing one or two or more kinds of the compound of the formula (I) or a salt thereof as an active ingredient can be prepared using excipients that are usually used in the art, that is, excipients for pharmaceutical preparation, carriers for pharmaceutical preparation, and the like according to the methods usually used.

Administration can be accomplished either by oral administration via tablets, pills, capsules, granules, powders, solutions, and the like, or parenteral administration injections, such as intraarticular, intravenous, or intramuscular injections, and the like, suppositories, ophthalmic solutions, eye ointments, transdermal liquid preparations, ointments, transdermal patches, transmucosal liquid preparations, transmucosal patches, inhalations, and the like.

The solid composition for oral administration is used in the form of tablets, powders, granules, or the like. In such a solid composition, one or more active ingredient(s) are mixed with at least one inactive excipient. According to a usual method, the composition may contain inactive additives, such as lubricants, disintegrating agents, stabilizing agents, and solubilization assisting agents. If necessary, tablets or pills may be coated with sugar or a film of a gastric or enteric coating substance.

The liquid composition for oral administration contains pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs, or the like, and also contains generally used inert diluents, for example, purified water or ethanol. In addition to the inert diluent, the liquid composition may also contain auxiliary agents, such as a solubilization assisting agent, a moistening agent, and a suspending agent, as well as sweeteners, flavors, aromatics, and antiseptics.

The injections for parenteral administration contain sterile aqueous or non-aqueous solutions, suspensions, or emulsions. Examples of the aqueous solvent include distilled water for injection use and physiological saline. Examples of the non-aqueous solvent include alcohols such as ethanol. Such a composition may further contain a tonicity agent, an antiseptic, a moistening agent, an emulsifying agent, a dispersing agent, a stabilizing agent, and a solubilization assisting agent. These are sterilized by filtration through a bacteria retaining filter, blending of a germicide, or irradiation. Furthermore, they may also be prepared in the form of sterile solid compositions and dissolved or suspended in sterile water or a sterile solvent for injecting prior to their use.

Examples of the formulation for external use include ointments, plasters, creams, jellies, patches, sprays, lotions, eye-drops, eye ointments, and the like. The drug contains generally used ointment bases, lotion bases, aqueous or non-aqueous liquid preparations, suspensions, emulsions, or the like.

Transmucosal agents such as inhalers, transnasal agents, and the like are used in the form of solids, liquids, or semisolids and can be prepared according to conventional known methods. For example, known excipients, and further, pH adjusters, antiseptics, surfactants, lubricants, stabilizing agents, thickeners, or the like may also be added where appropriate. For administration, suitable devices for inhalation or insufflation can be used. For example, using known devices and sprayers such as a metered dose inhaler, the compound can be administered independently or in the form of prescribed mixture powders. Furthermore, the compound combined with pharmaceutically acceptable carriers can also be administered in the form of solutions or suspensions. Dry powder inhalers and the like may be devices for single or multiple administrations, and dry powders or capsules containing powders can also be used. Still further, the devices may be in the form of a pressure aerosol spray or the like that use suitable ejection agents, for example, chlorofluoroalkane, hydrofluoroalkane, or a suitable gas such as carbon dioxide and the like.

Usually, in the case of oral administration, the daily dose is suitably from 0.001 to 100 mg/kg per body weight, preferably from 0.1 to 30 mg/kg, and more preferably from 0.1 to 10 mg/kg, and this is administered in one portion or dividing it into 2 to 4 portions. In the case of intravenous administration, the daily dose is suitably from about 0.0001 to 10 mg/kg per body weight, and this is administered once a day or two or more times a day. In addition, a transmucosal agent is administered at a dose from about 0.001 to 100 mg/kg per body weight, and this is administered once a day or two or more times a day. The dose is appropriately decided in response to an individual case by taking the symptoms, the age, the gender, and the like into consideration.

Although varying depending on administration routes, dosage forms, administration sites, or the types of excipients and additives, the pharmaceutical composition of the present invention contains 0.01 to 100% by weight, and in a certain embodiment, 0.01 to 50% by weight of one or more kinds of the compound of the formula (I) or a salt thereof, which is an active ingredient.

The compound of the formula (I) can be used in combination with various agents for treating or preventing the diseases, in which the compound of the formula (I) is considered effective, as described above. The combined preparation may be administered simultaneously or separately and continuously, or at a desired time interval. The preparations to be co-administered may be prepared individually or may be a pharmaceutical composition including various agents for treating or preventing the diseases, in which the compound of the formula (I) is considered effective, as described above, and the compound of the formula (I).

EXAMPLES

Hereinbelow, the preparation methods for the compound of the formula (I) and the starting compounds thereof will be described in more detail with reference to Examples.

The present invention is not limited to the compounds described in the Examples described below. Furthermore, the production processes for the starting compounds will be described in Preparation Examples. The preparation methods for the compound of the formula (I) are not limited to the preparation methods of the specific Examples as below, but the compound of the formula (I) can be prepared by any combination of the preparation methods or the methods that are apparent to a person skilled in the art.

Furthermore, the following abbreviations may be used in some cases in the Preparation Examples, Examples, and Tables below.

PEx: Preparation Example No., Ex: Example No., PSyn: Preparation Example No. prepared by the same method, Syn: Example No. prepared by the same method, No: Compound No., Str: Structural formula, Dat: Physicochemical Data, EI: m/z values in mass spectroscopy (Ionization EI, representing (M)⁺ unless otherwise specified), ESI+: m/z values in mass spectroscopy (Ionization ESI, representing (M+H)⁺unless otherwise specified), ESI−: m/z values in mass spectroscopy (Ionization ESI, representing (M−H)⁻ unless otherwise specified), FAB+: m/z values in mass spectroscopy (Ionization FAB, representing (M+H)⁺ unless otherwise specified), FAB−: m/z values in mass spectroscopy (Ionization FAB, representing (M−H)⁻ unless otherwise specified), APCI+: tm/z values in mass spectroscopy (Ionization APCI, representing (M+H)⁺ unless otherwise specified), NMR: δ (ppm) in ¹H NMR in DMSO-d₆, NMR-A: δ (ppm) in ¹H NMR in DMSO-d₆ (with addition of trifluoroacetic acid), NMR-C: δ (ppm) in ¹H NMR in CDCl₃, s: singlet (spectrum), d: doublet (spectrum), t: triplet (spectrum), q: quartet (spectrum), br: broad line (spectrum) (e.g.: br-s), mp: melting point (° C.).

Me: methyl, Et: ethyl, nPr: normal propyl, iPr: isopropyl, nBu: normal butyl, iBu: isobutyl, t-Bu: tert-butyl, cPr: cyclopropyl, cBu: cyclobutyl, cPen: cyclopentyl, cHex: cyclohexyl, Bz: benzyl, Boc: t-butoxycarbonyl, MeOH: methanol, EtOH: ethanol, EtOAc: ethyl acetate, HEX: n-hexane, DMF: N,N-dimethylformamide, TFA: trifluoroacetic acid, THF: tetrahydrofuran, DPPA: diphenylphosphorylazide, HOBt: 1-hydroxybenzotriazole.

HCl in the structural formula indicates that the Example compound is isolated as a hydrochloride. Further, a case where the structural formula of fumaric acid is described together in the structural formula indicates that the Example compound is isolated as fumarate. Also, a case where the structural formula of oxalic acid is described together in the structural formula indicates that the Example compound is isolated as an oxalate. In addition, a case where the structural formula of succinic acid is described together in the structural formula indicates that the Example compound is isolated as a succinate.

Furthermore, in the case where a numeral is prefixed to HCl, the numeral means a molar ratio of the compound to hydrochloric acid. For example, 2HCl represents dihydrochloride. Further, in the Example Compounds in which the structural formula of fumaric acid is described together in the structural formula, “M” described under the Example No. indicates that the Example Compound is isolated as monofumarate, “H” described as such indicates that the Example Compound is isolated as hemifumarate, and “S” described as such indicates that the Example Compound is isolated as sesquifumarate. Also, “T” of Example 267 indicates that the compound is isolated as 0.75 fumarate. Further, description of these “M”, “H”, and “S” has the same meanings in the Example Compound in which the structural formula of oxalic acid is described together in the structural formula and the Example Compound in which where the structural formula of succinic acid is described together in the structural formula.

Furthermore, for the sake of convenience, a concentration mol/l is expressed as M. For example, a 1 M aqueous sodium hydroxide solution means a 1 mol/l aqueous sodium hydroxide solution.

Preparation Example 1

To a solution of 27.11 g of 3-chloro-o-xylene in 300 ml of carbon tetrachloride were added 75 g of N-bromosuccinimide and 0.81 g of azaisobutyronitrile, followed by heating and refluxing for 2 hours. The reaction mixture was washed with water and saturated sodium hydrogen carbonate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 63.297 g of 1,2-bis(bromomethyl)-3-chlorobenzene as a reddish orange oily substance.

Preparation Example 2

To a solution of 9.5 g of sodium cyanide in 120 ml of water was added a solution of 57.533 g of 1,2-bis(bromomethyl)-3-chlorobenzene in 120 ml of EtOH, followed by heating and refluxing for 30 minutes. The reaction mixture was poured into ice, followed by stirring, and the precipitated solid was collected by filtration to obtain 32.941 g of 2,2′-(3-chloro-1,2-phenylene)diacetonitrile as a yellowish brown solid.

Preparation Example 3

To a suspension of 32.94 g of 2,2′-(3-chloro-1,2-phenylene)diacetonitrile in 100 ml of acetic acid was added dropwise 100 ml of a 33% hydrogen bromide-acetic acid solution over 1.5 hours while keeping the inner temperature at 20° C. or lower. The reaction mixture was stirred at room temperature for 3 hours, and then to the reaction mixture were added diethylether and acetone. The resulting candy-like dark brown solid substance and the suspension were separated, the suspension was concentrated under reduced pressure, and the candy-like substance was pulverized in acetone to obtain a suspension. The concentrated residue and the acetone suspension were combined and concentrated under reduced pressure, and to the residue was added EtOAc, followed by stirring. The solid was collected by filtration. The resulting solid was suspended in 400 ml of water which had been heated to 80° C., and 31.2 g of sodium acetate was added thereto, followed by stirring at 90° C. for 3 hours. The reaction mixture was cooled to room temperature and then the solid was collected by filtration to obtain 22.506 g of 6-chloro-1H-3-benzazepine-2,4(3H,5H)-dione as a brown solid.

Preparation Example 4

To a solution of 22.5 g of 6-chloro-1H-3-benzazepine-2,4(3H,5H)-dione in 200 ml of THF were added dropwise 38 ml of a 10 M borane-dimethyl sulfide complex at 0° C. for 20 minutes, followed by stirring for 2.5 hours. The reaction mixture was heated and refluxed, and further stirred. To the reaction mixture was added dropwise 30 ml of MeOH under ice-cooling, followed by stirring, and then 30 ml of 4 M hydrochloric acid was added dropwise thereto, followed by heating and refluxing for 1 hour after generation of bubbles substantially settled. The mixture was alkalified by the addition of aqueous ammonia and a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered. The filtrate was concentrated under reduced pressure, the residue was dissolved in EtOH, and activated carbon was added thereto, followed by heating and refluxing, and then filtering on amino silica gel, and the filtrate was concentrated under reduced pressure. To a solution of 18.7 g of the resulting residue in 180 ml of dichloromethane was added 17 ml of pyridine, followed by ice-cooling, and 13 ml of ethyl chlorocarbonate was added dropwise thereto, followed by stirring for 1.5 hours. The reaction mixture was concentrated under reduced pressure, the residue was diluted with EtOAc, then washed with 1 M hydrochloric acid and water, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 9.653 g of ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish brown oily substance.

Preparation Example 5

A solution of 11.86 g of ethyl 6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 30 ml of chloroform was ice-cooled, and while maintaining the inner temperature at 10° C. or lower, 60 ml of concentrated hydrochloric acid was added thereto. Then, 32 ml of concentrated nitric acid was added dropwise thereto, followed by stirring for 30 minutes. The reaction mixture was poured into ice, followed by extraction with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 6.442 g of ethyl 6-chloro-7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish orange viscous substance and 5.201 g of ethyl 6-chloro-9-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow solid.

Preparation Example 6

To 6.431 g of ethyl 6-chloro-7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was added 120 ml of EtOH, followed by stirring at 60° C. for dissolution, and 12.15 g of reduced iron and 60 ml of 1 M hydrochloric acid were added thereto, followed by heating and refluxing for 1 hour. The reaction mixture was alkalified by the addition of a 1 M aqueous sodium hydroxide solution and then filtered through celite, and then the organic solvent was evaporated under reduced pressure. The residue was extracted with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 5.743 g of ethyl 7-amino-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a reddish orange viscous substance.

Preparation Example 7

To a solution of 5.74 g of ethyl 7-amino-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 100 ml of dichloromethane was added portionwise 3.9 g of N-bromosuccinimide under ice-cooling, followed by stirring for 40 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 5.769 g of ethyl 7-amino-8-bromo-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a brown solid.

Preparation Example 8

To a solution of 4.37 g of ethyl 7-amino-8-bromo-6-chloro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 40 ml of DMF were added 2.1 ml of ethyl acrylate, 230 mg of tris-o-tolylphosphine, 85 mg of palladium(II) acetate, and 3.6 ml of triethylamine, followed by stirring at 120° C. for 3 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The resulting yellow solid was stirred and washed in diisopropylether to obtain 3.125 g of ethyl 7-amino-6-chloro-8-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow solid.

Preparation Example 9

To a solution of 2.12 g of ethyl 7-amino-6-chloro-8-[(1E)-3-ethoxy-3-oxoprop-1-en-1-yl]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 20 ml of chloroform and 20 ml of MeOH was added 65 mg of platinum(IV) oxide, followed by stirring for 20 hours at 1 atm under a hydrogen atmosphere. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 2.256 g of ethyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a milky white solid.

Preparation Example 10

To a suspension of 1.403 g of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one in 15 ml of dioxane were added 12 ml of triethylamine and 1.5 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 2 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.779 g of t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a milky white solid.

Preparation Example 11

To a solution of 1.772 g of t-butyl 11-chloro-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 10 ml of THF was added 10.1 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by elevating to room temperature and stirring for 3 hours. To the reaction mixture was added dropwise 10 ml of EtOH, and subsequently 10 ml of a 1 M aqueous sodium hydroxide solution was added dropwise thereto, followed by stirring. The mixed solution was diluted with water, followed by extraction with EtOAc. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 2.0707 g of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.

Preparation Example 12

To a solution of 205 mg of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 3 ml of acetonitrile were added 0.077 ml of 36% formalin, 58 mg of sodium cyanoborohydride, and 0.5 ml of acetic acid, followed by stirring at room temperature. To the reaction mixture was added water, followed by extraction with EtOAc, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 96 mg of t-butyl 11-chloro-1-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as an orange viscous substance.

Preparation Example 13

To a solution of 193 mg of t-butyl 11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of toluene was added 0.121 ml of isobutyric chloride, followed by stirring at 60° C. The reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 80 mg of t-butyl 1-acetyl-11-chloro-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless solid.

Preparation Example 14

To a solution of 1.75 g of 2,3,4,5-tetrahydro-1H-3-benzazepine in 20 ml of dichloromethane was added 2.884 ml of pyridine. The reaction mixture was ice-cooled, and 1.705 ml of ethyl chloroformate which had been dissolved in 5 ml of dichloromethane was added dropwise thereto, followed by stirring overnight. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 2.15 g of ethyl 1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a pale yellow oily substance.

Preparation Example 15

287 mg of ethyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was dissolved in 5 ml of DMF, and 65 mg of 60% sodium hydride was added thereto in an ice-bath, followed by stirring for 1 hour. 0.3 ml of methyl iodide was added thereto, followed by stirring at room temperature for 3 hours. Then, a saturated aqueous sodium hydrogen carbonate solution was added thereto, followed by extraction with chloroform. The solvent was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 94 mg of ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless solid.

Preparation Example 16

To 5 g of ethyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 40 ml of ethylene glycol and 28 ml of a 4 M aqueous sodium hydroxide solution, followed by stirring at 150° C. After stirring overnight, the reaction mixture was ice-cooled, then acidified by the addition of concentrated hydrochloric acid, and stirred at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, and then the residue was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The solvent was concentrated under reduced pressure and then the resulting dark brown residue was dissolved in dichloromethane, followed by addition of 4 g of di-t-butyl dicarbonate and 3.5 ml of triethylamine. The reaction mixture was stirred at room temperature overnight and concentrated under reduced pressure, and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH) to obtain 3.39 g of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.

Preparation Example 17

To a solution of 250 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2.5 ml of dichloroethane were added 0.175 ml of isobutyryl chloride and 0.4 ml of triethylamine, followed by elevating the temperature to 60° C. and stirring for 30 minutes. The reaction mixture was diluted with EtOAc and washed with 1 M hydrochloric acid, water, a 1 M aqueous sodium hydroxide solution, and saturated brine, and the solvent was concentrated. To the resulting residue was added 2 ml of THF and 3.5 ml of a 1 M solution of a borane-THF complex in THF was added thereto in an ice-bath, followed by stirring at room temperature overnight. The reaction mixture was ice-cooled, and EtOH was added thereto, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 213 mg of t-butyl 1-isobutyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.

Preparation Example 18

To a solution of 460 mg of t-butyl 11-bromo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 9 ml of dioxane were added 1.6 ml of a 2 M aqueous potassium carbonate solution under an argon atmosphere, and subsequently 449 mg of trimethylboroxine and 70 mg of tetrakistriphenylphosphine palladium, followed by stirring at 90° C. for 13 hours. The reaction mixture was allowed to cool, filtered, and then concentrated under reduced pressure, the resulting residue was diluted with EtOAc, and the organic layer was washed with water and saturated brine. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 380 mg of t-butyl 11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.

Preparation Example 19

To a solution of 670 mg of t-butyl 11-isopropenyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 10 ml of MeOH was added 200 mg of palladium on carbon, followed by stirring at room temperature for 3.5 hours at normal pressure under a hydrogen atmosphere. Further, after stirring overnight at 4.5 atm under a hydrogen atmosphere, the reaction mixture was filtered through celite, and the solvent was evaporated under reduced pressure. The resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 512 mg of t-butyl 11-isopropyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.

Preparation Example 20

To a solution of 140 mg of t-butyl 11-ethyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 1.86 ml of acetonitrile was added 0.12 ml of glycidylmethylether, followed by substitution with argon. In an ice-bath, 9 mg of ytterbium(III) trifluoromethanesulfonate was added thereto, followed by stirring at room temperature for 2 hours, then elevating the temperature to 50° C., and stirring overnight. To the reaction mixture were added EtOAc and aqueous sodium bicarbonate, and the organic layer was washed with water and saturated brine. The solvent was evaporated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 147 mg of t-butyl 11-ethyl-1-(2-hydroxy-3-methoxypropyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.

Preparation Example 21

To a solution of 215 mg of t-butyl 7-hydroxy-8-(tetrahydro-2H-pyran-4-ylamino)-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 4 ml of DMF were added 98 mg of potassium carbonate and 0.062 ml of methyl bromoacetate, followed by stirring at room temperature for 6 hours. To the reaction mixture was added water, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine three times, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. To a solution of 259 mg of the resulting residue in 7 ml of EtOH was added 1.2 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at 50° C. overnight. Further, 1.2 ml of a 1 M aqueous hydrochloric acid solution was added thereto under ice-cooling, followed by extraction with chloroform twice, and the combined organic layer was dried over anhydrous sodium sulfate and then filtered. The solvent was evaporated under reduced pressure. To a solution of 239 mg of the resulting residue in 4 ml of DMF were added 120 mg of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride and 84 mg of HOBt at room temperature, followed by stirring at room temperature overnight. Water was added thereto, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 153 mg of t-butyl 3-oxo-4-(tetrahydro-2H-pyran-4-yl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white solid.

Preparation Example 22

To a solution of 828 mg of t-butyl 7-hydroxy-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 25 ml of DMF were added 0.268 ml of methyl bromoacetate and 390 mg of potassium carbonate, followed by stirring at 55° C. for 13 hours. The reaction mixture was allowed to cool, and water added, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.076 g of t-butyl 7-(2-methoxy-2-oxoethoxy)-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a yellowish white solid.

Preparation Example 23

To a mixture of 967 mg of t-butyl 7-(2-methoxy-2-oxoethoxy)-6-methyl-8-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 25 ml of EtOH was added 97 mg of 10% palladium on carbon under an argon atmosphere, followed by stirring for 2 hours at normal pressure under a hydrogen atmosphere. To the reaction mixture was added 200 ml of THF, then the catalyst was removed using celite, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 629 mg of t-butyl 11-methyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white solid.

Preparation Example 24

To a solution of 120 mg of t-butyl 2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of DMF were added 0.026 ml of methyl iodide and 104 mg of potassium carbonate at room temperature, followed by stirring for 13 hours. To the reaction mixture were added 0.012 ml of methyl iodide and 26 mg of potassium carbonate, followed by further stirring for 3 hours. To the reaction mixture was added water, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 55 mg of t-butyl 2,4-dimethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a brown solid.

Preparation Example 25

To a solution of 120 mg of t-butyl 2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of DMF were added 0.113 ml of isopropyl iodide and 0.197 ml of diisopropylethylamine, followed by stirring at 100° C. for 6.5 hours. Further, to the reaction mixture were added 0.113 ml of isopropyl iodide and 0.197 ml of diisopropylethylamine, followed by stirring at 100° C. for 4 hours. Further, to the reaction mixture were added 0.226 ml of isopropyl iodide and 0.394 ml of diisopropylethylamine, followed by stirring at 100° C. for 19 hours. The reaction mixture was cooled to room temperature, and water added, followed by extraction with EtOAc twice. The combined organic layer was washed with saturated brine, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 90 mg of t-butyl 4-isopropyl-2-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a pale brown solid.

Preparation Example 26

To a solution of 130 mg of t-butyl 3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 4 ml of dichloromethane were added 0.036 ml of methanesulfonyl chloride and 0.089 ml of diisopropylethylamine under ice-cooling, followed by stirring at room temperature for 16 hours. To the reaction mixture were added 0.036 ml of methanesulfonyl chloride and 0.089 ml of diisopropylethylamine, followed by stirring at room temperature for additional 9 hours. To the reaction mixture was added water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the solvent was evaporated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 152 mg of t-butyl 4-(methylsulfonyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a colorless solid.

Preparation Example 27

To a mixture of 5 g of sodium borohydride and 30 ml of anhydrous THF was added a solution of 10.27 g of 2-methyl-3-nitrophenylacetic acid in 60 ml of anhydrous THF under ice-cooling, and then a solution of 35 ml of methanesulfonic acid in 10 ml of anhydrous THF was added dropwise thereto. The reaction mixture was heated to 70° C. and then stirred for 30 minutes, and 80 ml of 3 M hydrochloric acid was then added thereto under ice-cooling, followed by stirring. The mixed liquid was extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 9.701 g of an orange viscous substance. To a solution of 9.53 g of the resulting substance in 100 ml of dichloromethane were added dropwise 22 ml of diisopropylethylamine and 4.75 ml of chloromethylmethylether under ice-cooling, followed by stirring for 24 hours. 10 ml of chloromethylmethylether was added thereto, followed by further stirring for 24 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 11.26 g of a yellow oily substance. To a solution of 11.26 g of the resulting substance in 200 ml of EtOH was added 340 mg of platinum(IV) dioxide, followed by stirring at room temperature for 1 hour under a hydrogen atmosphere of 4 atm. The reaction mixture was removed using celite and the filtrate was concentrated under reduced pressure to obtain 9.21 g of an orange viscous substance. To a solution of the residue in 200 ml of dichloromethane and 40 ml of MeOH were added 14.2 g of calcium carbonate and 36.5 g of benzyl trimethylammonium dichloroiodate, followed by stirring at room temperature for 13 hours. The insoluble materials were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 15.93 g of 4,6-diiodo-3-[2-(methoxymethoxy)ethyl]-2-methylaniline as a dark red viscous substance.

Preparation Example 28

To a mixed liquid of 400 mg of palladium(II) acetate, 934 mg of triphenylphosphine, 9.91 g of tetrabutylammonium chloride, and 7 g of potassium acetate in 150 ml of DMF was added a solution of 15.93 g of 4,6-diiodo-3-[2-(methoxymethoxy)ethyl]-2-methylaniline in 150 ml of DMF, and 16 ml of ethyl acrylate was added thereto, followed by stirring at 80° C. for 3 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 12.11 g of a yellow solid. To a solution of 12.11 g of the resulting substance in 250 ml of EtOH and 250 ml of THF was added 701 mg of platinum(IV) oxide, followed by stirring at room temperature for 4 hours under a hydrogen atmosphere of 4 atm. The reaction mixture was removed using celite and the filtrate was concentrated under reduced pressure to obtain 11.39 g of ethyl 3-{7-[2-(methoxymethoxy)ethyl]-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}pronanoate as a milky white solid.

Preparation Example 29

To a solution of 10.81 g of ethyl 3-{7-[2-(methoxymethoxy)ethyl]-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}pronanoate in 100 ml of EtOH and 100 ml of THF was added 100 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 1 hour. The reaction mixture was neutralized by the addition of hydrochloric acid and then concentrated under reduced pressure to one third of the liquid amount, and the residue was extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To a solution of the resulting residue in 300 ml of t-butanol were added 90 ml of triethylamine and 70 ml of DPPA, followed by heating and refluxing for 24 hours. The reaction mixture was concentrated under reduced pressure, the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and then the resulting solid was washed with HEX to obtain 8.006 g of t-butyl (2-{7-[2-(methoxymethoxy)ethyl]-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}ethyl)carbamate as a milky white solid.

Preparation Example 30

To a suspension of 1.01 g of t-butyl (2-{7-[2-(methoxymethoxy)ethyl]-8-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl}ethyl)carbamate in 10 ml of THF was added 10 ml of 6 M hydrochloric acid, followed by stirring at 50° C. for 1 hour. The reaction mixture was alkalified by the addition of sodium hydroxide and then 675 mg of di-t-butyl dicarbonate was added thereto, followed by stirring at room temperature for 15 hours. The reaction mixture was extracted with chloroform, and the organic layer was dried over anhydrous magnesium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 1.105 g of t-butyl {2-[7-(2-hydroxyethyl)-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]ethyl}carbamate as a white foamed substance.

Preparation Example 31

To a solution of 1.793 g of t-butyl {2-[7-(2-hydroxyethyl)-6-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl]ethyl}carbamate in 30 ml of THF were added 0.48 ml of methanesulfonyl chloride and 15 ml of triethylamine under ice-cooling, followed by stirring for 30 minutes. To the reaction mixture was added portionwise 1.8 g of potassium t-butoxide under ice-cooling, followed by stirring for 1.5 hours. To the reaction mixture was added a saturated aqueous ammonium chloride solution, followed by extraction with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 1.06 g of t-butyl 11-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white foamed substance.

Preparation Example 32

To a solution of 167 mg of t-butyl 11-methyl-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of dichloromethane were added 0.221 ml of triethylamine and 0.062 ml of ethyl isocyanate, followed by stirring at room temperature for 15 hours. To the reaction mixture were added 3 ml of toluene and 0.062 ml of ethyl isocyanate, followed by heating to 60° C. and stirring for 15 hours. Then, the reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 200 mg of t-butyl 1-(ethylcarbamoyl)-11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.

Preparation Example 33

To a solution of 201 mg of t-butyl 11-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of pyridine was added 0.1 ml of ethyl chloroformate, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 261 mg of 8-t-butyl 1-ethyl 11-methyl-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-dicarboxylate as a colorless viscous substance.

Preparation Example 34

To a suspension of 2 g of 3-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propionic acid in 40 ml of t-butanol were added 2.1 ml of DPPA and 2.6 ml of triethylamine, followed by heating and refluxing at 100° C. for 18 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH) to obtain 1.832 g of t-butyl[2-(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as an orange solid.

Preparation Example 35

To a mixed solution of 770 mg of t-butyl[2-(1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate in 15 ml of dichloromethane and 3 ml of MeOH were added 420 mg of calcium carbonate and 970 mg of benzyltrimethylammonium dichloroiodate, followed by stirring at room temperature for 2 hours. The insoluble materials were removed by filtration and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 595 mg of t-butyl[2-(6-iodo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a reddish brown viscous substance.

Preparation Example 36

To a solution of 595 mg of t-butyl[2-(6-iodo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate in 3 ml of dichloromethane were added 3 ml of water and 376 mg of sodium hydrogen carbonate, and a solution of 0.273 ml of benzyl chloroformate in 3 ml of dichloromethane wad added dropwise under ice-cooling while stirring, followed by stirring for additional 5 hours. The reaction mixture was extracted with EtOAc, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 877 mg of benzyl 7-{2-[(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate as a reddish orange solid.

Preparation Example 37

To a solution of 793 mg of benzyl 7-{2-[(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate in 10 ml of THF was added dropwise 1.8 ml of a 1 M solution of sodium bistrimethylsilylamide in THF under ice-cooling, followed by stirring for 5 minutes. Then, 0.166 ml of allyl bromide was added thereto, followed by stirring for 18 hours while slowly elevating the temperature to room temperature. To the reaction mixture were added a saturated aqueous ammonium chloride solution and water, followed by extraction with EtOAc, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 788 mg of benzyl 7-{2-[alkyl(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate.

Preparation Example 38

To a mixture of 403 mg of potassium acetate, 441 mg of tetrabutylammonium bromide, 9 mg of triphenylphosphine, and 4 mg of palladium(II) acetate was added a solution of 788 mg of benzyl 7-{2-[allyl(t-butoxycarbonyl)amino]ethyl}-6-iodo-3,4-dihydroquirolin-1(2H)-carboxylate in 25 ml of DMF, followed by substitution with argon and stirring at 80° C. for 4 hours. The reaction mixture was diluted with EtOAc, washed with water and saturated brine, and concentrated under reduced pressure. To 25 ml of a solution of the resulting residue in MeOH was added 36 mg of platinum(IV) oxide, followed by stirring at room temperature overnight under a hydrogen atmosphere of 4 atm. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure to obtain 570 mg of 1-benzyl 8-t-butyl 6-methyl-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-dicarboxylate as an orange foamed substance.

Preparation Example 39

To a mixed liquid of 9.3 g of aluminum chloride in 30 ml of dichloromethane was added dropwise 1.6 ml of acetyl chloride under ice-cooling, followed by stirring. Then, a solution of 5 g of 7-methoxy-1-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine in 70 ml of dichloromethane was added thereto, followed by stirring for 13 hours while slowly elevating the temperature to room temperature. The reaction mixture was ice-cooled, and 30 ml of 1 M hydrochloric acid was added dropwise thereto, followed by addition of water and extraction with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by flash chromatography (elution solvent: HEX-EtOAc) to obtain 5.137 g of 1-[8-hydroxy-5-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]ethanone as a pale brown solid.

Preparation Example 40

To a suspension of 5.13 g of 1-[8-hydroxy-5-methyl-3-(trifluoroacetyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]ethanone in 50 ml of MeOH was added 50 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure to a half of the amount, and to the residue were added 50 ml of dioxane and 4.27 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 30 minutes. The reaction mixture was neutralized by the addition of 1 M hydrochloric acid and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 4.385 g of t-butyl 8-acetyl-7-hydroxy-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a yellow viscous substance.

Preparation Example 41

To a solution of 1.715 g of t-butyl 8-acetyl-7-(2-ethoxy-2-oxoethoxy)-1-methyl-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 20 ml of EtOH was added 325 mg of hydroxylamine hydrochloride, followed by heating and refluxing for 3 hours. 500 mg of hydroxylamine hydrochloride was added thereto, followed by further heating and refluxing for 2 hours. The reaction mixture was concentrated under reduced pressure, and to the residue was added water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To 10 ml of a solution of the resulting residue in acetonitrile were added 24 mg of cyanuric chloride and 33 mg of zinc(II) chloride, followed by heating and refluxing for 12 hours. The reaction mixture was concentrated under reduced pressure. To the resulting residue were added 10 ml of dioxane, 10 ml of a 1 M aqueous sodium hydroxide solution and 1.2 g of di-t-butyl dicarbonate, followed by stirring at room temperature for 24 hours. The reaction mixture was concentrated under reduced pressure to a half of the amount, made weakly acidic by the addition of 1 M hydrochloric acid, and extracted with chloroform. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. To the resulting residue was added 60 ml of a 17% aqueous sulfuric acid solution, followed by stirring at 100° C. for 1 hour. The reaction mixture was ice-cooled and alkalified by the addition of 15 g of sodium hydroxide, and 50 ml of dioxane and 1.21 g of di-t-butyl dicarbonate were added thereto, followed by stirring at room temperature for 3 hours. The reaction mixture was diluted with water and extracted with EtOAc. The organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 735 mg of t-butyl 6-methyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a pale yellow solid.

Preparation Example 42

To a solution of 704 mg of t-butyl 6-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate in 15 ml of dichloromethane was added portionwise 438 mg of N-bromosuccinimide under ice-cooling, followed by stirring for 30 minutes. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 446 mg of a pale yellow foamed substance. To a mixture of 445 mg of the resulting compound, 144 mg of cyclopropylboric acid, 724 mg of potassium phosphate, 65 mg of tricyclohexylphosphine, and 28 mg of palladium(II) acetate were added 10 ml of toluene and 0.5 ml of water, followed by stirring at 110° C. for 12 hours. The reaction mixture was filtered through celite and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 379 mg of t-butyl 5-cyclopropyl-6-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a pale brown foamed substance.

Preparation Example 334

To a solution of 500 mg of t-butyl 3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 10 ml of DMF were added 250 μl of 1-(bromomethyl)-3-fluorobenzoate and 800 mg of cesium carbonate, followed by stirring at 50° C. for 16 hours under an argon atmosphere. The reaction mixture was cooled to room temperature, and water added, followed by extraction with ethyl acetate twice. The combined organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. The solvent was evaporated and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 609 mg of t-butyl 4-(3-fluorobenzyl)-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate.

Preparation Example 339

To a solution of 600 mg of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 9 ml DMF were added 426 mg of potassium t-butoxide and 451 μl of benzyl bromide in an ice-bath, followed by stirring at room temperature for 3 hours. Water and ethyl acetate were added thereto, and the organic layer was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 644 mg of t-butyl 1-benzyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a pale yellow solid.

Preparation Example 344

To a solution of 3.83 g of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 40 ml of dichloromethane were added 1.3 ml of pyridine and 1.29 g of triphosgene under ice-cooling, followed by stirring for 3 hours. The reaction mixture was concentrated under reduced pressure, diluted with ethyl acetate, washed with water and an aqueous ammonium chloride solution, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. To the residue was added hexane, followed by stirring, and the solid was collected by filtration and dried to obtain 3.07 g of t-butyl 1-(chlorocarbonyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white solid.

Preparation Example 345

To a solution of 200 mg of t-butyl 1-(chlorocarbonyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of pyridine was added 140 μl of phenethyl alcohol, followed by stirring at 100° C. for 5.5 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 68 mg of 8-t-butyl 1-(2-phenylethyl) 3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-carboxylate as a yellow viscous substance.

Preparation Example 349

To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate and 318 mg of 2-(2-methoxyphenyl)ethyl 4-nitrophenylcarbonate in 5 ml of dichloroethane was added 0.11 ml of pyridine, followed by stirring at room temperature for 2 days. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) and basic silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 243 mg of 8-t-butyl 1-[2-(methoxyphenyl)ethyl]-3,4,6,7,9,10-hexahydro-1H-azepino[4,5-g]quinoline-1,8(2H)-carboxylate as a pale yellow viscous substance.

Preparation Example 367

To a solution of 150 mg of t-butyl 11-chloro-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 3 ml of tetrahydrofuran was added 1.5 ml of a 1 M aqueous sodium hydrogen carbonate solution, followed by ice-cooling, and 64 μl of ethyl chloroformate was added dropwise thereto followed by stirring. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 149 mg of 8-t-butyl 4-ethyl-11-chloro-2,3,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-4,8-dicarboxylate as a colorless foamed substance.

Preparation Example 375

To 500 mg of t-butyl 11-bromo-1-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate, 350 mg of potassium carbonate, 290 mg of copper iodide, 173 mg of 1H-pyrazole, and 313 mg of N,N-dimethylglycine was added 6.25 ml of dimethylsulfoxide under argon, followed by stirring at 135° C. for 36 hours. To the reaction mixture were added water and ethyl acetate, followed by stirring, and then the solid was separated by filtration. The organic layer was washed with aqueous sodium bicarbonate and concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 43 mg of t-butyl 1-methyl-11-(1H-pyrazol-1-yl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous liquid.

Preparation Example 376

A solution of 200 mg of t-butyl 11-bromo-1-(2-methoxyethyl)1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate, 34 mg of zinc cyanide, 13 mg of bis(tri-t-butylphosphine)palladium, and 10 mg of zinc powder in 4 ml of DMF was substituted with argon and then stirred at 100° C. for 15 hours. The reaction mixture was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 132 mg of t-butyl 11-cyano-1-(2-methoxyethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless viscous substance.

Preparation Example 377

1.1946 g of 1-[11-bromo-1-(2-methoxyethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-yl]-2,2,2-trifluoroethanone, 2.2395 g of sodium trifluoroacetate, and 1.568 g of copper iodide were added to 24 ml of N-methylpyrrolidone under an argon atmosphere, followed by stirring at 170° C. for 18 hours. To the reaction mixture were added water and ethyl acetate, and filtered through celite was performed. The filtrate was subjected to liquid separation, the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 239 mg of 2,2,2-trifluoro-1-[1-(2-methoxyethyl)-11-(trifluoromethyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-yl]ethanone as a pale yellow solid.

Preparation Example 379

To 7.87 g of 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoic acid were added 25 ml of t-butanol, 1.1 ml of triethylamine, and 0.83 ml of diphenylphosphoryl azide, followed by heating and refluxing for 70 hours. The reaction mixture was cooled to room temperature, then diluted by the addition of water, and stirred, and the solid was collected by filtration and dried to obtain 1.40 g of t-butyl[2-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a pale brown solid. Further, the solid precipitated from the filtrate was collected by filtration to obtain 665 mg of t-butyl[2-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)ethyl]carbamate as a white solid.

Preparation Example 380

168 mg of t-butyl 1-[(benzyloxy)methyl]-6-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was stirred at room temperature for 3.5 hours in a 48% aqueous hydrobromic acid solution. The reaction mixture was extracted with hexane and a side-product, benzyl bromide, was removed. Then, the aqueous layer was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, and 20 ml of tetrahydrofuran was added thereto. To the mixed liquid was added 500 mg of di-t-butyl dicarbonate, followed by stirring at room temperature for 2 hours. The reaction mixture was extracted with ethyl acetate and the organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered. The filtrate was concentrated under reduced pressure to obtain 513 mg of t-butyl 6-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a colorless foamed substance.

Preparation Example 381

Under an argon atmosphere, to a solution of 1.7 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 30 ml of DMF was added 283 mg of sodium hydride under ice-cooling, followed by stirring at the same temperature for 10 minutes. Then, 1.54 g of t-butyl (4R)-4-methyl-1,2,3-oxathiazolidine-3-carboxylate was added thereto, followed by stirring at room temperature for 18 hours. To the reaction was added water and 1 M aqueous hydrochloric acid sequentially, followed by stirring, and the precipitated solid was collected by filtration. To 20 ml of a suspension of the resulting solid in ethanol was added 10 ml of a 4 M hydrochloric acid-ethyl acetate solution under ice-cooling, followed by stirring at 60° C. for 1 hour. The reaction mixture was evaporated under reduced pressure, and to the residue were added chloroform and saturated aqueous sodium bicarbonate. After extraction with chloroform, the combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, filtered, and concentrated under reduced pressure to obtain 2.26 g of ethyl 7-{[(2R)-2-aminopropyl]oxy}-8-bromo-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as an opaque cream-colored oily substance.

Preparation Example 383

Under an argon atmosphere, to a solution of 1.64 g of ethyl 7-{[(2R)-2-aminopropyl]oxy}-8-bromo-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 41 ml of toluene were added 509 mg of sodium t-butoxide, 275 mg of 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and 202 mg of tris(dibenzylideneacetone)dipalladium (0) in this order, followed by heating at 100° C. for 24 hours. Further, 509 mg of sodium t-butoxide, 275 mg of 2,2′-bis(diphenylphosphino)-1,1′-binaphthyl, and 202 mg of tris(dibenzylideneacetone)dipalladium (0) were added thereto, followed by stirring at 100° C. for additional 24 hours. The reaction mixture was returned to room temperature, then filtered through celite, and washed with ethyl acetate, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 610 mg of ethyl (3R)-3-methyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.

Preparation Example 385

Under an argon atmosphere, to a solution of 1.032 g of ethyl 7-[(3-methylbut-2-enoyl)amino]-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 10.5 ml of dichloromethane was added 870 mg of aluminum chloride at room temperature, followed by stirring at room temperature for 3 hours. Further, 435 mg of aluminum chloride was added thereto, followed by stirring at room temperature for 2 hours. The reaction mixture was poured into ice-water, followed by extraction with chloroform. The combined organic layer was washed with water, a saturated aqueous sodium hydrogen carbonate solution, water, and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: Hex-AcOEt) to obtain 431 mg of ethyl 4,4-dimethyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate as a white solid.

Preparation Example 386

Under an argon atmosphere, to a solution of 1 g of ethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate and 539 mg of 1,1-dimethylprop-2-in-1-yl acetate in 10 ml of tetrahydrofuran was added 43 mg of copper chloride, followed by heating at 90° C. for 5 hours. The reaction mixture was concentrated under reduced pressure, ethyl acetate added, and washed with a saturated aqueous ammonium chloride solution, and saturated brine. The aqueous layer was extracted with ethyl acetate twice, the combined organic layer was washed with saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography to obtain 272 mg of ethyl 2,2-dimethyl-1,2,6,7,9,10-hexahydro-8H-azepine[4,5-g]quinoline-8-carboxylate.

Preparation Example 387

To ethyl 7-amino-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate was added a 5% aqueous sulfuric acid solution, followed by stirring under ice-cooling. An aqueous solution (30 ml) of 10.22 g of sodium nitrite was added dropwise in portions thereto, and followed by stirring at the same temperature for 0.5 hours and then stirring at 60° C. for 3 hours. The reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain a crude purified product having ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a main component. The crude purified product was recrystallized from ethyl acetate twice to obtain 15.66 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate.

Preparation Example 388

To a solution of 30 g of ethyl 7-nitro-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 300 ml of ethanol was added 3 g of 10% palladium on carbon, followed by stirring at room temperature for 16 hours under a hydrogen atmosphere of 4 atm. The reaction mixture was filtered through celite, and the filtrate was ice-cooled and then 21.6 ml of anhydrous acetic acid was added dropwise thereto, followed by stirring for 16 hours. The reaction mixture was concentrated under reduced pressure and to the residue was added diethylether to wash the solid, thereby obtaining 26.45 g of ethyl 7-acetamide-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a white solid.

Preparation Example 389

The mixed liquid of 12 g of ethyl 7-acetamide-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate, 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline, and 33.12 g of cesium carbonate in 240 ml of dioxane was substituted with argon, followed by stirring at 100° C. for 18 hours. The reaction mixture was diluted with ethyl acetate, the insoluble materials were removed using celite, and the filtrate was concentrated under reduced pressure to obtain a milky white solid. The resulting residue was suspended in 240 ml of dioxane, and 1.93 g of copper iodide, 1.89 g of 1,10-phenanthroline, and 33.1 g of cesium carbonate were added thereto, followed by stirring at 100° C. for 3 days. The reaction mixture was cooled to room temperature, diluted with ethyl acetate, and filtered through celite to remove the solid, and the filtrate was concentrated under reduced pressure to obtain 9.245 g of ethyl 2-methyl-5,6,8,9-tetrahydro-7H-[1,3]oxazolo[4,5-h][3]benzazepine-7-carboxylate as a milky white solid.

Preparation Example 390

To a solution of 7 g of ethyl 2-methyl-5,6,8,9-tetrahydro-7H-[1,3]oxazolo[4,5-h][3]benzazepine-7-carboxylate in 130 ml of ethanol was added 130 ml of 1 M aqueous hydrochloric acid, followed by stirring for 16 hours. Ethanol was evaporated under reduced pressure, dried, dissolved in chloroform, and washed with water. The organic layer was dried over anhydrous sodium sulfate and then the solvent was evaporated under reduced pressure to obtain 6.84 g of ethyl 7-acetamide-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a brownish white solid.

Preparation Example 408

To a solution of 860 mg of t-butyl 4-ethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 25 ml of dichloromethane was added 1.1 g of sodium hydrogen carbonate, and further, a solution of 200 μl of bromine in 5 ml of dichloromethane was added dropwise thereto over about 30 minutes, followed by stirring at room temperature. To the reaction mixture was slowly added a 3% aqueous sodium thiosulfate solution, followed by stirring vigorously and extracting with chloroform twice. The combined organic layer was washed with saturated brine and then dried over anhydrous sodium sulfate. The solvent was evaporated and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 490 mg of t-butyl 5-bromo-4-ethyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate.

Preparation Example 409

Under an argon atmosphere, to a mixed solution of 5.0 g of ethyl 7-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate in 100 ml of dichloromethane and 20 ml of methanol was added portionwise 8.05 g of N,N,N-trimethylanilinium tribromide under ice-cooling, followed by stirring at the same temperature for 1 hour. The reaction mixture was concentrated under reduced pressure, the residue was extracted by the addition of ethyl acetate and water, and the organic layer was washed with 1 N aqueous hydrochloric acid and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure to obtain 6.67 g of ethyl 7-bromo-8-hydroxy-1,2,4,5-tetrahydro-3H-3-benzazepine-3-carboxylate as a beige solid.

Preparation Example 411

To a solution of t-butyl 1-(3-methoxypropyl)-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 4.2 ml of acetonitrile were added 107 mg of N-bromosuccinimide and 3.7 mg of ammonium nitrate, followed by stirring at room temperature for 3.5 hours. The reaction mixture was concentrated to about ¼, and ethyl acetate, an aqueous sodium thiosulfate solution, and aqueous sodium bicarbonate was added thereto. The organic layer was washed with saturated brine and then dried over anhydrous magnesium sulfate. The solvent was evaporated to obtain 198 mg of t-butyl 11-bromo-1-(3-methoxypropyl)-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate.

Preparation Example 426

To a solution of ethyl 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoate in 200 ml of ethanol was added 150 ml of a 1 M aqueous sodium hydroxide solution, followed by stirring at room temperature for 2 hours. The reaction mixture was made weakly acidic by the addition dropwise of concentrated hydrochloric acid and diluted by the addition of water. The precipitated solid was collected by filtration and dried to obtain 8.88 g of 3-(6-iodo-2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)propanoic acid as a pale brown solid.

Preparation Example 427

To 3.421 g of ethyl 8-acetamide-6-bromo-7-(2-ethoxy-2-oxoethoxy)-1,2,4,5-tetrahydro-3H-benzazepine-3-carboxylate were added 30 ml of acetic acid and 30 ml of 8 M hydrochloric acid, followed by stirring at 150° C. for 16 hours. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in 35 ml of THF, and alkalified by the addition of 35 ml of a 1 M aqueous sodium hydroxide solution. 2 g of di-t-butyl dicarbonate was added thereto, followed by stirring at room temperature for 1 hour. The reaction mixture was extracted with ethyl acetate, the organic layer was dried over anhydrous magnesium sulfate and then filtered, and the filtrate was concentrated under reduced pressure to obtain 1.373 g of t-butyl 11-bromo-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate.

Preparation Example 495

To a solution of 590 mg of t-butyl 4-benzyl-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 10 ml of tetrahydrofuran was added 3.5 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by stirring at room temperature for 14 hours. The reaction mixture was cooled, and MeOH and a 1 M aqueous sodium hydroxide solution were added thereto, followed by stirring at room temperature for 3 hours. The reaction mixture was concentrated, to the residue were added ethyl acetate and water, and the organic layer was washed with saturated brine and dried over anhydrous sodium sulfate. The solvent was evaporated, and to a solution of 578 mg of the resulting residue in 10 ml of dichloromethane was added 620 mg of sodium hydrogen carbonate. Further, a solution of 280 mg of bromine in 5 ml of dichloromethane was added dropwise thereto over about 30 minutes, followed by stirring at room temperature. To the reaction mixture was slowly added a 3% aqueous sodium thiosulfate solution, followed by stirring vigorously and extracting with chloroform twice. The combined organic layer was washed with saturated brine, dried over anhydrous sodium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 518 mg of t-butyl 4-benzyl-5-bromo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate.

Preparation Example 540

To a solution of 1.10 g of 2,4,5-trifluorobenzonitrile and 500 mg of t-butyl 5-cyclopropyl-4-(2-hydroxyethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 15 ml of THF was added portionwise 150 mg of potassium t-butoxide, followed by stirring at −30° C. for 2 hours. Further, to the reaction mixture was added 0.15 ml of MeOH and then 150 mg of potassium t-butoxide was added portionwise thereto, followed by elevating the temperature to −10° C. and stirring for 15 hours. Further, to the reaction mixture were added 0.15 ml of MeOH, and then 150 mg of potassium t-butoxide was added portionwise thereto, followed by elevating the temperature to 0° C. and stirring for additional 14 hours. The reaction mixture was diluted with ethyl acetate, washed with water and saturated brine, dried over anhydrous magnesium sulfate, and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc)) to obtain 726 mg of t-butyl 4-[2-(4-cyano-2-fluoro-5-methoxyphenyl)ethyl]-5-cyclopropyl-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a colorless viscous substance.

Preparation Example 543

To a solution of 270 mg of t-butyl 5-cyclopropyl-4-[2-(2,6-difluoro-4-formylphenoxy)ethyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 6 ml of MeOH was added 30 mg of sodium borohydride, followed by stirring at room temperature for 4 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc)) to obtain 220 mg of t-butyl 5-cyclopropyl-4-{2-[2,6-difluoro-4-(hydroxymethyl)phenoxy]ethyl}-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a white solid.

Preparation Example 545

To a solution of 400 mg of t-butyl 5-cyclopropyl-4-(2-hydroxyethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 4 ml of dichloromethane were added 217 mg of p-toluenesulfonyl chloride, 0.22 ml of triethylamine, and 125 μl of N-methylimidazole in this order, followed by stirring for 1 hour. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 541 mg of t-butyl 5-cyclopropyl-4-(2-{[(4-methylphenyl)sulfonyl]oxy}ethyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a white solid.

Preparation Example 549

To 400 mg of t-butyl 5-cyclopropyl-4-[(2R)-2-methoxy-3-{[(4-methylphenyl)sulfonyl]oxy}propyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate was added 7 ml of a 1 M solution of t-butylammonium fluoride in THF, followed by heating and stirring at 60° C. for 13 hours under an argon atmosphere. The reaction mixture was cooled to room temperature and a saturated aqueous sodium hydrogen carbonate solution was added thereto, followed by extraction with ethyl acetate twice. The combined organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 257 mg of t-butyl 5-cyclopropyl-4-[(2R)-3-fluoro-2-methoxypropyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepine-8(2H)-carboxylate as a white foamed solid.

Preparation Example 565

To a solution of 300 mg of t-butyl 5-cyclopropyl-4-(2-hydroxy-3-methoxypropyl)-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 3 ml of toluene were added 0.1 ml of o-fluorophenol and 250 mg of cyanomethylenetributylphosphorane, followed by stirring at 80° C. for 20 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc) to obtain 277 mg of t-butyl 5-cyclopropyl-4-[2-(2-fluorophenoxy)-3-methoxypropyl]-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate as a pale yellow viscous substance.

In the same manner as in the methods of Preparation Examples above, the compounds of Preparation Examples as shown in the Tables below were prepared. For the compounds of the Preparation Examples, the structures are shown in Tables 2 to 81 and the preparation methods and the physicochemical data are shown in Tables 82 to 96.

Example 1

To 1.865 g of ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 20 mL of ethylene glycol and 20 mL of a 40% aqueous potassium hydroxide solution, followed by heating to 120° C. for 18 hours. The reaction mixture was ice-cooled and adjusted to pH 1 by the addition of concentrated hydrochloric acid, followed by stirring for 1 hour. The reaction mixture was alkalified by the addition of a 1 M aqueous sodium hydroxide solution, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered. The filtrate was concentrated under reduced pressure to obtain 1.451 g of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one as a brown solid. To 60 mg of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one were added 1 ml of EtOAc and then EtOH, followed by dissolution under heating. The precipitated solid was collected by filtration to obtain 29.5 mg of 11-chloro-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one as a white solid.

Example 2

To 47 mg of t-butyl 11-chloro-1-isobutyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate was added 1 ml of a 4 M hydrogen chloride solution in EtOAc, followed by stirring at room temperature for 3 hours. The reaction mixture was concentrated under reduced pressure and the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH). 26 mg of the resulting pale yellow viscous substance was dissolved in EtOH, followed by addition of 10.3 mg of fumaric acid and stirring. The precipitated solid was collected by filtration to obtain 23.2 mg of 11-chloro-1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate as a white solid.

Example 3

To a solution of 200 mg of t-butyl 2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2 ml of THF was added 1.9 ml of a 1 M solution of a borane-THF complex in THF under ice-cooling, followed by elevating the temperature to room temperature and stirring for 6 hours, and then elevating the temperature to 45° C. After stirring for 3 hours, 1.9 ml of a 1 M solution of a borane-THF complex in THF was added thereto in an ice-bath. After an additional 2 hours, MeOH was added dropwise thereto, followed by stirring for 20 minutes. The mixed solution was diluted with water, followed by extraction with chloroform. The organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. The residue was dissolved in 1.6 ml of dichloromethane, and 0.4 ml of trifluoroacetic acid was added thereto, followed by stirring at room temperature for 1 hour and then concentrating under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc), and the resulting solid was dissolved in 0.25 ml of hot EtOH, followed by addition of 21 mg of fumaric acid. While stirring, the resultant was cooled to room temperature and the precipitated solid was filtered to obtain 36 mg of 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate as a pale yellow solid.

Example 4

To 150 mg of ethyl 1-methyl-2-oxo-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate were added 4 ml of ethylene glycol and 2 ml of a 40% aqueous potassium hydroxide solution, followed by heating at 120° C. and stirring for 18 hours. The reaction mixture was ice-cooled and the liquid was made acidic by the addition of concentrated hydrochloric acid, followed by stirring for an additional 1 hour. The reaction mixture was neutralized with a 1 M aqueous sodium hydroxide solution and then extracted with chloroform, the organic layer was dried over anhydrous sodium sulfate and then filtered, and the filtrate was concentrated under reduced pressure. Then, the residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). To a solution of the resulting residue in 2 ml of EtOAc was added 0.2 ml of a 4 M hydrogen chloride solution in EtOAc, followed by stirring. The solvent was concentrated under reduced pressure and the resulting solid was dissolved in 2 ml of EtOH under heating, followed by stirring at room temperature. The precipitated solid was collected by filtration to obtain 43.7 mg of 1-methyl-1,3,4,6,7,8,9,10-octahydro-2H-azepino[4,5-g]quinolin-2-one monohydrochloride as a pale yellow solid.

Example 5

To a solution of 140 mg of t-butyl 11-cyclopropyl-1-(methoxyacetyl)-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 1 ml of EtOH was added 2 ml of 4 M hydrogen chloride solution in EtOAc, followed by stirring at room temperature for 3 hours. The reaction mixture was poured into a 1 M aqueous sodium hydroxide solution, the aqueous layer was extracted with chloroform, and the organic layer was dried over sodium sulfate. The solvent was concentrated under reduced pressure and the resulting residue was purified by silica gel chromatography (elution solvent: chloroform-MeOH-aqueous ammonia) to obtain 102 mg of 11-cyclopropyl-1-(methoxyacetyl)-2,3,4,6,7,8,9,10-octahydro-8H-azepino[4,5-g]quinoline as a pale yellow oily substance.

Example 6

To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 2.13 ml of dichloroethane were added 0.553 ml of triethylamine and 0.19 ml of ethyl chloroformate, followed by stirring at 60° C. for 2 hours. The reaction mixture was cooled to room temperature, and then the reaction mixture was diluted with EtOAc, washed with 1 M hydrochloric acid, water, a 1 M aqueous sodium hydroxide solution, and saturated brine, and concentrated, and the residue was purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in chloroform, followed by adding 0.005 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 76 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 79 mg of ethyl 2,3,4,6,7,8,9,10-octahydro-1H-azepino[4.5-g]quinoline-1-carboxylate hemifumarate.

Example 7

To a solution of 300 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 5.26 ml of pyridine was added 0.455 ml of N,N-dimethylcarbamoyl chloride, followed by stirring at 80° C. for 3 hours. To the reaction mixture was added 1 M hydrochloric acid, followed by extraction with EtOAc. The organic layer was washed with saturated brine and the solvent was evaporated. The resulting residue was purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 6 ml of chloroform, followed by adding 3 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in 4.5 ml of EtOH and 115 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 120 mg of N,N-dimethyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline-1-carboxamide fumarate.

Example 8

To a solution of 300 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of toluene was added 1.16 ml of ethyl isocyanate, followed by stirring at 90° C. overnight. The reaction mixture was concentrated under reduced pressure and then purified by silica gel column chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 7.5 ml of chloroform, followed by adding 3 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 115 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 247 mg of N-ethyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline-1-carboxamide monofumarate.

Example 9

To a solution of 200 mg of t-butyl 1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of dichloromethane were added 0.148 ml of triethylamine, 0.093 ml of ethanesulfonyl chloride, and 54 mg of 1-methylimidazole under ice-cooling, followed by stirring at room temperature overnight. To the reaction mixture were added EtOAc and saturated brine, and the organic layer was washed with saturated brine and then concentrated under reduced pressure. The residue was purified by silica gel chromatography (elution solvent: HEX-EtOAc). The resulting substance was dissolved in 4 ml of chloroform, followed by adding 2 ml of trifluoroacetic acid and stirring for 30 minutes. After concentration under reduced pressure, the resultant was dissolved in 4.5 ml of EtOH, neutralized by the addition of triethylamine, and then concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: chloroform-MeOH-aqueous ammonia). The resulting substance was dissolved in EtOH and 76 mg of fumaric acid was added thereto. The resulting white solid was collected by filtration and dried to obtain 61 mg of 1-(ethylsulfonyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline monofumarate.

Example 112

To a solution of 283 mg of t-butyl 4-(3-chlorobenzyl)-3-oxo-3,4,6,7,9,10-hexahydro[1,4]oxazino[2,3-h][3]bensazepine-8(2H)-carboxylate in 1.8 ml of tetrahydrofuran was added 1.46 ml of a 1 M solution of a borane-THF complex in THF, followed by stirring at 50° C. for 4 hours. The reaction mixture was ice-cooled, and MeOH was added thereto, followed by stirring at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure and MeOH was added thereto, followed by concentration again. The residue was dissolved in 2.8 ml of EtOH, and 1M hydrochloric acid was added thereto, followed by stirring overnight. After concentration under reduced pressure, the resultant was dissolved in EtOH, neutralized by the addition of obtain ethylamine, and concentrated under reduced pressure. Then, the residue was purified by silica gel column chromatography (elution solvent: CHCl₃-MeOH). The resulting substance was dissolved in ethanol and fumaric acid was added thereto, followed by stirring for a while. The solid was generated, then dissolved by heating once, and stirred at room temperature for 3 hours. The resulting white solid was collected by filtration and dried to obtain 23 mg of 4-(3-chlorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]bensazepine fumarate.

Example 282

To a solution of 606 mg of t-butyl 11-bromo-1-(2-methoxyethyl)-10-methyl-1,2,3,4,6,7,9,10-octahydro-8H-azepino[4,5-g]quinoline-8-carboxylate in 6 ml of dichloromethane was added 3 ml of trifluoroacetic acid, followed by stirring at room temperature for 1 hour. The reaction mixture was concentrated under reduced pressure and the residue was purified by basic silica gel chromatography (elution solvent: CHCl₃-MeOH). 150 mg of the resulting residue was collected by separation using DAICEL CHIRALPAK AD-H (2 cmΦ×25 cm) to obtain 51 mg of a low-polarity material and 45 mg of a high-polarity material. Each was dissolved in ethanol and fumaric acid was added thereto to form a salt. The precipitated solid was recrystallized from ethanol to obtain 42 mg and 36 mg of enantiomers of 11-bromo-1-(2-methoxyethyl)-10-methyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline fumarate as white solids, respectively.

In this regard, while the products are shown with a single planar structure in the Tables below with respect to the compounds of Example 282, and Example 280 and Example 281 in which preparation was performed as in Example 282, each of two kinds of enantiomers was isolated and obtained similarly as described above but the stereochemistry indentification was not carried out.

In the same manner as in the methods of Examples above, the compounds of Examples shown in the Tables below were prepared. The structure of the compounds of the Examples are shown in Tables 97 to 147 and the preparation methods and the physicochemical data are shown in Tables 148 to 181.

Furthermore, the structures of the other compounds of the present invention are shown in Tables 182 to 190. These can be easily synthesized by the methods described in the preparation methods and Examples above, methods apparent to a person skilled in the art, or modified methods thereof.

TABLE 2 PEx Str 1

2

3

4

5

6

7

8

TABLE 3 PEx Str 9

10

11

12

13

14

15

16

17

TABLE 4 PEx Str 18

19

20

21

22

23

24

25

TABLE 5 PEx Str 26

27

28

29

30

31

32

33

TABLE 6 PEx Str 34

35

36

37

38

39

40

41

TABLE 7 PEx Str 42

43

44

45

46

47

48

49

50

51

TABLE 8 PEx Str 52

53

54

55

56

57

58

59

60

TABLE 9 PEx Str 61

62

63

64

65

66

67

68

69

TABLE 10 PEx Str 70

71

72

73

74

75

76

77

78

TABLE 11 PEx Str 79

80

81

82

83

84

85

86

TABLE 12 PEx Str 87

88

89

90

91

92

93

94

TABLE 13 PEx Str 95

96

97

98

99

100 

101 

102 

TABLE 14 PEx Str 103

104

105

106

107

108

109

TABLE 15 PEx Str 110

111

112

113

114

115

TABLE 16 PEx Str 116

117

118

119

120

121

TABLE 17 PEx Str 122

123

124

125

126

127

128

129

TABLE 18 PEx Str 130

131

132

133

134

135

136

TABLE 19 PEx Str 137

138

139

140

143

TABLE 20 PEx Str 144

145

146

149

150

151

TABLE 21 PEx Str 152

153

154

155

156

157

158

TABLE 22 PEx Str 159

160

161

162

163

164

165

TABLE 23 PEx Str 166

167

168

169

170

171

172

173

TABLE 24 PEx Str 175

176

177

178

179

180

181

TABLE 25 PEx Str 182

183

184

185

186

187

188

189

TABLE 26 PEx Str 190

192

193

195

196

197

TABLE 27 PEx Str 198

199

200

201

202

203

204

TABLE 28 PEx Str 205

206

207

208

209

210

211

TABLE 29 PEx Str 212

213

214

215

216

217

TABLE 30 PEx Str 218

219

220

221

222

223

TABLE 31 PEx Str 224

225

226

227

228

229

230

TABLE 32 PEx Str 231

232

233

234

235

236

237

TABLE 22 PEx Str 238

239

240

241

242

243

244

TABLE 34 PEx Str 245

246

247

248

249

250

TABLE 35 PEx Str 251

252

253

254

255

256

257

TABLE 36 PEx Str 258

259

260

261

262

263

264

TABLE 37 PEx Str 265

266

267

268

269

270

271

TABLE 38 PEx Str 272

273

274

275

276

277

TABLE 39 PEx Str 278

279

280

281

282

283

TABLE 40 PEx Str 284

285

286

287

288

289

TABLE 41 PEx Str 290

291

292

293

294

295

296

297

TABLE 42 PEx Str 298

299

300

301

302

303

TABLE 43 PEx Str 304

305

306

307

308

309

310

TABLE 44 PEx Str 311

312

313

314

315

316

TABLE 45 PEx Str 317

318

319

320

321

322

323

TABLE 46 PEx Str 324

325

326

327

328

329

330

TABLE 47 PEx Str 331

332

333

334

335

336

337

TABLE 48 PEx Str 338

339

340

341

342

343

344

345

TABLE 49 PEx Str 346

347

348

349

350

351

352

353

TABLE 50 PEx Str 354

355

356

357

358

359

360

361

TABLE 51 PEx Str 362

363

364

365

366

367

368

369

TABLE 52 PEx Str   370

371

372

373

374

375

376

377

TABLE 53 PEx Str   378

379

380

381

382

383

384

385

386

TABLE 54 PEx Str   387

388

389

390

391

392

393

TABLE 55 PEx Str   394

395

396

397

398

399

400

401

TABLE 56 PEx Str   402

403

404

405

406

407

408

TABLE 57 PEx Str 409

410

411

412

413

414

415

416

TABLE 58 PEx Str   417

418

419

420

421

422

423

TABLE 59 PEx Str   424

425

426

427

428

429

430

431

TABLE 60 PEx Str   432

433

434

435

436

437

438

439

TABLE 61 PEx Str   440

441

442

443

444

445

446

TABLE 62 PEx Str   447

448

449

450

451

452

453

TABLE 63 PEx Str   454

455

456

457

458

459

TABLE 64 PEx Str   460

461

462

463

464

465

466

467

TABLE 65 PEx Str   468

469

470

471

472

473

474

TABLE 66 PEx Str   475

476

477

478

479

480

481

TABLE 67 PEx Str 482

483

484

485

486

487

TABLE 68 PEx Str 488

489

490

491

492

493

TABLE 69 PEx Str 494

495

496

497

498

499

TABLE 70 PEx Str 500

501

502

503

504

505

TABLE 71 PEx Str 506

507

508

509

510

511

512

513

TABLE 72 PEx Str 514

515

516

517

518

519

520

521

TABLE 73 PEx Str 522

523

524

525

526

527

TABLE 74 PEx Str 528

529

530

531

532

533

TABLE 75 PEx Str 534

535

536

537

538

539

TABLE 76 PEx Str 540

541

542

543

544

TABLE 77 PEx Str 545

546

547

548

549

550

TABLE 78 PEx Str 551

552

553

554

555

556

TABLE 79 PEx Str 557

558

559

560

561

562

TABLE 80 PEx Str 563

564

565

566

567

568

TABLE 81 PEx Str 569

570

571

572

573

574

TABLE 82 PEx Psyn Dat 1 1 EI: 296, 298, 300 2 2 EI: 190, 192 3 3 EI: 209, 211 4 4 ESI+: 254, 256 5 5 FAB+: 299, 301 6 6 EI: 268, 270 7 7 EI: 346, 348, 350 8 8 ESI+: 367, 369 9 9 EI: 322, 324 10 10 ESI+: 351, 353 11 11 ESI+: 337, 339 12 12 ESI+: 351, 353 13 13 ESI+: 379 14 14 APCI+: 220 15 15 ESI+; 303 16 16 ESI+; 331 17 17 ESI+; 359 18 18 ESI+; 317 19 19 ESI+; 345 20 20 ESI+; 419 21 21 ESI+: 403 22 22 ESI+: 417 23 23 FAB−: 331 24 24 ESI+: 333 25 25 ESI+: 361 26 26 ESI+: 383, 405 ([M + Na]⁺) 27 27 ESI+: 447 28 28 ESI+: 350 29 29 ESI+: 393 30 30 ESI+: 349 31 31 ESI+: 331 32 32 ESI+: 388 33 33 ESI+: 389 34 34 ESI+: 291 35 35 ESI+: 403 36 36 FAB+: 537 37 37 ESI+: 577 38 38 ESI+: 473 ([M + Na]⁺) 39 39 EI: 315 40 40 FAB+: 320

TABLE 83 PEx Psyn Dat 41 41 FAB+: 333 42 42 ESI+: 359 43 27 EI: 181 44 4 ESI+: 182, 184 45 19 ESI+: 235 46 7 EI; 312 47 8 ESI+; 333 48 5 EI; 264 49 9 EI; 288 50 22 ESI+: 403 ([M + Na]⁺) 51 15 ESI+: 333 52 11 ESI+: 319 53 11 ESI+: 365, 367 54 11 ESI+: 305 55 13 ESI+: 393, 395 56 13 ESI+: 407, 409 57 13 ESI+: 409, 411 58 23 FAB−: 317 59 11 ESI+; 317 60 15 ESI+: 347, 369 ([M + Na]⁺) 61 11 ESI+: 379, 381 62 11 ESI+: 395, 397 63 11 ESI+: 393, 395 64 11 ESI+: 333 65 11 ESI+: 319 66 25 ESI+: 333 67 7 ESI+: 383, 385 68 18 ESI+: 319 69 25 ESI+: 347 70 24 APCI+: 333 71 16 ESI+; 317 72 11 ESI+; 203 73 7 ESI+: 381, 383 74 11 ESI+; 331 75 13 FAB+; 345 76 24 ESI+: 397, 399 77 13 ESI+; 373 78 18 ESI+: 345 79 13 ESI+: 405, 407 80 13 ESI+: 419, 421

TABLE 84 PEx Psyn Dat 81 11 ESI+: 391, 393 82 11 ESI+: 405, 407 83 13 ESI+: 433, 435 84 13 ESI+: 441, 443 85 18 ESI+; 379 86 15 ESI+; 331 87 11 ESI+: 419, 421 88 11 ESI+: 427, 429 89 13 ESI+: 447, 449 90 11 ESI+: 433, 435 91 22 ESI+: 431 ([M + Na]⁺) 92 23 FAB−: 331 93 11 ESI+: 319 94 24 ESI+: 363 95 24 ESI+: 359 96 13 ESI+: 375 97 24 ESI+: 361 98 15 ESI+: 391 99 11 ESI+: 377 100 15 ESI+: 431 ([M + Na]⁺) 101 15 ESI+: 375 102 17 ESI+: 437 103 11 ESI+: 395 104 11 ESI+: 361 105 15 ESI+: 391 106 11 ESI+: 377 107 15 ESI+: 417 108 11 ESI+: 403 109 7 ESI+: 361 110 18 ESI+: 381 111 17 ESI+; 361 112 18 ESI+; 409 113 18 ESI+; 447, 449 114 18 ESI+; 413, 415 115 17 ESI+; 471, 473 116 17 ESI+; 505, 507 117 18 ESI+; 397 118 17 ESI+; 465 119 12 ESI+: 363 120 13 ESI+: 403

TABLE 85 PEx Psyn Dat 121 17 ESI+; 467 122 17 ESI+; 455 123 15 ESI+; 375 124 18 ESI+; 343 125 17 ESI+; 399 126 17 ESI+; 401 127 15 ESI+: 405 128 11 ESI+: 391 129 11 ESI+: 389 130 18 ESI+: 395 131 13 ESI+: 467 132 11 ESI+: 453 133 15 ESI+: 391 134 15 ESI+: 405 135 11 ESI+: 377 136 11 ESI+: 391 137 18 ESI+; 343 138 13 ESI+: 439 ([M + Na]⁺) 139 12 ESI+: 347 140 11 ESI+: 403 143 11 ESI+: 389 144 22 ESI+: 406 145 27 ESI+: 226 146 27 EI: 195 149 21 ESI+: 387 150 17 ESI+; 403 151 28 ESI+: 392 152 13 ESI+: 391 153 29 ESI+: 322 154 41 ESI+: 421 155 41 ESI+: 393 156 11 ESI+: 319 157 42 ESI+: 397, 399 158 11 ESI+: 373 159 18 ESI+: 395, 417 ([M + Na]⁺) 160 13 ESI+: 431

TABLE 86 PEx Psyn Dat 161 13 ESI+: 389 162 13 ESI+: 417 163 11 ESI+: 417 164 11 ESI+: 377 165 11 ESI+: 381 166 12 ESI+: 351 167 18 ESI+: 331 168 18 ESI+: 345 169 19 ESI+: 333 170 11 ESI+: 375 171 11 ESI+: 361 172 18 ESI+: 329 173 19 ESI+; 331 175 13 ESI+: 405 176 21 ESI+: 391 177 17 ESI+; 389 178 18 ESI+; 359 179 11 ESI+: 391 180 11 ESI+: 377 181 19 ESI+: 347 182 13 FAB+: 419 183 11 ESI+: 277 184 11 ESI+: 405 185 15 FAB+: 379 186 11 ESI+: 365 187 13 ESI+: 453 ([M + Na]⁺) 188 11 ESI+: 417 189 13 ESI+: 457, 479 ([M + Na]⁺) 190 11 ESI+: 443 192 13 ESI+: 431, 453 ([M + Na]⁺) 193 11 ESI+: 417 195 22 NMR: 1.19 (3H, t, J = 7.1 Hz), 1.38 (9H, s), 1.54 (6H, s), 2.80-2.93 (4H, br), 3.39-3.51 (4H, br), 4.20 (2H, q, J = 7.1 Hz), 6.79 (1H, s), 7.68 (1H, s) 196 22 ESI+: 457, 459 197 22 ESI+: 413, 415 198 22 ESI+: 431 ([M + Na]⁺) 199 22 ESI+: 447 ([M + Na]⁺) 200 22 ESI+: 459 ([M + Na]⁺)

TABLE 87 PEx Psyn Dat 201 18 ESI+: 439 202 18 ESI+: 435 203 18 ESI+: 399 204 18 ESI+: 405 205 18 ESI+: 345 206 18 ESI+: 417 207 18 ESI+: 359 208 18 ESI+: 457 209 18 ESI+: 417 210 18 ESI+: 465 211 18 ESI+: 403 212 18 ESI+: 439 213 18 ESI+: 445 214 18 ESI+: 445 215 18 ESI+: 427 216 18 ESI+: 493 217 18 ESI+: 453 218 18 ESI+: 383 219 18 ESI+: 493 220 18 ESI+: 529 221 18 ESI+: 535 222 18 ESI+: 385 223 18 ESI+: 427 224 18 ESI+: 417 225 18 ESI+: 403 226 18 ESI+: 429, 451 ([M + Na]⁺) 227 18 ESI+: 417 228 18 ESI+: 405, 427 ([M + Na]⁺) 229 18 ESI+: 401 230 18 ESI+: 395 231 18 ESI+: 345 232 18 ESI+: 359 233 18 ESI+: 383 234 18 ESI+: 415 235 18 ESI+: 415 236 18 ESI+: 429 237 18 ESI+: 405 238 18 ESI+: 431 239 18 ESI+: 347 240 18 ESI+: 391

TABLE 88 PEx Psyn Dat 241 18 ESI+: 401 242 18 ESI+: 391 243 18 ESI+: 379 244 18 ESI+: 427 245 18 ESI+: 427 246 18 ESI+: 403 247 18 ESI+: 403 248 18 ESI+: 379 249 18 ESI+: 435 250 18 ESI+: 469, 471 251 18 ESI+: 469, 471 252 18 ESI+: 453 253 18 ESI+: 391 254 18 ESI+: 453 255 13 ESI+: 459, 481 ([M + Na]⁺) 256 13 ESI+: 317 257 13 ESI+: 401 258 13 ESI+: 403 259 13 ESI+: 427 260 13 ESI+: 391 261 13 ESI+: 391 262 13 ESI+: 445, 467 ([M + Na]⁺) 263 13 ESI+: 485, 507 ([M + Na]⁺) 264 13 ESI+: 459, 481 ([M + Na]⁺) 265 13 ESI+: 467 ([M + Na]⁺) 266 13 ESI+: 457 267 13 ESI+: 443 268 13 ESI+: 457, 479 ([M + Na]⁺) 269 13 ESI+: 457 270 13 ESI+: 415, 437 ([M + Na]⁺) 271 13 ESI+: 445, 467 ([M + Na]⁺) 272 13 ESI+: 507 273 13 ESI+: 419 274 13 ESI+: 479 275 13 ESI+: 493 276 13 ESI+: 323 ([M − Boc]⁺) 277 13 ESI+: 529 278 13 ESI+: 529 279 13 ESI+: 491 280 13 ESI+: 507

TABLE 89 PEx Psyn Dat 281 13 ESI+: 463 282 13 ESI+: 463 283 13 ESI+: 485 284 13 ESI+: 385 ([M − Boc]⁺) 285 13 ESI+: 501 286 13 ESI+: 491 287 13 ESI+: 493 288 13 ESI+: 485 289 13 ESI+: 501 290 13 ESI+: 507 291 17 ESI+: 389 292 17 ESI+: 387 293 17 ESI+: 373 294 15 ESI+: 536.9 295 15 ESI+: 361, 383 ([M + Na]⁺) 296 15 ESI+: 375 297 15 ESI+: 447 298 15 ESI+: 447 299 15 ESI+: 417 300 15 ESI+: 523 301 15 ESI+: 391 302 20 ESI+: 433, 455 ([M + Na]⁺) 303 20 ESI+: 433 304 20 ESI+: 403 305 20 ESI+: 509 306 334 ESI+: 377 307 334 ESI+: 389 308 334 ESI+: 373 309 334 ESI+: 439 310 334 ESI+: 443, 445 311 334 ESI+: 391 312 334 ESI+: 465 ([M + Na]⁺), 467 ([M + Na]⁺) 313 334 ESI+: 465 ([M + Na]⁺), 467 ([M + Na]⁺) 314 334 ESI+: 461 ([M + Na]⁺) 315 334 ESI+: 416 316 334 ESI+: 410 317 334 ESI+: 439 318 334 ESI+: 437 319 334 ESI+: 359 320 334 ESI+: 405, 427 ([M + Na]⁺)

TABLE 90 PEx Psyn Dat 321 334 ESI+: 403 322 334 ESI+: 377 323 334 ESI+: 405 324 334 ESI+: 403, 425 ([M + Na]⁺) 325 334 ESI+: 391, 413 ([M + Na]⁺) 326 334 ESI+: 379, 401 ([M + Na]⁺) 327 334 ESI+: 403 328 334 ESI+: 379, 401 ([M + Na]⁺) 329 334 ESI+: 405.427 ([M + Na]⁺) 330 334 ESI+: 389 331 334 ESI+: 419 332 334 ESI+: 401 333 334 ESI+: 401 334 334 ESI+: 416 335 334 ESI+: 391, 413 ([M + Na]⁺) 336 334 ESI+: 427 337 339 ESI+: 345 338 339 ESI+: 359 339 339 ESI+: 407 340 339 ESI+: 361 341 339 ESI+: 389 342 339 ESI+: 411, 413 343 339 ESI+: 389 344 344 ESI+: 365, 367 345 345 ESI+: 451 346 345 ESI+: 485, 487 347 345 ESI+: 485, 487 348 349 ESI+: 485, 487 349 349 ESI+: 481 350 349 ESI+: 481 351 349 ESI+: 453 352 349 ESI+: 509 ([M + Na]⁺), 511 ([M + Na]⁺) 353 349 ESI+: 509 ([M + Na]⁺), 511 ([M + Na]⁺) 354 349 ESI+: 509 ([M + Na]⁺), 511 ([M + Na]⁺) 355 349 ESI+: 483 356 349 ESI+: 483 357 349 ESI+: 471 358 349 ESI+: 471 359 349 ESI+: 471 360 349 ESI+: 531, 533

TABLE 91 PEx Psyn Dat 361 349 ESI+: 467 362 349 ESI+: 467 363 367 ESI+: 437 364 367 ESI+: 403 365 367 ESI+: 389 366 367 ESI+: 375 367 367 ESI+: 411, 413 368 27 ESI+: 448 369 38 ESI+: 451 370 28 ESI+: 350 371 29 ESI+: 393 372 30 ESI+: 349 373 31 ESI+: 331 374 37 ESI+: 577 375 375 ESI+: 383 376 376 ESI+: 386 377 377 ESI+: 425 378 377 ESI+: 427 379 379 ESI+: 417 380 380 ESI+: 331 381 381 NMR-C: 1.19 (3H, d, J = 6.6 Hz), 1.28 (3H, t, J = 7.1 Hz), 2.75-2.89 (4H, m), 3.34-3.44 (1H, m), 3.51-3.65 (4H, m), 3.69 (1H, dd, J = 8.7, 7.6 Hz), 3.93 (1H, dd, J = 8.7, 4.1 Hz), 4.18 (2H, q, J = 7.1 Hz), 6.66 (1H, s), 7.28 (1H, s) 382 381 ESI+: 371, 373 383 383 ESI+: 291 384 383 ESI+: 291 385 385 ESI+: 317 386 386 ESI+: 301 387 387 ESI+: 236 388 388 ESI+: 277 389 389 ESI+: 275 390 390 ESI+: 293 391 545 ESI+: 587 392 7 ESI+: 374 393 7 ESI+: 371, 373 394 7 ESI+: 327, 329 395 408 ESI+: 441, 443 396 408 ESI+: 455 397 408 ESI+: 457 398 408 ESI+: 443, 445 399 408 ESI+: 455, 457 400 408 ESI+: 465; 467

TABLE 92 PEx Psyn Dat 401 408 ESI+: 491; 493 402 408 ESI+: 467, 469 403 408 ESI+: 455, 457 404 408 ESI+: 443, 445 405 408 ESI+: 467, 469 406 408 ESI+: 443, 445 407 408 ESI+: 469, 471 408 408 ESI+: 413 409 409 ESI+: 314, 316 410 411 ESI+: 453; 455 411 411 ESI+: 467; 469 412 411 ESI+: 355, 357 413 411 ESI+: 437; 439 414 411 ESI+: 455 415 411 ESI+: 529, 531 416 411 ESI+: 467, 469 417 411 ESI+: 455, 457 418 411 ESI+: 479, 481 419 411 ESI+: 409, 411 420 411 ESI+: 455, 457 421 411 ESI+: 467, 469 422 411 ESI+: 467, 469 423 411 ESI+: 479, 481 424 411 ESI+: 479, 481 425 549 ESI+: 435 426 426 ESI+: 346 427 427 FAB−: 395, 397 428 427 ESI+: 353, 355 429 23 ESI+: 369 ([M + Na]⁺) 430 23 ESI+: 347, 369 ([M + Na]⁺) 431 23 ESI+: 385 ([M + Na]⁺) 432 23 ESI+: 361, 383 ([M + Na]⁺) 433 11 ESI+: 439, 441 434 11 NMR-C: 0.44-0.51 (2H, m), 0.95 (6H, s), 0.97-1.06 (2H, m), 1.47 (9H, s), 1.58-1.68 (1H, m), 2.69-2.78 (2H, m), 3.04 (2H, s), 3.06-3.18 (4H, m), 3.21 (3H, s), 3.29-3.36 (2H, m), 3.46-3.58 (4H, m), 4.15-4.22 (2H, m), 6.48 (1H, s) 435 11 ESI+: 383, 385 436 11 ESI+: 377 437 11 ESI+: 331 438 11 ESI+: 345 439 11 ESI+: 453, 455 440 11 ESI+: 389

TABLE 93 PEx Psyn Dat 441 11 ESI+: 441, 443 442 11 ESI+: 391 443 11 ESI+: 465, 467 444 11 ESI+: 387 445 11 ESI+: 389 446 11 ESI+: 339, 341 447 11 ESI+: 397, 399 448 11 ESI+: 413 449 11 ESI+: 395, 397 450 11 ESI+: 377 451 11 ESI+: 377 452 11 ESI+: 391 453 11 ESI+: 441, 443 454 11 ESI+: 389 455 11 ESI+: 377 456 11 ESI+: 365 457 11 ESI+: 453, 455 458 11 ESI+: 453, 455 459 11 ESI+: 389 460 11 ESI+: 365 461 11 ESI+: 431 462 11 ESI+: 471 463 11 ESI+: 445 464 11 ESI+: 333 465 11 ESI+: 349 466 11 ESI+: 347 467 11 ESI+: 391 468 11 ESI+: 405 469 11 ESI+: 347 470 11 ESI+: 361 471 11 ESI+: 465, 467 472 11 ESI+: 465 473 11 ESI+: 431 474 11 ESI+: 443 475 11 ESI+: 429 476 11 ESI+: 443 477 11 ESI+: 401 478 11 ESI+: 443 479 11 ESI+: 465 480 11 ESI+: 493

TABLE 94 PEx Psyn Dat 481 11 ESI+: 431 482 11 ESI+: 405 483 11 ESI+: 479 484 11 ESI+: 309 ([M − Boc]⁺) 485 11 ESI+: 515 486 11 ESI+: 515 487 11 ESI+: 477 488 11 ESI+: 493 489 11 ESI+: 449 490 11 ESI+: 449 491 11 ESI+: 377 492 11 ESI+: 471 493 11 ESI+: 471 494 11 ESI+: 487, 489 495 495 ESI+: 473, 475 496 495 ESI+: 507, 509 497 495 ESI+: 507, 509 498 495 EI: 491, 493 499 495 ESI+: 492, 493 500 12 ESI+: 429; 431 501 12 ESI+: 425 502 12 ESI+: 413 503 12 ESI+: 420 504 12 ESI+: 463 505 12 ESI+: 409 506 19 ESI+: 303 507 19 ESI+: 473 508 19 ESI+: 405 509 19 ESI+: 501 510 19 ESI+: 495 511 19 ESI+: 361 512 19 ESI+: 347 513 19 ESI+: 433 514 19 ESI+: 393 515 16 ESI+: 345 516 16 ESI+: 319 517 16 ESI+: 331 518 16 ESI+: 319 519 162 ESI+: 437, 439 520 162 ESI+: 435, 437

TABLE 95 PEx Psyn Dat 521 18 ESI+: 417 522 18 ESI+: 417 523 13 ESI+: 479 524 13 ESI+: 493 525 13 ESI+: 479 526 13 ESI+: 533 527 13 ESI+: 497 528 13 ESI+: 513 529 13 ESI+: 493 530 13 ESI+: 485 531 13 ESI+: 485 532 15 ESI+: 523 533 15 ESI+: 537 534 15 ESI+: 559 535 15 ESI+: 431 536 20 ESI+: 433 537 20 ESI+: 509 538 339 ESI+: 486 539 540 ESI+: 526.4 540 540 ESI+: 538 541 540 ESI+: 467 542 540 ESI+: 467 543 543 ESI+: 531 544 545 ESI+: 587 545 545 ESI+: 543 546 545 ESI+: 601 547 408 ESI+: 455, 457 548 408 ESI+: 455, 457 549 549 ESI+: 435 550 549 ESI+: 449 551 11 ESI+: 465 552 11 ESI+: 477 553 11 ESI+: 479 554 11 ESI+: 471 555 11 ESI+: 487, 489 556 11 ESI+: 493 557 11 ESI+: 479 558 11 ESI+: 465 559 11 ESI+: 519 560 11 ESI+: 479

TABLE 96 PEx Psyn Dat 561 11 ESI+: 483 562 11 ESI+: 499, 501 563 11 ESI+: 471 564 11 ESI+: 471 565 565 ESI+: 527 566 565 ESI+: 527 567 565 ESI+: 527 568 565 ESI+: 561, 563 569 565 ESI+: 563 570 565 ESI+: 545 571 19 ESI+: 433 572 19 ESI+: 447 573 20 ESI+: 363 574 15 ESI+: 377

TABLE 97 Ex Str 1

2 M

3 M

4

5

6 H

7 M

8 M

TABLE 98 Ex Str  9 M

10 M

11

12 M

13 H

14 M

15

16

TABLE 99 Ex Str 17

18

19 M

20 M

21

22 H

23 H

24 M

TABLE 100 Ex Str 25 H

26 M

27 M

28 H

29

30

31 M

32 M

TABLE 101 Ex Str 33 M

34 M

35 M

36

37 M

38 M

39 M

40 M

TABLE 102 Ex Str 41 M

42 M

43 M

44 M

45 M

46

47 M

TABLE 103 Ex Str 48 M

49 M

50

51

52 M

53 M

54 H

TABLE 104 Ex Str 55 M

56

57

58

59 M

60

61

TABLE 105 Ex Str 62 H

63 M

64

65

66 M

67 M

TABLE 106 Ex Str 68 H

69 H

70 M

71 M

72 M

73 H

TABLE 107 Ex Str 74 M

75 H

76 M

77

78 M

79 M

80 M

TABLE 108 Ex Str 81 M

82 H

83 M

84 M

85 M

86

TABLE 109 Ex Str 87

88 H

89 M

90 M

91 M

92 H

93 M

TABLE 110 Ex Str  94 H

 95 M

 96

 97 M

 98 M

 99 H

100

TABLE 111 Ex Str 101 M

102 M

103

104 M

105

106 H

TABLE 112 Ex Str 107 M

108 M

109 M

110 M

111

112 M

TABLE 113 Ex Str 113

114 M

115 M

116 M

117 M

118 H

TABLE 114 Ex Str 119

120 M

121 H

122

123

124

125

TABLE 115 Ex Str 126

127 M

128 M

129 M

130 M

131 M

132 M

TABLE 116 Ex Str 133

134 M

135 M

136 M

137 M

138 M

TABLE 117 Ex Str 139 M

140 M

141 H

142 H

143 H

144 M

TABLE 118 Ex Str 145 M

146 M

147 M

148 M

149

150 H

TABLE 119 Ex Str 151 M

152 H

153 H

154 H

155 M

156 M

157 M

TABLE 120 Ex Str 158 M

159

160 M

161 M

162 M

163 M

TABLE 121 Ex Str 164 M

165

166

167

168

169 M

TABLE 122 Ex Str 170 M

171 M

172 M

173 M

174 H

175

TABLE 123 Ex Str 176

177 M

178 M

179 M

180 M

181 H

TABLE 124 Ex Str 182 H

183 M

184 M

185 M

186 M

TABLE 125 Ex Str 187 M

188 H

189

190

191

192 H

193 H

TABLE 126 Ex Str 194 H

195 M

196 M

197 M

198 M

199 M

TABLE 127 Ex Str 200 H

201 M

202

203 M

204 H

205 H

TABLE 128 Ex Str 206 M

207 M

208 H

209 H

210 M

211 M

TABLE 129 Ex Str 212 M

213 M

214 H

215

216 M

217 H

TABLE 130 Ex Str 218 H

219 H

220 H

221 M

222 H

223 H

TABLE 131 Ex Str 224 M

225

226

227

228 H

229 M

230

TABLE 132 Ex Str 231

232 H

233 H

234 M

235 M

236 M

TABLE 133 Ex Str 237 M

238 M

239 M

240 M

241 M

242 M

243 M

TABLE 134 Ex Str 244 M

245 M

246 M

247 M

248 M

249 M

TABLE 135 Ex Str 250

251 H

252

253

254 S

255 H

TABLE 136 Ex Str 256 M

257 H

258 M

259 M

260 H

261

TABLE 137 Ex Str 262

263 H

264

265 H

266 M

267 T

TABLE 138 Ex Str 268 M

269 H

270 M

271 M

272 M

TABLE 139 Ex Str 273 M

274 M

275 M

276 M

277 M

TABLE 140 Ex Str 278

279

280 M

281 M

282 M

283 H

TABLE 141 Ex Str 284 H

285 H

286 M

287 M

288 M

TABLE 142 Ex Str 289 H

290 M

291 H

292 M

293 M

294 M

TABLE 143 Ex Str 295 M

296 M

297 M

298 M

299 M

TABLE 144 Ex Str 300 M

301 M

302 M

303 M

304 M

TABLE 145 Ex Str 305 M

306 M

307 M

308 M

TABLE 146 Ex Str 309 M

310 M

311 S

312 H

313 H

TABLE 147 Ex Str 314 M

315 M

316 M

317 M

318

319

TABLE 148 Ex Syn Dat 1 1 ESI+: 251, 253 NMR: 2.44-2.53 (3H, m), 2.72-2.74 (4H, m), 2.79-2.85 (4H, m), 3.02-3.04 (2H, m), 6.93 (1H, s), 9.20 (1H, s) mp: 165-167 2 2 ESI+: 293, 295 NMR: 0.96 (6H, d, J = 6.5 Hz), 1.69-1.75 (2H, m), 1.98-2.07 (1H, m), 2.67-2.70 (4H, m), 2.90-2.95 (2H, m), 2.97-3.04 (6H, m), 3.10-3.65 (5H, m), 6.46 (2H, s), 6.81 (1H, s) mp: 159-163 3 3 ESI+: 203 NMR: 1.69-1.81 (2H, m), 2.57 (2H, t, J = 6.2 Hz), 2.75-2.86 (4H, m), 2.94-3.06 (4H, m), 3.08-3.15 (2H, m), 6.23 (1H, s), 6.44 (2H, s), 6.62 (1H, s) 4 4 ESI+: 231 NMR: 2.49-2.56 (2H, m), 2.76-2.83 (2H, m), 2.98-3.20 (8H, m), 3.23 (3H, s), 6.97 (1H, s), 7.05 (1H, s), 9.14 (2H, s) 5 5 ESI+: 315 NMR: 0.22-0.32 (1H, m), 0.38-0.49 (1H, m), 0.97-1.07 (2H, m), 1.50-1.70 (2H, m), 2.17-2.30 (1H, m), 2.31-2.43 (1H, m), 2.51-2.61 (1H, m), 2.74-3.18 (8H, m), 3.30-3.42 (1H, m), 3.34 (3H, s), 3.73 (1H, d, J = 14.3 Hz), 4.14 (1H, d, J = 14.3 Hz), 4.70-4.81 (1H, m), 6.85 (1H, s) 6 6 ESI+: 275 NMR: 1.23 (3H, t, J = 7.1 Hz), 1.78-1.86 (2H, m), 2.66 (2H, t, J = 6.6 Hz), 2.83-2.91 (4H, m), 2.91-2.99 (4H, m), 3.61-3.67 (2H, m), 4.13 (2H, q, J = 7.1 Hz), 6.40 (1H, s), 6.88 (1H, s), 7.43 (1H, s) mp: 178 (decomp.) 7 7 ESI+: 274 NMR: 1.78-1.86 (2H, m), 2.65 (2H, t, J = 6.7 Hz), 2.76-2.86 (10H, m), 2.86-2.94 (4H, m), 3.36-3.41 (2H, m), 6.39 (1H, s), 6.56 (1H, s), 6.83 (1H, s) mp: 230 (decomp.) 8 8 ESI+: 274 NMR: 1.05 (3H, t, J = 7.1 Hz), 1.74-1.82 (2H, m), 2.62 (2H, t, J = 6.5 Hz), 2.89-2.97 (4H, m), 3.01-3.15 (6H, m), 3.52 (2H, m), 6.45 (2H, s), 6.65 (1H, t, J = 5.4 Hz), 6.89 (1H, s), 7.25 (1H, s) mp: 174-176 9 9 ESI+: 295 NMR: 1.20 (3H, t, J = 7.3 Hz), 1.85-1.94 (2H, m), 2.73 (2H, t, J = 6.7 Hz), 2.91-3.00 (4H, m), 3.00-3.10 (4H, m), 3.23 (2H, q, J = 7.3 Hz), 3.62-3.69 (2H, m), 6.45 (2H, s), 6.96 (1H, s), 7.30 (1H, s) mp: 176 (decomp.) 10 2 ESI+: 261 NMR: 1.75-1.83 (2H, m), 2.55-2.62 (2H, m), 2.78-2.84 (2H, m), 2.84-2.90 (2H, m), 2.94-3.06 (4H, m), 3.20-3.28 (2H, m), 3.26 (3H, s), 3.34-3.41 (2H, m), 3.44-3.50 (2H, m), 6.40 (1H, s), 6.43 (2H, s), 6.65 (1H, s)

TABLE 149 Ex Syn Dat 11 5 ESI+: 313 NMR: 0.26-0.33 (1H, m), 0.36-0.43 (1H, m), 0.82 (3H, d, J = 6.6 Hz), 0.92-1.05 (2H, m), 1.15 (3H, d, J = 6.9 Hz), 1.48-1.70 (2H, m), 2.13-2.29 (1H, m), 2.32-2.45 (1H, m), 2.50-2.59 (1H, m), 2.62-3.13 (9H, m), 3.35-3.45 (1H, m), 4.67-4.78 (1H, m), 6.84 (1H, s) 12 2 ESI+: 237, 239.1 NMR: 1.73-1.79 (2H, m), 2.64 (2H, t, J = 6.2 Hz), 2.74-4.34 (13H, m), 5.40 (1H, s), 6.44 (2H, s), 6.67 (1H, s) 13 2 ESI+: 251, 253 NMR: 1.72-1.78 (2H, m), 2.67-2.70 (5H, m), 2.85-2.92 (6H, m), 2.96-2.99 (2H, m), 3.13-3.76 (4H, m), 6.40 (1H, s), 6.79 (1H, s) 14 2 ESI+: 219 NMR: 2.78 (3H, s), 2.81-2.87 (2H, m), 2.87-2.93 (2H, m), 2.98-3.09 (4H, m), 3.13-3.19 (2H, m), 4.15-4.21 (2H, m), 6.44 (2H, s), 6.50 (1H, s), 6.54 (1H, s) 15 2 ESI+: 279, 281 NMR: 1.58-3.32 (16H, m), 4.05-4.12 (0.35H, m), 4.51-4.58 (0.65H, m), 7.04 (0.35H, s), 7.16 (0.65H, s), 9.06-9.18 (2H, br) 16 2 ESI+: 265, 267 NMR: 1.19 (3H, t, J = 6.9 Hz), 1.68-1.74 (2H, m), 2.69 (2H, t, J = 6.6 Hz), 2.85 (2H, q, J = 6.9 Hz), 2.95-2.98 (2H, m), 3.00-3.02 (2H, m), 3.13-3.18 (4H, m), 3.29-3.32 (2H, m), 6.86 (1H, s), 9.01-9.20 (2H, br) mp: 221-223 17 2 ESI+: 219 NMR: 2.96-3.04 (4H, m), 3.05-3.14 (4H, m), 4.52 (2H, s), 6.72 (1H, s), 6.82 (1H, s), 9.26-9.42 (2H, br), 10.71 (1H, s) 18 2 ESI+: 233 NMR: 3.01-3.19 (8H, m), 3.25 (3H, s), 4.61 (2H, s), 6.88 (1H, s), 7.05 (1H, s), 9.33-9.47 (2H, br) 19 2 FAB+: 233 NMR: 2.04 (3H, s), 2.78 (3H, s), 2.85-3.09 (8H, br), 3.12-3.23 (2H, m), 4.17-4.28 (2H, m), 6.42 (1H, s), 6.44 (2H, s) 20 2 FAB+: 205 NMR: 2.75-2.89 (4H, br), 2.93-3.08 (4H, br), 3.15-3.31 (2H, m), 3.99-4.13 (2H, m), 5.17-5.93 (0.7H, br), 6.36 (1H, s), 6.44 (1.8H, s), 6.46 (1H, s) mp: 192-195 21 2 ESI+: 307, 309 NMR: 0.73 (3H, d, J = 6.3 Hz), 1.07-1.19 (4H, m), 1.54-2.19 (2H, m), 2.38-2.75 (6H, m), 3.07-3.39 (6H, m), 4.14-4.27 (0.15H, br), 4.49-4.55 (0.85H, br), 7.01-7.20 (1H, m), 9.00-9.27 (2H, br) mp: 245-249 22 2 ESI+: 279, 281 NMR: 0.87 (3H, t, J = 7.3 Hz), 1.64-1.73 (4H, m), 2.65-2.68 (2H, m), 2.72-2.76 (2H, m), 2.84-2.91 (6H, m), 2.96-2.98 (2H, m), 3.02-3.70 (4H, m), 6.41 (1H, s), 6.77 (1H, s) 23 2 ESI+: 295, 297 NMR: 1.69-1.75 (2H, m), 2.67 (2H, t, J = 6.4 Hz), 2.85-2.91 (6H, m), 2.98 (2H, t, J = 6.4 Hz), 3.02-3.04 (2H, m), 3.10-3.60 (6H, m), 3.67 (2H, t, J = 6.4 Hz), 6.41 (1H, s), 6.78 (1H, s)

TABLE 150 Ex Syn Dat 24 2 ESI+: 217 NMR: 1.79-1.90 (2H, m), 2.61 (2H, t, J = 6.2 Hz), 2.79 (3H, s), 2.74-2.93 (4H, m), 2.94-3.07 (4H, m), 3.07-3.15 (2H, m), 6.40 (1H, s), 6.43 (2H, s), 6.67 (1H, s) 25 2 FAB+: 219 NMR: 2.02 (3H, s), 2.65-2.95 (8H, m), 3.15-3.28 (2H, m), 4.05-4.14 (2H, m), 5.32-5.54 (1H, br), 6.21 (1H, s), 6.37 (1H, s) 26 2 FAB+: 233 NMR: 1.04 (3H, t, J = 7.0 Hz), 2.78-2.94 (4H, br), 2.95-3.08 (4H, br), 3.15-3.24 (2H, m), 3.28 (2H, q, J = 7.0 Hz), 4.06-4.18 (2H, m), 6.44 (2H, s), 6.49 (1H, s), 6.55 (1H, s) 27 2 FAB+: 283, 285 NMR: 2.81-2.90 (2H, m), 2.90-3.00 (4H, m), 3.11-3.20 (2H, m), 3.29-3.37 (2H, m), 4.02-4.10 (2H, m), 5.31-5.39 (1H, br), 6.43 (1.3H, s), 6.57 (1H, s) 28 2 ESI+: 219 NMR: 1.99 (3H, s), 2.74-2.83 (2H, m), 2.86-2.97 (6H, m), 3.24-3.31 (2H, m), 3.98-4.06 (2H, m), 4.86-5.09 (1H, br), 6.37 (1H, s), 6.38 (1H, s) 29 2 ESI+: 283 NMR: 2.97-3.06 (4H, m), 3.07-3.18 (7H, m), 3.74-3.81 (2H, m), 4.20-4.28 (2H, m), 6.80 (1H, s), 7.40 (1H, s), 9.28-9.42 (2H, br) 30 2 ESI+: 247 NMR: 1.12 (6H, d, J = 6.6 Hz), 2.87-3.14 (8H, br), 3.15-3.25 (2H, br), 4.02-4.20 (3H, m), 6.57 (1H, s), 6.75 (1H, s), 9.31-9.52 (2H, br) 31 2 ESI+: 233 NMR: 2.19 (3H, s), 2.56 (3H, s), 2.88-2.94 (2H, m), 2.95-3.08 (8H, m), 4.04-4.11 (2H, m), 6.44 (2H, s), 6.51 (1H, s) 32 2 ESI+: 281, 283 NMR: 1.69-1.80 (2H, m), 2.64 (2H, t, J = 6.2 Hz), 2.80-2.89 (2H, m), 2.89-3.01 (4H, m), 3.13-3.21 (2H, m), 3.21-3.29 (2H, m), 6.42 (1.4H, s), 6.69 (1H, s) 33 2 ESI+: 245 NMR: 1.78-1.89 (2H, m), 2.15 (3H, s), 2.64 (2H, t, J = 6.6 Hz), 2.88-3.08 (8H, m), 3.64 (2H, t, J = 6.2 Hz), 6.44 (2H, s), 6.96 (1H, s) mp: 159-162 34 2 ESI+: 231 NMR: 1.03 (3H, t, J = 7.0 Hz), 1.78-1.87 (2H, m), 2.59 (2H, t, J = 6.2 Hz), 2.79-2.84 (2H, m), 2.86-2.92 (2H, m), 2.96-3.06 (4H, m), 3.16 (2H, t, J = 5.5 Hz), 3.28 (2H, q, J = 7.0 Hz), 6.41 (1H, s), 6.43 (2H, s), 6.65 (1H, s) 35 2 ESI+: 297, 299 NMR: 2.72 (3H, s), 2.93-3.12 (8H, m), 3.23-3.33 (2H, m), 4.08-4.20 (2H, m), 6.46 (2H, s), 6.72 (1H, s) mp: 200-204 36 2 ESI+: 245 NMR: 0.50-0.64 (2H, m), 0.99-1.12 (2H, m), 1.57-1.68 (1H, m), 2.90-3.01 (2H, m), 3.04-3.17 (4H, m), 3.23-3.34 (2H, m), 3.36-3.47 (2H, m), 4.20-4.33 (2H, br), 6.62 (1H, s), 9.19-9.38 (2H, br) mp: 193-197

TABLE 151 Ex Syn Dat 37 2 ESI+: 273 NMR: 1.01 (6H, d, J = 6.6 Hz), 1.78-1.90 (2H, m), 2.64 (2H, t, J = 6.8 Hz), 2.91-3.14 (9H, m), 3.64 (2H, t, J = 6.2 Hz), 6.46 (2H, s), 7.00 (1H, s), 7.09-7.24 (1H, br) 38 2 ESI+: 259 NMR: 0.89 (6H, d, J = 6.5 Hz), 1.76-1.84 (2H, m), 1.92-2.04 (1H, m), 2.60 (2H, t, J = 6.3 Hz), 2.77-2.84 (2H, m), 2.85-2.91 (2H, m), 2.97 (2H, d, J = 7.4 Hz), 2.97-3.06 (4H, m), 3.16-3.25 (2H, m), 6.33 (1H, s), 6.44 (2H, s), 6.65 (1H, s) 39 2 ESI+: 305, 307 NMR: 0.52-0.98 (4H, m), 1.43-2.77 (6H, m), 2.89-4.33 (11H,), 4.42-4.54 (1H, m), 6.48 (2H, s), 6.97-7.11 (1H, m) 40 2 ESI+: 319, 321 NMR: 1.39-4.80 (24H, m), 6.48 (2H, s), 6.99 (0.4H, s), 7.08 (0.6H, s) 41 2 ESI+: 291, 293 NMR: 0.17-0.20 (2H, m), 0.47-0.52 (2H, m), 1.04-1.15 (1H, m), 1.69-1.75 (2H, m), 2.67 (2H, t, J = 6.7 Hz), 2.74 (2H, d, J = 6.4 Hz), 2.85-2.91 (6H, m), 3.05-3.80 (6H, m), 6.41 (1H, s), 6.78 (1H, s) 42 2 ESI+: 305, 307 NMR: 1.69-1.92 (6H, m), 1.99-2.05 (2H, m), 2.65-2.75 (3H, m), 2.82-3.95 (15H, m), 6.46 (2H, s), 6.80 (1H, s) mp: 141-143 43 2 ESI+: 333, 335 NMR: 1.18-2.12 (10H, m), 2.32-2.75 (4H, m), 2.92-4.18 (11H, m), 4.18-4.29 (0.25H, br), 4.48-4.59 (0.75H, br), 6.48 (2H, s), 6.99 (0.25H, s), 7.11 (0.75H, s) 44 2 ESI+: 341, 343 NMR: 11.68-1.83 (1H, br), 2.64-2.82 (2H, m), 2.82-4.02 (14H, m), 6.48 (2H, s), 7.08 (1H, s), 7.14-7.71 (5H, br) 45 2 ESI+: 319, 321 NMR: 1.30-1.38 (2H, m), 1.47-1.63 (4H, m), 1.70-1.77 (4H, m), 2.28 (1H, quint, J = 7.5 Hz), 2.68 (2H, t, J = 6.7 Hz), 2.82 (2H, d, J = 7.3 Hz), 2.91-2.94 (2H, m), 2.99-3.05 (6H, m), 3.11-3.71 (5H, m), 6.46 (2H, s), 6.81 (1H, s) mp: 151-153 46 2 ESI+: 327, 329 NMR: 1.72-1.78 (2H, m), 2.74 (2H, t, J = 6.6 Hz), 2.81-2.84 (2H, m), 3.05-3.07 (2H, m), 3.15-3.20 (4H, m), 3.32-3.35 (2H, m), 4.09 (2H, s), 6.93 (1H, s), 7.28 (1H, t, J = 7.4 Hz), 7.37 (2H, t, J = 7.4 Hz), 7.54 (2H, d, J = 7.4 Hz), 9.0-9.30 (2H, br) 47 2 ESI+: 347, 348 NMR: 0.73-3.85 (26H, m), 4.13-4.24 (0.2H, br), 4.46-4.55 (0.8H, br), 6.45 (1H, s), 6.93-7.00 (0.2H, br), 7.08 (0.8H, s) 48 2 ESI+: 333, 335 NMR: 0.94-1.04 (2H, m), 1.13-1.27 (3H, m), 1.62-1.75 (6H, m), 1.83 (2H, d, J = 12.8 Hz), 2.66-2.72 (4H, m), 2.91-2.94 (2H, m), 2.99-3.03 (6H, m), 3.11-3.74 (5H, m), 6.46 (2H, s), 6.81 (1H, s) 49 2 ESI+: 217 NMR: 1.69-1.79 (2H, m), 1.95 (3H, s), 2.61 (2H, t, J = 6.2 Hz), 2.79-2.87 (2H, m), 2.93-3.05 (6H, m), 3.21 (2H, t, J = 5.3 Hz), 6.44 (2H, s), 6.54 (1H, s)

TABLE 152 Ex Syn Dat 50 2 ESI+: 219 NMR: 1.33 (3H, d, J = 6.4 Hz), 2.91-3.22 (9H, m), 3.44-3.54 (1H, m), 4.26-4.37 (1H, m), 6.75 (1H, s), 6.87 (1H, s), 9.36-9.58 (2H, br) mp: 193-194 51 2 ESI+: 279 NMR: 1.79-1.97 (2H, m), 2.58-2.69 (2H, m), 2.69-2.80 (2H, m), 2.93-3.08 (4H, m), 3.08-3.23 (4H, m), 6.95 (1H, s), 7.15-7.29 (2H, m), 7.37-7.56 (3H, m), 9.11-9.33 (2H, m) 52 2 FAB+; 231 NMR: 1.67-1.79 (2H, m), 2.18 (3H, s), 2.53 (3H, s), 2.66 (2H, t, J = 6.6 Hz), 2.85-2.93 (2H, m), 2.93-3.06 (8H, m), 6.43 (2H, s), 6.67 (1H, s) 53 2 ESI+: 263 NMR: 2.80-2.94 (4H, m), 2.96-3.09 (4H, m), 3.26 (3H, s), 3.29-3.34 (2H, m), 3.38 (2H, t, J = 5.4 Hz), 3.50 (2H, t, J = 5.4 Hz), 4.04-4.12 (2H, m), 6.44 (1.8H, s), 6.50 (1H, s), 6.54 (1H, s) 54 2 ESI+: 233 NMR-A: 1.26 (3H, d, J = 6.3 Hz), 2.74-2.98 (8H, m), 3.06-3.18 (4H, br), 3.19-3.26 (1H, m), 4.18-4.28 (1H, m), 6.54 (1H, s), 6.56 (1H, s), 6.64 (1H, s), 8.65-8.98 (2H, br) 55 2 ESI+: 261 NMR: 1.05 (3H, d, J = 6.5 Hz), 1.12 (3H, d, J = 6.5 Hz), 1.26 (3H, d, J = 6.2 Hz), 2.63-2.73 (1H, m), 2.76-3.12 (8H, m), 3.19-3.30 (1H, m), 3.98-4.13 (2H, m), 6.44 (1.7H, s), 6.50 (1H, s), 6.62 (1H, s) 56 2 ESI+: 259 NMR: 0.18-0.32 (2H, m), 0.41-0.57 (2H, m), 0.92-1.08 (1H, m), 2.83-3.22 (10H, m), 3.30-3.48 (2H, m), 4.10-4.24 (2H, m), 6.57 (1H, s), 6.73 (1H, s), 9.27-9.55 (2H, br) mp: 179-182 57 2 ESI+: 275 NMR: 1.06 (6H, d, J = 6.6 Hz), 2.94-3.04 (4H, m), 3.08-3.19 (5H, m), 3.80-3.90 (2H, m), 4.16-4.28 (2H, m), 6.76 (1H, s), 7.25-7.86 (1H, br), 9.10-9.36 (2H, br) 58 2 ESI+: 261 NMR: 0.90 (6H, d, J = 6.7 Hz), 1.91-2.05 (1H, m), 2.82-2.99 (6H, m), 3.05-3.15 (4H, br), 3.24-3.30 (2H, m), 4.07-4.12 (2H, m), 6.50 (1H, s), 6.52 (1H, s), 8.80-8.96 (2H, br) mp: 157 59 2 ESI+: 277 NMR: 1.68-1.80 (2H, m), 2.77-2.92 (4H, m), 2.96-3.09 (4H, m), 3.17-3.30 (7H, m), 3.36 (2H, t, J = 6.1 Hz), 4.05-4.15 (2H, m), 6.44 (2H, s), 6.49 (1H, s), 6.51 (1H, s) mp: 141-145 60 1 ESI+: 337 NMR: 1.70-1.80 (2H, m), 2.36-2.42 (2H, m), 2.66-2.80 (4H, m), 2.86-2.93 (2H, m), 2.97-3.07 (4H, m), 3.02 (3H, s), 3.11-3.17 (2H, m), 3.21-3.28 (2H, m), 6.82 (1H, s), 7.07-7.13 (2H, m), 7.28-7.34 (1H, m), 7.36-7.42 (2H, m) 61 2 ESI+: 261 NMR: 0.92 (3H, t, J = 7.3 Hz), 1.26-1.40 (2H, m), 1.45-1.58 (2H, m), 2.85-3.14 (8H, m), 3.16-3.34 (4H, m), 4.08-4.23 (2H, m), 6.54 (1H, s), 6.60 (1H, s), 9.30-9.54 (2H, br) 62 2 ESI+: 295 NMR: 2.70-2.97 (8H, m), 3.22-3.31 (2H, m), 4.10-4.20 (2H, m), 4.42 (2H, s), 6.39 (1H, s), 6.51 (1H, s), 6.55 (1H, s), 7.21-7.40 (5H, m)

TABLE 153 Ex Syn Dat 63 2 ESI+: 277 NMR: 1.10 (3H, t, J = 6.9 Hz), 2.78-2.95 (4H, m), 2.97-3.10 (4H, m), 3.29-3.48 (6H, m), 3.53 (2H, t, J = 5.7 Hz), 4.04-4.12 (2H, m), 6.44 (1.8H, s), 6.50 (1H, s), 6.55 (1H, s) 64 2 ESI+: 303 NMR: 1.17-1.32 (2H, m), 1.52-1.64 (2H, br), 1.85-2.00 (1H, m), 2.81-3.18 (10H, m), 3.21-3.36 (4H, m), 3.79-3.92 (2H, m), 4.02-4.17 (2H, m), 6.51 (1H, s), 6.54 (1H, s), 9.30-9.52 (2H, br) 65 2 ESI+: 281 NMR: 2.59-2.70 (2H, m), 2.90-3.17 (6H, m), 3.20-3.32 (2H, m), 4.14-4.24 (2H, m), 6.73 (1H, s), 7.19-7.30 (2H, m), 7.39-7.54 (3H, m), 9.29-9.49 (2H, br) 66 2 ESI+: 309 NMR: 1.66-1.78 (2H, m), 2.51-2.58 (2H, m), 2.61-2.70 (2H, m), 2.82-2.95 (4H, m), 2.97-3.12 (4H, m), 3.76 (3H, s), 6.43 (2H, s), 6.65 (1H, d, J = 2.0 Hz), 6.67 (1H, d, J = 7.7 Hz), 6.72 (1H, s), 6.94 (1H, dd, J = 2.0, 7.8 Hz), 7.38 (1H, dd, J = 7.7, 7.8 Hz) 67 2 ESI+: 313, 315 NMR: 1.64-1.80 (2H, m), 2.46-2.56 (2H, m), 2.66 (2H, t, J = 6.2 Hz), 2.79-2.93 (3H, m), 2.94-3.02 (2H, m), 3.03-3.13 (2H, m), 3.88-3.99 (1H, br), 6.40 (1.5H, s), 6.73 (1H, s), 7.03-7.10 (1H, m), 7.12-7.16 (1H, m), 7.40-7.46 (1H, m), 7.49 (1H, dd, J = 7.6, 7.9 Hz) mp: 159-162 68 2 ESI+: 347, 349 NMR: 1.66-1.78 (2H, m), 2.41-2.47 (2H, m), 2.65 (2H, t, J = 6.2 Hz), 2.72-2.84 (4H, m), 2.84-2.94 (2H, m), 3.01-3.11 (2H, m), 4.08-4.15 (1H, br), 6.37 (1H, s), 6.71 (1H, s), 7.07 (1H, dd, J = 1.8, 8.2 Hz), 7.32 (1H, d, J = 1.8 Hz), 7.68 (1H, d, J = 8.2 Hz) 69 2 ESI+: 371, 373 NMR: 1.62-1.73 (2H, m), 2.38-2.45 (2H, m), 2.52-2.65 (4H, m), 2.66-2.73 (2H, m), 2.74-2.83 (2H, m), 2.84-2.99 (6H, m), 2.95 (3H, s), 6.38 (1H, s), 6.84 (1H, s), 7.07-7.12 (1H, m), 7.17-7.21 (1H, m), 7.38-7.50 (2H, m) 70 2 ESI+: 405, 407 NMR: 1.61-1.73 (2H, m), 2.39-2.74 (8H, m), 2.77-2.99 (8H, m), 2.96 (3H, s), 6.40 (0.8H, s), 6.87 (1H, s), 7.13 (1H, dd), 7.41 (1H, d, J = 1.8 Hz), 7.70 (1H, d, J = 8.2 Hz) 71 2 ESI+: 275 NMR: 2.47-2.53 (2H, m), 2.71-2.80 (2H, m), 2.88-3.08 (8H, m), 3.24 (3H, s), 3.48 (2H, t, J = 6.1 Hz), 4.02 (2H, t, J = 6.1 Hz), 6.44 (1.7H, s), 6.99 (1H, s), 7.01 (1H, s) mp: 164-166 72 2 ESI+: 365 NMR: 0.34 (3H, d, J = 6.8 Hz), 0.35 (3H, d, J = 6.8 Hz), 1.13-1.29 (1H, m), 1.58-1.78 (2H, m), 2.18-2.36 (2H, m), 2.56-2.66 (2H, m), 2.71 (2H, t, J = 6.6 Hz), 2.81-3.09 (8H, m), 3.74 (3H, s), 6.42 (2H, s), 6.63-6.73 (2H, m), 6.85 (1H, s), 6.88 (1H, dd, J = 1.8, 7.8 Hz), 7.30 (1H, dd, J = 7.7, 7.8 Hz) 73 2 ESI+: 367 NMR: 1.61-1.73 (2H, m), 2.30-2.50 (4H, m), 2.53-2.60 (2H, m), 2.60-2.73 (4H, m), 2.73-2.81 (2H, m), 2.82-2.97 (4H, m), 2.93 (3H, s), 3.75 (3H, s), 6.37 (1H, s), 6.66-6.70 (2H, m), 6.80 (1H, s), 6.88-6.93 (1H, m), 7.33 (1H, dd, J = 7.9, 8.2 Hz) 74 2 ESI+: 243 NMR: 0.23-0.33 (2H, m), 0.98-1.08 (2H, m), 1.29-1.39 (1H, m), 1.70-1.81 (2H, m), 2.60 (2H, t, J = 6.2 Hz), 2.76-2.85 (2H, m), 2.92-3.08 (4H, m), 3.13-3.23 (2H, m), 3.23-3.29 (2H, m), 4.97 (1H, s), 6.42 (2H, s), 6.57 (1H, s)

TABLE 154 Ex Syn Dat 75 2 ESI+: 355 NMR: 1.70-1.81 (2H, m), 2.47-2.53 (2H, m), 2.61-2.66 (2H, m), 2.66-2.74 (2H, m), 2.79 (2H, t, J = 6.6 Hz), 2.82-2.89 (2H, m), 2.90-3.05 (6H, m), 3.04 (3H, s), 6.47 (1H, s), 6.92 (1H, s), 7.01-7.10 (2H, m), 7.21-7.31 (1H, m), 7.51-7.60 (1H, dd, J = 7.1, 14.4 Hz) 76 2 ESI+: 291 NMR: 1.07 (6H, d, J = 6.1 Hz), 2.79-2.94 (4H, m), 2.96-3.10 (4H, m), 3.28-3.41 (4H, m), 3.48-3.59 (3H, m), 4.04-4.13 (2H, m), 6.44 (1.8H, s), 6.50 (1H, s), 6.54 (1H, s) mp: 135 77 2 ESI+: 289 NMR: 1.51-1.64 (1H, m), 1.92-2.04 (1H, m), 2.54-2.65 (1H, m), 2.84-3.35 (12H, m), 3.38-3.49 (1H, m), 3.58-3.68 (1H, m), 3.69-3.84 (2H, m), 4.06-4.15 (2H, m), 6.53 (1H, s), 6.59 (1H, s), 9.28-9.54 (2H, br) 78 2 ESI+: 353 NMR: 2.34 (3H, s), 2.39-2.48 (2H, m), 2.54-2.65 (4H, m), 2.77-3.09 (11H, m), 3.96-4.08 (2H, m), 6.40 (1.5H, s), 6.67 (1H, s), 6.93 (1H, d, J = 7.6 Hz), 6.98 (1H, s), 7.18 (1H, d, J = 7.6 Hz), 7.33 (1H, t, J = 7.6 Hz) mp: 173-176 79 2 ESI+: 295 NMR: 2.35 (3H, s), 2.52-2.61 (2H, m), 2.81-2.97 (4H, m), 2.97-3.12 (2H, m), 3.12-3.25 (2H, m), 3.92-4.12 (3H, m), 6.42 (1.8H, s), 6.57 (1H, s), 6.92 (1H, d, J = 7.7 Hz), 6.95 (1H, s), 7.19 (1H, d, J = 7.7 Hz), 7.36 (1H, t, J = 7.7 Hz) 80 2 ESI+: 299 NMR: 0.29-0.38 (2H, m), 0.81 (6H, d, J = 6.7 Hz), 0.89-1.00 (2H, m), 1.54-1.66 (1H, m), 1.66-1.77 (2H, m), 1.84-1.99 (1H, m), 2.58 (2H, t, J = 6.3 Hz), 2.78-2.85 (2H, m), 2.92 (2H, d, J = 7.3 Hz), 2.94-3.05 (4H, m), 3.07-3.17 (2H, m), 3.17-3.25 (2H, m), 6.40 (1H, s), 6.62 (1H, s) 81 2 ESI+: 301 NMR: 0.30-0.42 (2H, m), 0.93-1.04 (2H, m), 1.57-1.74 (3H, m), 2.61 (2H, t, J = 6.4 Hz), 2.83-2.94 (2H, m), 2.98-3.32 (13H, m), 3.56 (2H, t, J = 6.2 Hz), 6.43 (2H, s), 6.65 (1H, s) 82 2 ESI+: 291 NMR: 1.29 (3H, d, J = 7.3 Hz), 2.73 (1H, dd, J = 12.0, 7.3 Hz), 2.80-3.00 (5H, m), 3.11-3.18 (1H, m), 3.25 (3H, s), 3.53 (2H, t, J = 5.6 Hz), 4.01-4.12 (2H, m), 4.58 (2H, s), 6.44 (1H, s), 6.79 (1H, s), 7.04 (1H, s) 83 2 ESI+: 305 NMR: 1.32 (3H, d, J = 7.4 Hz), 1.79 (2H, quint, J = 6.6 Hz), 2.80 (1H, dd, J = 13.0, 7.4 Hz), 2.85-3.09 (5H, m), 3.20-3.28 (4H, m), 3.36 (2H, t, J = 6.6 Hz), 3.94 (2H, t, J = 6.6 Hz), 4.57 (2H, s), 6.48 (2H, s), 6.83 (1H, s), 6.96 (1H, s) 84 2 ESI+: 277 NMR: 1.27 (3H, d, J = 7.2 Hz), 2.77-2.88 (4H, m), 3.02-3.14 (3H, m), 3.26 (3H, s), 3.31-3.33 (2H, m), 3.38-3.41 (2H, m), 3.51 (2H, t, J = 5.5 Hz), 4.07-4.09 (2H, m), 6.45 (2H, s), 6.48 (1H, s), 6.51 (1H, s) 85 2 ESI+: 291 NMR: 1.28 (3H, d, J = 7.2 Hz), 1.74 (2H, quint, J = 6.3 Hz), 2.76-2.89 (4H, m), 3.04-3.16 (3H, m), 3.22-3.29 (7H, m), 3.37 (2H, t, J = 6.3 Hz), 4.10-4.12 (2H, m), 6.45 (2H, s), 6.48 (1H, s), 6.50 (1H, s)

TABLE 155 Ex Syn Dat 86 2 ESI+: 289 NMR: 1.53-1.62 (2H, br), 1.62-1.77 (2H, m), 2.84-3.15 (8H, m), 3.16-3.26 (2H, m), 3.45 (2H, t, J = 11.2 Hz), 3.80-3.97 (3H, m), 4.05-4.14 (2H, m), 6.54 (1H, s), 6.75 (1H, s), 9.24-9.48 (1.8H, br) 87 2 ESI+: 245 NMR: 1.31 (6H, d, J = 7.1 Hz), 1.83-1.95 (2H, m), 2.68-2.80 (2H, m), 2.97-3.27 (8H, m), 3.27-3.45 (3H, m), 6.94 (1H, s), 9.27 (2H, s) 88 2 ESI+: 303 NMR: 0.41-0.48 (2H, m), 0.96-1.03 (2H, m), 1.56-1.64 (1H, m), 2.75-2.85 (2H, m), 2.85-2.97 (4H, m), 3.08-3.18 (6H, m), 3.25 (3H, s), 3.62 (2H, t, J = 6.0 Hz), 3.97-4.03 (2H, m), 6.38 (1H, s), 6.47 (1H, s) 89 2 ESI+: 303 NMR: 1.23 (6H, d, J = 7.1 Hz), 1.65-1.81 (2H, m), 2.63-2.70 (2H, m), 2.76-2.91 (4H, m), 2.93-3.15 (8H, m), 3.29 (3H, s), 3.58 (2H, t, J = 6.2 Hz), 3.85-3.99 (1H, m), 6.43 (2H, s), 6.68 (1H, s) 90 2 ESI+: 277 NMR: 2.18 (3H, s), 2.80-2.86 (2H, m), 2.87-2.93 (2H, m), 2.94-3.10 (8H, m), 3.30 (3H, s), 3.61 (2H, t, J = 5.8 Hz), 4.02-4.08 (2H, m), 6.42 (1.7H, s), 6.49 (1H, s) mp: 166-170 91 2 ESI+: 273 NMR: 1.46-1.84 (8H, m), 2.79-2.94 (4H, m), 2.95-3.07 (4H, m), 3.12-3.19 (2H, m), 4.08-4.22 (3H, m), 6.43 (1.7H, s), 6.49 (1H, s), 6.67 (1H, s) 92 2 ESI+: 281 NMR: 2.66-2.74 (2H, m), 2.77-2.97 (6H, m), 3.60-3.70 (2H, m), 4.15-4.22 (2H, m), 6.38 (1H, s), 6.62-6.66 (2H, br), 7.02-7.09 (1H, m), 7.18-7.25 (2H, m), 7.31-7.39 (2H, m) mp: 220-222 93 2 ESI+: 317 NMR: 0.43-0.49 (1H, m), 0.61-0.66 (1H, m), 0.98-1.05 (2H, m), 1.28 (3H, d, J = 7.4 Hz), 1.60-1.67 (1H, m), 2.61-2.67 (2H, m), 2.90-2.93 (1H, m), 3.04-3.25 (8H, m), 3.32 (2H, dd, J = 13.2, 4.8 Hz), 3.62 (2H, t, J = 5.9 Hz), 3.97-4.03 (2H, m), 4.14-4.20 (1H, m), 6.44-6.46 (3H, m) 94 2 ESI+: 275 NMR: 1.67-1.73 (2H, m), 2.15 (3H, s), 2.64 (2H, t, J = 6.7 Hz), 2.79-2.84 (4H, m), 2.88-2.93 (6H, m), 3.02-3.04 (2H, m), 3.28 (3H, s), 3.59 (2H, t, J = 6.2 Hz), 6.37 (1H, s), 6.62 (1H, s) 95 2 ESI+: 261 NMR: 1.67-1.73 (2H, m), 2.17 (3H, s), 2.65 (2H, t, J = 6.7 Hz), 2.72 (2H, t, J = 6.7 Hz), 2.89-2.91 (2H, m), 2.99-3.04 (8H, m), 3.66 (2H, t, J = 6.7 Hz), 6.43 (2H, s), 6.66 (1H, s) 96 2 ESI+: 231 NMR: 1.08 (3H, t, J = 7.3 Hz), 1.88-1.98 (2H, m), 2.62-2.79 (4H, m), 2.98-3.18 (8H, m), 3.27-3.37 (2H, m), 6.92 (1H, s), 9.33 (2H, s) 97 2 ESI+: 289 NMR: 1.03 (3H, t, J = 7.4 Hz), 1.68-1.78 (2H, m), 2.66 (2H, t, J = 6.9 Hz), 2.72 (2H, q, J = 7.4 Hz), 2.86 (2H, t, J = 6.3 Hz), 2.90-2.95 (2H, m), 2.95-3.05 (4H, m), 3.06-3.13 (4H, m), 3.30 (3H, s), 3.59 (2H, t, J = 6.3 Hz), 6.52 (2H, s), 6.69 (1H, s)

TABLE 156 Ex Syn Dat 98 2 ESI+: 291 NMR: 1.04 (3H, t, J = 7.4 Hz), 2.71 (2H, q, J = 7.4 Hz), 2.84-2.93 (4H, m), 2.94-3.08 (8H, m), 3.31 (3H, s), 3.61 (2H, t, J = 5.9 Hz), 4.06-4.12 (2H, m), 6.44 (2H, s), 6.50 (1H, s) mp: 159-163 99 2 ESI+: 277 NMR: 1.07 (3H, d, J = 6.7 Hz), 2.79-2.94 (4H, m), 2.97-3.09 (4H, m), 3.14-3.22 (2H, m), 3.24 (3H, s), 3.32-3.39 (1H, m), 3.41-3.48 (1H, m), 4.01-4.11 (3H, m), 6.44 (2H, s), 6.50 (1H, s), 6.63 (1H, s) 100 2 ESI+: 259 NMR: 0.88 (6H, d, J = 6.6 Hz), 1.77-1.98 (3H, m), 2.54-2.78 (4H, m), 2.91-3.17 (8H, m), 3.26-3.33 (2H, m), 6.88 (1H, s), 9.34 (2H, s) 101 2 ESI+: 305 NMR: 1.24 (6H, d, J = 7.4 Hz), 2.80-2.92 (4H, m), 2.98-3.13 (8H, m), 3.30 (3H, s), 3.60 (2H, t, J = 5.9 Hz), 3.80-3.97 (1H, m), 4.04-4.12 (2H, m), 6.43 (1.8H, s), 6.51 (1H, s) 102 2 ESI+: 319 NMR: 1.01 (3H, t, J = 7.2 Hz), 1.62-1.87 (2H, m), 2.62-2.82 (6H, m), 2.85-3.07 (8H, m), 3.16-3.28 (2H, m), 3.26 (3H, s), 3.30 (2H, d, J = 5.5 Hz), 3.91-3.99 (1H, m), 6.43 (2H, s), 6.67 (1H, s) 103 2 ESI+: 265 NMR: 1.83-1.98 (2H, m), 2.85-3.00 (4H, m), 3.01-3.14 (4H, br), 3.22-3.29 (2H, m), 3.29-3.37 (2H, m), 4.09-4.18 (2H, m), 4.53 (2H, dt, J = 47.4, 5.8 Hz), 6.54 (1H, s), 6.57 (1H, s), 9.30-9.46 (2H, br) 104 2 ESI+: 317 NMR: 0.40-0.50 (2H, m), 0.96-1.05 (2H, m), 1.10 (3H, t, J = 7.0 Hz), 1.58-1.67 (1H, m), 2.84-2.92 (2H, m), 2.99-3.18 (8H, m), 3.18-3.27 (2H, m), 3.43 (2H, q, J = 7.0 Hz), 3.65 (2H, t, J = 6.0 Hz), 3.98-4.05 (2H, m), 6.44 (1.8H, s), 6.52 (1H, s) mp: 140-145 105 2 ESI+: 343 NMR: 0.35-0.56 (6H, m), 0.97-1.08 (2H, m), 1.64-1.75 (1H, m), 2.90-2.98 (2H, m), 3.00-3.36 (15H, m), 4.04-4.13 (2H, m), 6.54 (1H, s), 9.24-9.38 (1.8H, br) mp: 166-167 106 2 ESI+: 317 NMR: 0.39-0.47 (2H, m), 0.95-1.03 (2H, m), 1.56-1.65 (1H, m), 1.82-1.92 (2H, m), 2.78-2.85 (2H, m), 2.87-3.00 (6H, m), 3.02-3.08 (2H, m), 3.13-3.23 (5H, m), 3.34 (2H, t, J = 6.2 Hz), 3.95-4.01 (2H, m), 6.37 (1H, s), 6.48 (1H, s) mp: 169-171 107 2 ESI+: 351 NMR: 1.29 (3H, d, J = 7.2 Hz), 1.84 (2H, quint, J = 6.3 Hz), 2.70 (2H, t, J = 6.3 Hz), 2.72-2.88 (3H, m), 2.97-3.23 (4H, m), 3.69 (2H, t, J = 6.3 Hz), 5.17 (2H, s), 6.47 (2H, s), 6.92 (1H, s), 7.31-7.42 (5H, m), 7.45 (1H, s) 108 2 ESI+: 289 NMR: 1.06-1.23 (3H, br), 161-1.74 (1H, br), 1.96-2.08 (4H, br), 2.62-2.70 (1H, m), 2.91-3.13 (7H, m), 3.16-3.27 (2H, m), 3.52-4.29 (7H, m), 6.87 (1H, s) mp: 185-186

TABLE 157 Ex Syn Dat 109 2 ESI+: 288 NMR: 0.98 (3H, t, J = 7.1 Hz), 1.73-1.84 (2H, br), 2.05 (3H, s), 2.56 (2H, t, J = 6.8 Hz), 2.99-3.08 (6H, m), 3.11-3.18 (4H, m), 3.29-4.63 (5H, br), 5.88-6.09 (1H, br), 6.87 (1H, s) mp: 170-171 110 112 ESI+: 293 NMR: 1.82-1.95 (2H, m), 2.61-2.71 (2H, m), 2.74-2.87 (4H, m), 2.91-3.07 (4H, m), 3.22-3.32 (2H, m), 4.45 (2H, s), 6.36 (1H, s), 6.42 (2H, s), 6.70 (1H, s), 7.17-7.37 (5H, m) mp: 148 (decomp.) 111 112 ESI+: 325 NMR: 2.85-2.94 (4H, m), 3.00-3.12 (4H, m), 3.24-3.28 (2H, m), 3.73 (3H, s), 4.12-4.19 (2H, m), 4.41 (2H, s), 6.56 (1H, s), 6.60 (1H, s), 6.79-6.89 (3H, m), 7.22-7.28 (1H, m), 9.23-9.44 (2H, br) 112 112 ESI+: 329, 331 NMR: 2.78-2.88 (4H, m), 2.96-3.08 (4H, m), 3.27-3.34 (2H, m), 4.12-4.21 (2H, m), 4.44 (2H, s), 6.47 (2H, s), 6.54 (1H, s), 6.56 (1H, s), 7.23-7.42 (4H, m) mp: 151 (decomp.) 113 112 ESI+: 325 NMR: 2.85-2.96 (4H, m), 3.01-3.11 (4H, m), 3.20-3.27 (2H, m), 3.73 (3H, s), 4.11-4.17 (2H, m), 4.36 (2H, s), 6.55 (1H, s), 6.66 (1H, s), 6.87-6.92 (2H, m), 7.20-7.27 (2H, m), 9.30-9.49 (2H, br) 114 112 ESI+: 329, 331 NMR: 2.28 (4H, s), 2.72-2.82 (4H, m), 2.92-3.04 (4H, m), 3.24-3.33 (2H, m), 4.10-4.20 (2H, m), 4.42 (2H, s), 6.52 (1H, s), 6.54 (1H, s), 7.29-7.35 (2H, m), 7.37-7.42 (2H, m) mp: 178 (decomp.) 115 112 ESI+: 325 NMR: 2.28 (4H, s), 2.73-2.88 (4H, m), 2.94-3.05 (4H, m), 3.37-3.46 (2H, m), 3.63 (2H, t, J = 5.6 Hz), 4.07-4.18 (4H, m), 6.51 (1H, s), 6.61 (1H, s), 6.89-6.98 (3H, m), 7.23-7.33 (2H, m) mp: 132-134 116 112 ESI+: 296 NMR: 2.73-2.86 (4H, m), 2.90-3.04 (4H, m), 3.40-3.48 (2H, m), 4.14-4.22 (2H, m), 4.52 (2H, s), 6.43 (2H, s), 6.46 (1H, s), 6.54 (1H, s), 7.23-7.35 (2H, m), 7.70-7.79 (1H, m), 8.50-8.57 (1H, m) 117 112 ESI+: 302 NMR: 2.78-2.90 (4H, m), 2.95-3.06 (4H, m), 3.38-3.45 (2H, m), 4.11-4.17 (2H, m), 4.57 (2H, s), 6.44 (2H, s), 6.51 (1H, s), 6.66 (1H, s), 7.53 (1H, d, J = 2 Hz), 9.06 (1H, d, J = 2 Hz) mp: 134-138 118 2 ESI+: 339 NMR-A: 2.41-2.47 (2H, m), 2.54-2.67 (4H, m), 2.94 (3H, s), 2.96-3.03 (6H, m), 3.13-3.20 (2H, m), 4.00-4.07 (2H, m), 6.63 (1H, s), 6.74 (1H, s), 7.15-7.21 (2H, m), 7.36-7.42 (1H, m), 7.44-7.50 (2H, m) mp: 199-201

TABLE 158 Ex Syn Dat 119 2 ESI+: 249 NMR: 2.85-2.98 (4H, m), 3.03-3.12 (4H, m), 3.29 (2H, t, J = 6.1 Hz), 3.32-3.38 (2H, m), 3.57 (2H, t, J = 6.1 Hz), 4.02-4.17 (2H, m), 5.33-5.89 (2H, br), 6.52 (1H, s), 6.56 (1H, s), 9.17-9.42 (2H, br) 120 2 ESI+: 303 NMR: 0.35-0.39 (2H, m), 0.97-1.01 (2H, m), 1.59-1.72 (3H, m), 1.90-2.03 (2H, m), 2.27 (4H, s), 2.61 (2H, t, J = 6.4 Hz), 2.82-2.84 (2H, m), 3.00-3.03 (2H, m), 3.05-3.09 (6H, m), 3.19-3.22 (2H, m), 4.40 (1H, t, J = 5.8 Hz), 4.52 (1H, t, J = 5.8 Hz), 6.66 (1H, s) 121 2 ESI+: 353, 355 NMR: 2.42-2.48 (2H, m), 2.69-2.76 (2H, m), 2.92-3.01 (6H, m), 3.03 (3H, s), 3.23-3.35 (4H, m), 4.19 (2H, t, J = 5.4 Hz), 6.42 (1H, s), 7.09 (1H, s) mp: 99-104 122 2 ESI+: 337 NMR: 1.78-1.88 (2H, m), 2.67 (2H, t, J = 6.5 Hz), 2.95-3.05 (4H, m), 3.08-3.17 (4H, m), 3.66-3.73 (2H, m), 5.17 (2H, s), 6.95 (1H, s), 7.28-7.44 (5H, m), 7.50 (1H, s), 9.20-9.43 (2H, br) mp: 185-188 123 2 ESI+: 303 NMR: 0.92 (6H, d, J = 6.8 Hz), 1.77-1.97 (3H, m), 2.68 (2H, t, J = 6.5 Hz), 2.95-3.04 (4H, m), 3.10-3.18 (4H, m), 3.63-3.70 (2H, m), 3.90 (2H, d, J = 6.4 Hz), 6.96 (1H, s), 7.48 (1H, s), 9.06-9.26 (2H, br) mp: 202-207 124 2 ESI+: 245 NMR: 1.12 (3H, t, J = 7.0 Hz), 2.46-2.52 (2H, m), 2.72-2.82 (2H, m), 3.00-3.24 (8H, m), 3.88 (2H, q, J = 7.0 Hz), 6.99 (1H, s), 7.04 (1H, s), 9.26-9.50 (2H, br) mp: 241 (decomp.) 125 2 ESI+: 259 NMR: 0.87 (3H, t, J = 7.4 Hz), 1.47-1.61 (2H, m), 2.46-2.52 (2H, m), 2.73-2.82 (2H, m), 3.00-3.21 (8H, m), 3.81 (2H, t, J = 7.5 Hz), 6.98 (1H, s), 7.04 (1H, s), 9.23-9.49 (2H, br) mp: 125-129 126 2 ESI+: 307 NMR: 2.61-2.70 (2H, m), 2.82-3.16 (10H, m), 5.11 (2H, s), 6.83 (1H, s), 7.06 (1H, s), 7.18-7.35 (5H, m), 9.21-9.40 (2H, br) mp: 177-180 127 2 ESI+: 273 NMR: 0.83 (6H, d, J = 6.7 Hz), 1.84-1.97 (1H, m), 2.30 (4H, s), 2.45-2.54 (2H, m), 2.73-2.81 (2H, m), 2.86-3.07 (8H, m), 3.72-3.80 (2H, m), 6.96 (1H, s), 7.01 (1H, s) mp: 142-144

TABLE 159 Ex Syn Dat 128 2 ESI+: 289 NMR: 1.24 (6H, d, J = 6.2 Hz), 1.78-1.84 (2H, m), 2.29 (4H, s), 2.66 (2H, t, J = 6.5 Hz), 2.87-2.89 (4H, br), 2.99-3.01 (4H, br), 3.61-3.64 (2H, m), 4.87 (1H, quint, J = 6.2 Hz), 6.90 (1H, s), 7.44 (1H, s) 129 2 ESI+: 367, 369 NMR: 1.52-1.67 (2H, m), 2.38-2.47 (2H, m), 2.71-2.82 (2H, m), 3.01-3.10 (9H, m), 3.15 (2H, t, J = 6 Hz), 3.30-3.39 (2H, m), 4.06 (2H, t, J = 7.1 Hz), 6.47 (2H, s), 7.13 (1H, s) mp: 153-155 130 2 ESI+: 331 NMR: 2.93-3.10 (10H, m), 3.13-3.21 (2H, m), 3.24 (3H, s), 3.58 (2H, t, J = 5.9 Hz), 4.12 (2H, t, J = 4.4 Hz), 6.46 (2H, s), 6.91 (1H, s) mp: 180 (decomp.) 131 2 ESI+: 329 NMR: 1.66-1.81 (2H, m), 2.68 (2H, t, J = 6.4 Hz), 2.90-3.18 (12H, m), 3.20 (3H, s), 3.52 (2H, t, J = 6.0 Hz), 6.45 (2H, s), 7.02 (1H, s) mp: 175 (decomp.) 132 2 ESI+: 261 NMR: 0.88 (3H, t, J = 7.4 Hz), 1.49-1.63 (2H, m), 2.86-3.07 (8H, m), 3.77-3.88 (2H, m), 4.57 (2H, s), 6.43 (2H, s), 6.84 (1H, s), 7.03 (1H, s) mp: 183 (decomp.) 133 2 ESI+: 309 NMR: 2.89-3.18 (8H, m), 3.32 (3H, s), 4.75 (2H, s), 5.12 (2H, s), 6.90 (1H, s), 6.94 (1H, s), 7.21-7.36 (5H, m), 9.19-9.37 (2H, br) mp: 233 (decomp.) 134 2 ESI+: 351 NMR: 1.74-1.80 (2H, m), 2.30 (4H, s), 2.64 (2H, t, J = 6.6 Hz), 2.76-2.79 (2H, br), 2.84-2.87 (2H, br), 2.93-2.99 (6H, m), 3.57-3.60 (2H, m), 4.33 (2H, t, J = 6.6 Hz), 6.88 (1H, s), 7.21-7.33 (6H, m) 135 2 ESI+: 341, 343 NMR-A: 2.98-3.05 (4H, m), 3.07-3.13 (2H, m), 3.14-3.23 (4H, m), 3.28-3.35 (5H, m), 3.74 (2H, t, J = 6.18 Hz), 4.10-4.16 (2H, m), 6.64 (2H, s), 6.77 (1H, s), 8.89 (2H, s) mp: 183 (decomp.) 136 2 ESI+: 337, 339 NMR: 0.70 (3H, t, J = 7.4 Hz), 1.29-1.45 (2H, m), 2.41-2.48 (2H, m), 2.72-2.80 (2H, m), 3.00-3.11 (6H, m), 3.28-3.40 (2H, m), 3.98 (2H, t, J = 7.3 Hz), 6.47 (2H, s), 6.98 (1H, s) mp: 187 (decomp.) 137 2 ESI+: 335 NMR: 0.46 (3H, t, J = 7.4 Hz), 0.91-1.03 (2H, m), 2.30 (4H, s), 2.45-2.52 (2H, m), 2.71-2.84 (6H, m), 2.89-3.11 (6H, m), 7.13 (1H, s), 7.16-7.23 (2H, m), 7.38-7.52 (3H, m) mp: 196-200

TABLE 160 Ex Syn Dat 138 2 ESI+: 339 NMR: 2.28 (3H, s), 2.74-2.96 (8H, m), 3.72 (3H, s), 4.73 (2H, s), 5.08 (2H, s), 6.79-6.89 (5H, m), 7.18-7.29 (1H, m) mp: 188-189 139 2 ESI+: 343, 345 NMR: 2.29 (3H, s), 2.74-2.98 (8H, m), 4.75 (2H, s), 5.12 (2H, s), 6.83-6.89 (2H, m), 7.21-7.26 (1H, m), 7.30-7.40 (3H, m) mp: 192-194 140 2 ESI+: 299 NMR: 0.25-0.36 (2H, m), 0.66 (3H, t, J = 7.4 Hz), 0.95-1.04 (2H, m), 1.24-1.36 (2H, m), 1.81-1.99 (1H, m), 2.27-2.45 (8H, m), 2.60-2.74 (2H, m), 2.87-3.87 (8H, m), 6.94 (1H, s) mp: 170-171 141 2 ESI+: 305 NMR: 0.37-0.50 (2H, m), 0.95-1.04 (2H, m), 1.57-1.67 (1H, m), 1.95-2.11 (2H, m), 2.78-2.85 (2H, m), 2.86-3.03 (6H, m), 3.03-3.10 (2H, m), 3.11-3.21 (2H, m), 3.99 (2H, t, J = 4.3 Hz), 4.50 (2H, dt, J = 47.5, 5.8 Hz), 6.37 (1H, s), 6.49 (1H, s) mp: 144-147 142 2 ESI+: 245 NMR: 0.33-0.42 (2H, m), 0.81-0.95 (2H, m), 1.38-1.48 (1H, m), 2.70-2.79 (2H, m), 2.84-2.98 (4H, m), 3.05-3.15 (2H, m), 3.17-3.26 (2H, m), 4.03-4.11 (2H, m), 5.32-5.62 (1H, br), 6.24 (1H, s), 6.36 (1H, s) 143 2 ESI+: 286 NMR: 1.71-1.77 (2H, m), 2.29 (2H, s), 2.64 (2H, t, J = 6.4 Hz), 2.79-2.85 (4H, m), 2.90-2.92 (2H, m), 3.04-3.07 (2H, m), 3.14-3.17 (2H, m), 3.27 (3H, s), 3.38 (2H, t, J = 6.3 Hz), 3.69 (2H, t, J = 6.3 Hz), 7.02 (1H, s) 144 2 ESI+: 339 NMR: 2.30 (4H, s), 2.78-2.99 (8H, m), 3.71 (3H, s), 4.71 (2H, m), 5.04 (2H, s), 6.84 (1H, s), 6.85-6.91 (2H, m), 6.92 (1H, s), 7.19-7.24 (2H, m) mp: 173-176 145 2 ESI+: 343, 345 NMR: 2.81-3.03 (8H, m), 4.74 (2H, s), 5.11 (2H, s), 6.44 (2H, s), 6.86 (1H, s), 6.88 (1H, s), 7.27-7.34 (2H, m), 7.36-7.43 (2H, m) mp: 207 (decomp.) 146 2 ESI+: 343.2, 345.2 NMR: 2.28 (3H, s), 2.71-2.96 (8H, m), 4.77 (2H, s), 5.11 (2H, s), 6.86 (1H, s), 6.88 (1H, s), 7.04-7.09 (1H, m), 7.24-7.35 (2H, m), 7.50-7.54 (1H, m) mp: 119-127

TABLE 161 Ex Syn Dat 147 2 ESI+: 385, 387 NMR: 1.74-1.80 (2H, m), 2.30 (4H, s), 2.64 (2H, t, J = 6.5 Hz), 2.78-2.81 (2H, br), 2.85-2.87 (2H, br), 2.96-2.99 (4H, br), 3.09 (2H, t, J = 6.5 Hz), 3.57-3.60 (2H, m), 4.36 (2H, t, J = 6.5 Hz), 6.88 (1H, s), 7.26-7.33 (3H, m), 7.39-7.46 (2H, m) mp: 187-188 148 2 ESI+: 337 NMR: 1.78-1.94 (2H, m), 2.65 (2H, t, J = 7.6 Hz), 2.89-3.12 (8H, m), 3.87 (2H, t, J = 7.5 Hz), 4.58 (2H, s), 6.46 (2H, s), 6.85 (1H, s), 6.87 (1H, s), 7.15-7.35 (5H, m) mp: 218 (decomp.) 149 2 ESI+: 339 NMR: 2.97-3.20 (8H, m), 4.12-4.32 (4H, m), 4.62 (2H, s), 6.83-6.98 (4H, m), 7.18-7.34 (3H, m), 9.22-9.41 (2H, br) mp: 246 (decomp.) 150 2 ESI+: 291 NMR: 1.39 (3H, d, J = 6.7 Hz), 2.83-3.07 (8H, m), 3.24 (3H, s), 3.46-3.55 (2H, m), 3.97-4.10 (2H, m), 4.63 (1H, q, J = 6.7 Hz), 6.41 (1H, s), 6.82 (1H, s), 7.06 (1H, s) mp: 189 (decomp.) 151 2 ESI+: 273 NMR: 0.42-0.50 (2H, m), 0.96-1.05 (2H, m), 1.17 (3H, t, J = 7.0 Hz), 1.61-1.70 (1H, m), 2.85-2.99 (4H, m), 3.00-3.13 (6H, m), 3.19-3.28 (2H, m), 3.94-4.01 (2H, m), 6.45 (2H, s), 6.53 (1H, s) mp: 174-177 152 2 ESI+: 287 NMR: 0.41-0.48 (2H, m), 0.86 (3H, t, J = 7.4 Hz), 0.95-1.03 (2H, m), 1.57-1.72 (3H, m), 2.76-2.88 (4H, m), 2.88-2.98 (4H, m), 3.02-3.09 (2H, m), 3.11-3.20 (2H, m), 3.95-4.01 (2H, m), 6.37 (1H, s), 6.47 (1H, s) mp: 138-141 153 2 ESI+: 289 NMR: 0.39-0.47 (2H, m), 0.94-1.03 (2H, m), 1.55-1.65 (1H, m), 2.77-2.84 (2H, m), 2.87-2.99 (4H, m), 3.03 (2H, t, J = 6.5 Hz), 3.10-3.20 (4H, m), 3.69 (2H, t, J = 6.5 Hz), 3.97-4.05 (2H, m), 6.37 (1H, s), 6.47 (1H, s) mp: 146-150 154 2 ESI+: 277 NMR: 1.23 (3H, d, J = 6.3 Hz), 2.75-2.81 (2H, m), 2.81-2.87 (2H, m), 2.90-3.03 (5H, m), 3.25 (3H, s), 3.28-3.37 (2H, m), 3.38-3.55 (3H, m), 4.02-4.12 (1H, m), 6.39 (1H, s), 6.48 (1H, s), 6.51 (1H, s) mp: 170 (decomp.) 155 2 ESI+: 329, 331 NMR: 2.75-2.87 (4H, m), 2.91-3.06 (4H, m), 3.30-3.38 (2H, m), 4.16-4.24 (2H, m), 4.48 (2H, s), 6.36 (1H, s), 6.43 (2H, s), 6.57 (1H, s), 7.26-7.35 (3H, m), 7.45-7.52 (1H, m) mp: 184 (decomp.)

TABLE 162 Ex Syn Dat 156 2 ESI+: 317 NMR: 0.17-0.26 (1H, m), 0.59-0.69 (1H, m), 0.93-1.07 (2H, m), 1.23 (3H, d, J = 6.1 Hz), 1.58-1.69 (1H, m), 2.52-2.58 (1H, m), 2.75-2.87 (1H, m), 2.89-3.05 (3H, m), 3.05-3.21 (5H, m), 3.25 (3H, s), 3.29-3.43 (2H, m), 3.54-3.67 (2H, m), 3.96-4.07 (1H, m), 6.44 (2H, s), 6.51 (1H, s) mp: 102-103 157 2 ESI+: 259 NMR: 0.49-0.56 (2H, m), 0.96-1.05 (2H, m), 1.62-1.71 (1H, m), 2.77 (3H, s), 2.85-2.93 (2H, m), 2.99-3.12 (6H, m), 3.20-3.28 (2H, m), 3.97-4.03 (2H, m), 6.43 (2H, s), 6.53 (1H, s) mp: 211 (decomp.) 158 2 ESI+: 353, 355 NMR: 1.07-1.29 (3H, br), 1.62-1.77 (1H, br), 1.95-2.11 (1H, br), 2.63-2.77 (2H, br), 2.86-3.42 (9H, m), 3.94-4.27 (3H, m), 7.08 (1H, s) mp: 187-189 159 2 ESI+: 231 NMR: 1.27 (6H, s), 1.84-1.91 (2H, m), 3.05-3.20 (8H, m), 3.26-3.32 (2H, m), 6.99 (1H, s), 7.37 (1H, s), 9.36-9.59 (1.9H, br) mp: 288-290 160 2 ESI+: 429, 431 NMR: 1.60-2.08 (2H, m), 2.65-3.38 (12H, m), 3.93-4.41 (4H, m), 6.94-7.39 (6H, m) mp: 176-177 161 2 ESI+: 245 NMR: 1.19 (6H, s), 1.64-1.70 (2H, m), 2.81 (3H, s), 2.86-2.94 (4H, m), 2.99-3.15 (6H, m), 6.39 (1H, s), 6.44 (1.8H, s), 6.93 (1H, s) mp: 197-200 162 2 ESI+: 385, 387 NMR: 1.74-1.81 (2H, m), 2.64 (2H, t, J = 6.6 Hz), 2.81-2.83 (2H, br), 2.88-2.90 (2H, br), 2.95-3.01 (6H, m), 3.57-3.60 (2H, m), 4.34 (2H, t, J = 6.4 Hz), 6.45 (2H, s), 6.89 (1H, s), 7.23-7.36 (5H, m) mp: 201 (decomp.) 163 2 ESI+: 381 NMR: 1.74-1.81 (2H, m), 2.64 (2H, t, J = 6.6 Hz), 2.82-2.84 (2H, br), 2.89-2.94 (4H, m), 2.98-3.02 (4H, br), 3.57-3.60 (2H, m), 3.78 (3H, s), 4.28 (2H, t, J = 6.6 Hz), 6.45 (2H, s), 6.86-6.90 (2H, m), 6.98 (1H, d, J = 7.9 Hz), 7.16-7.19 (1H, m), 7.21-7.25 (1H, m), 7.30 (1H, br) mp: 190 (decomp.) 164 2 ESI+: 381 NMR: 1.75-1.81 (2H, m), 2.64 (2H, t, J = 6.6 Hz), 2.81-2.83 (2H, br), 2.89-2.93 (4H, m), 2.98-3.02 (4H, br), 3.58-3.61 (2H, m), 3.72 (3H, s), 4.33 (2H, t, J = 6.5 Hz), 6.45 (2H, s), 6.79-6.84 (3H, m), 6.89 (1H, s), 7.22 (1H, t, J = 8.1 Hz), 7.26 (1H, br) mp: 196 (decomp.)

TABLE 163 Ex Syn Dat 165 2 ESI+: 325 NMR: 2.81-2.94 (4H, m), 2.97-3.11 (4H, m), 3.28-3.37 (2H, m), 3.83 (3H, s), 4.09-4.20 (2H, m), 4.37 (2H, s), 6.45 (1H, s), 6.56 (1H, s), 6.85-6.93 (1H, m), 7.00-7.06 (1H, m), 7.11-7.16 (1H, m), 7.21-7.30 (1H, m), 9.12-9.41 (2H, br) 166 2 ESI+: 313 NMR: 2.81-2.94 (4H, m), 2.98-3.15 (4H, m), 3.22-3.38 (2H, m), 4.09-4.24 (2H, m), 4.46 (2H, s), 6.55 (1H, s), 6.57 (1H, s), 7.01-7.20 (3H, m), 7.32-7.45 (1H, m), 9.13-9.41 (2H, br) 167 2 ESI+: 309 NMR: 2.29 (3H, s), 2.84-2.95 (4H, m), 2.99-3.11 (4H, m), 3.23-3.31 (2H, m), 4.11-4.19 (2H, m), 4.39 (2H, s), 6.56 (1H, s), 6.60 (1H, s), 7.05-7.14 (3H, m), 7.22 (1H, t, J = 7.5 Hz), 9.28-9.54 (2H, br) 168 2 ESI+: 320 NMR: 2.83-2.95 (4H, m), 2.99-3.13 (4H, m), 3.28-3.37 (2H, m), 4.14-4.24 (2H, m), 4.49 (2H, s), 6.54 (1H, s), 6.58 (1H, s), 7.52-7.60 (1H, m), 7.63-7.69 (1H, m), 7.71-7.80 (2H, m), 9.17-9.53 (2H, br) 169 2 ESI+: 363 NMR: 2.76-2.88 (4H, m), 2.94-3.07 (4H, m), 3.2-3.34 (2H, m), 4.13-4.21 (2H, m), 4.53 (2H, s), 6.44 (2H, s), 6.56 (1H, s), 6.58 (1H, s), 7.54-7.70 (4H, m) mp: 141-146 170 2 ESI+: 289 NMR: 1.18 (6H, s), 1.58-1.64 (2H, m), 2.85-2.93 (4H, m), 3.00-3.10 (4H, m), 3.24-3.30 (5H, m), 3.37-3.45 (2H, m), 3.46-3.52 (2H, m), 6.40 (1H, s), 6.44 (2H, s), 6.92 (1H, s) mp: 172-175 171 2 ESI+: 385, 387 NMR: 1.74-1.81 (2H, m), 2.64 (2H, t, J = 6.5 Hz), 2.81-2.83 (2H, br), 2.89-2.92 (2H, br), 2.95 (2H, t, J = 6.4 Hz), 2.99-3.03 (4H, br), 3.57-3.60 (2H, m), 4.33 (2H, t, J = 6.4 Hz), 6.45 (2H, s), 6.89 (1H, s), 7.22 (1H, br), 7.30 (2H, d, J = 8.5 Hz), 7.37 (2H, d, J = 8.5 Hz) 172 2 ESI+: 353 NMR: 2.29 (4H, s), 2.73-2.75 (2H, br), 2.81-2.83 (2H, m), 2.93-2.98 (6H, m), 3.74 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.37 (2H, t, J = 6.5 Hz), 6.67 (1H, s), 7.21-7.34 (5H, m), 7.36-7.44 (1H, br) mp: 185-187 173 2 ESI+: 387, 389 NMR: 2.30 (4H, s), 2.73-2.75 (2H, br), 2.82-2.84 (2H, br), 2.94-2.98 (6H, m), 3.73 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.37 (2H, t, J = 6.4 Hz), 6.67 (1H, s), 7.30-7.38 (5H, m) mp: 186 (decomp.) 174 2 ESI+: 357 NMR: 2.52-3.04 (17H, m), 3.97-4.12 (2H, m), 6.36 (1H, s), 6.71 (1H, s), 7.16-7.24 (1H, m), 7.26-7.34 (2H, m), 7.41-7.50 (1H, m) mp: 179-182

TABLE 164 Ex Syn Dat 175 2 ESI+: 355, 357 NMR: 3.13-3.21 (6H, m), 3.23 (3H, s), 3.30-3.37 (2H, m), 3.52 (2H, t, J = 5.7 Hz), 4.09 (2H, t, J = 5.7 Hz), 4.73 (2H, s), 7.22 (1H, s), 9.19-9.38 (2H, br) mp: 244 (decomp.) 176 2 ESI+: 341, 343 NMR: 3.00-3.06 (2H, m), 3.07-3.15 (4H, m), 3.21-3.27 (5H, m), 3.35-3.40 (2H, m), 3.42-3.53 (4H, m), 4.10-4.24 (2H, m), 6.64 (1H, s), 9.20-9.42 (2H, br) mp: 107-110 177 2 ESI+: 387, 389 NMR: 2.30 (4H, s), 2.75-2.77 (2H, br), 2.81-2.83 (2H, br), 2.93-2.97 (4H, br), 3.11 (2H, t, J = 6.4 Hz), 3.74 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.40 (2H, t, J = 6.4 Hz), 6.67 (1H, s), 7.26-7.33 (2H, m), 7.41-7.46 (3H, m) mp: 169-170 178 2 ESI+: 387, 389 NMR: 2.30 (4H, s), 2.74-2.76 (2H, br), 2.81-2.84 (2H, br), 2.93-3.00 (6H, m), 3.74 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.39 (2H, t, J = 6.4 Hz), 6.67 (1H, s), 7.25-7.38 (5H, m) mp: 160-162 179 2 ESI+: 383 NMR: 2.30 (4H, s), 2.75-2.77 (2H, br), 2.81-2.84 (2H, br), 2.92-2.98 (6H, m), 3.73 (2H, t, J = 4.5 Hz), 3.78 (3H, s), 4.14 (2H, t, J = 4.5 Hz), 4.32 (2H, t, J = 6.6 Hz), 6.67 (1H, s), 6.87-6.90 (1H, m), 6.97-6.99 (1H, m), 7.18-7.25 (2H, m), 7.39-7.51 (1H, br) mp: 158-160 180 2 ESI+: 383 NMR: 2.30 (4H, s), 2.73-2.75 (2H, br), 2.81-2.84 (2H, br), 2.92-2.98 (6H, m), 3.72 (3H, s), 3.74 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.37 (2H, t, J = 6.5 Hz), 6.67 (1H, s), 6.79-6.82 (1H, m), 6.84-6.86 (2H, m), 7.22 (1H, t, J = 8.1 Hz), 7.35-7.44 (1H, br) mp: 134-136 181 2 ESI+: 317 NMR: 1.41 (3H, s), 1.88 (3H, s), 2.61-3.16 (12H, m), 3.25 (3H, s), 3.37-3.52 (2H, m), 3.92-4.09 (2H, m), 5.06 (1H, s), 6.38 (1H, s), 6.55 (1H, s) mp: 173-176 182 2 ESI+: 367 NMR: 2.57-2.68 (2H, m), 2.83-3.10 (14H, m), 3.26 (3H, s), 3.58 (2H, t, J = 5.8 Hz), 4.11-4.14 (2H, m), 6.44 (1H, s), 6.54 (1H, s), 7.15-7.34 (5H, m) 183 2 ESI+: 305 NMR: 0.96 (3H, t, J = 7.7 Hz), 1.28-1.45 (2H, m), 2.58-2.68 (2H, m), 2.78-3.09 (12H, m), 3.31 (3H, s), 3.61 (2H, t, J = 6.3 Hz), 4.03-4.21 (2H, m), 6.40 (1H, s), 6.48 (1H, s) 184 2 ESI+: 339 NMR: 2.52-2.60 (2H, m), 2.85-2.99 (4H, m), 3.03-3.10 (2H, m), 3.28 (3H, s), 3.29-3.35 (2H, m), 3.41-3.58 (4H, m), 3.92-4.01 (2H, m), 6.42 (2H, s), 6.62 (1H, s), 7.05-7.14 (2H, m), 7.27-7.33 (1H, m), 7.35-7.41 (2H, m) mp: 169 (decomp.)

TABLE 165 Ex Syn Dat 185 2 ESI+: 371 NMR: 2.30 (4H, s), 2.75-2.77 (2H, br), 2.81-2.84 (2H, br), 2.94-2.98 (4H, br), 3.01 (2H, t, J = 6.4 Hz), 3.73 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.37 (2H, t, J = 6.4 Hz), 6.67 (1H, s), 7.14-7.20 (2H, m), 7.27-7.33 (1H, m), 7.36-7.47 (2H, m) mp: 186-187 186 2 ESI+: 371 NMR: 2.30 (4H, s), 2.73-2.75 (2H, br), 2.81-2.83 (2H, br), 2.93-2.98 (4H, br), 3.00 (2H, t, J = 6.4 Hz), 3.73 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.39 (2H, t, J = 6.4 Hz), 6.67 (1H, s), 7.03-7.08 (1H, m), 7.12-7.17 (2H, m), 7.32-7.43 (2H, m) mp: 162-164 187 2 ESI+: 371 NMR: 2.30 (4H, s), 2.74-2.76 (2H, br), 2.82-2.84 (2H, br), 2.94-2.98 (6H, m), 3.74 (2H, t, J = 4.5 Hz), 4.14 (2H, t, J = 4.5 Hz), 4.36 (2H, t, J = 6.5 Hz), 6.67 (1H, s), 7.10-7.16 (2H, m), 7.29-7.35 (2H, m), 7.35-7.44 (1H, br)mp: 179-181 188 2 ESI+: 305 NMR: 1.36 (6H, s), 2.81-3.02 (8H, m), 3.24 (3H, s), 3.50 (2H, t, J = 6.0 Hz), 4.04 (2H, t, J = 5.9 Hz), 6.40 (1H, s), 6.78 (1H, s), 7.02 (1H, s) mp: 175-176 189 2 ESI+: 287 NMR: 2.85-3.00 (4H, m), 3.04-3.15 (4H, m), 3.37-3.48 (2H, m), 4.03-4.20 (4H, m), 6.59 (1H, s), 6.73 (1H, s), 9.09-9.33 (2H, br) mp: 221-222 190 2 ESI+: 365, 367 NMR: 3.04-3.19 (8H, m), 3.33-3.39 (2H, m), 3.72 (2H, q, J = 9.3 Hz), 4.20-4.27 (2H, m), 6.81 (1H, s), 9.17-9.38 (2H, br) mp: 214-215 191 2 ESI+: 365, 367 NMR: 2.99-3.17 (6H, m), 3.21-3.29 (2H, m), 3.46 (2H, t, J = 4.2 Hz), 4.13-4.26 (4H, m), 6.83 (1H, s), 9.10-9.33 (2H, br) mp: 216-221 192 2 ESI+: 345 NMR-A: 2.57-2.68 (6H, m), 2.95-3.22 (11H, m), 4.00-4.08 (2H, m), 6.63 (1H, s), 6.72 (1H, s), 6.98 (1H, dd, J = 4.9, 1.2 Hz), 7.33 (1H, dd, J = 2.8, 1.2 Hz), 7.66 (1H, dd, J = 4.9, 2.8 Hz) mp: 200 (decomp.) 193 2 ESI+: 345 NMR: 2.65-2.79 (6H, m), 2.94-3.22 (11H, m), 4.02-4.10 (2H, m), 6.64 (1H, s), 6.78 (1H, s), 6.97 (1H, dd, J = 3.5, 1.2 Hz), 7.18 (1H, dd, J = 5.3, 3.5 Hz), 7.69 (1H, dd, J = 5.3, 1.2 Hz) mp: 200 (decomp.)

TABLE 166 Ex Syn Dat 194 2 ESI+: 327 NMR: 0.35-0.43 (2H, m), 0.86-0.96 (2H, m), 1.40-1.52 (1H, m), 2.77-2.86 (2H, m), 2.86-2.98 (4H, m), 3.05-3.18 (2H, m), 3.36-3.42 (2H, m), 4.00-4.16 (4H, m), 6.37 (1H, s), 6.57 (1H, s) mp: 177 (decomp.) 195 2 ESI+: 289 NMR: 1.16 (6H, s), 1.66 (2H, t, J = 6.6 Hz), 2.61 (2H, t, J = 6.6 Hz), 2.81-2.95 (4H, m), 2.98-3.10 (4H, m), 3.30 (3H, s), 3.31-3.37 (2H, m), 3.38-3.44 (2H, m), 6.35 (1H, s), 6.44 (1.8H, s), 6.71 (1H, s) mp: 156-158 196 2 ESI+: 367 NMR: 1.26 (3H, d, J = 7.0 Hz), 2.30 (4H, s), 2.71-2.72 (2H, br), 2.81-2.83 (2H, m), 2.93-2.97 (4H, m), 3.10-3.19 (1H, m), 3.69-3.71 (2H, m), 4.09-4.12 (2H, m), 4.26 (2H, d, J = 7.1 Hz), 6.66 (1H, s), 7.21-7.35 (6H, m) mp: 177-179 197 2 ESI+: 367 NMR: 1.26 (3H, d, J = 6.3 Hz), 2.29 (4H, s), 2.80-2.85 (4H, m), 2.91 (2H, d, J = 6.4 Hz), 2.96-2.98 (4H, m), 3.64-3.69 (1H, m), 3.77-3.83 (1H, m), 3.99-4.04 (1H, m), 4.12-4.17 (1H, m), 5.00-5.08 (1H, m), 6.67 (1H, s), 7.19-7.23 (3H, m), 7.27-7.31 (2H, m), 7.48 (1H, brs) mp: 85-87 198 2 ESI+: 431, 433 NMR: 2.31 (4H, s), 2.79-2.82 (2H, m), 2.91-2.99 (6H, m), 3.15-3.18 (2H, m), 3.76 (2H, t, J = 4.4 Hz), 4.26 (2H, t, J = 4.4 Hz), 4.39 (2H, t, J = 6.5 Hz), 7.21-7.33 (5H, m), 7.39-7.45 (1H, br) mp: 142-143 199 2 ESI+: 297, 299 NMR: 2.29 (4H, s), 2.85-2.88 (2H, m), 2.95-2.99 (4H, m), 3.02-3.05 (2H, m), 3.25 (3H, s), 3.35-3.38 (2H, m), 3.41-3.44 (2H, m), 3.49-3.51 (2H, m), 4.16-4.18 (2H, m), 6.56 (1H, s) mp: 139-141 200 2 ESI+: 311, 313 NMR: 1.26 (3H, t, J = 7.1 Hz), 2.28 (2H, s), 2.86-2.91 (6H, m), 3.08-3.11 (2H, m), 3.82-3.84 (2H, m), 4.18 (2H, q, J = 7.1 Hz), 4.29-4.31 (2H, m), 7.61 (1H, brs); mp: 145-147 201 2 ESI+: 393 NMR: 0.38-0.43 (2H, m), 0.92-0.97 (2H, m), 1.46-1.53 (1H, m), 2.28 (4H, s), 2.74-2.77 (2H, m), 2.94-2.97 (4H, m), 3.01-3.03 (2H, m), 3.17-3.19 (2H, m), 3.70-3.72 (2H, m), 4.16-4.18 (2H, m), 4.36 (2H, t, J = 6.5 Hz), 7.21-7.34 (6H, m) mp: 142-144

TABLE 167 Ex Syn Dat 202 2 ESI+: 313 NMR: 2.84-2.99 (4H, m), 3.02-3.15 (4H, m), 3.34-3.40 (5H, m), 3.56-3.76 (4H, m), 4.03-4.14 (2H, m), 6.57 (1H, s), 6.63 (1H, s), 9.06-9.25 (2H, br) mp: 172-173 203 2 ESI+: 353 NMR: 0.35-0.46 (2H, m), 0.97-1.06 (2H, m), 1.59-1.70 (1H, m), 2.83-2.91 (2H, m), 2.96-3.10 (4H, m), 3.16-3.23 (5H, m), 3.24-3.31 (2H, m), 3.51 (2H, t, J = 13.3 Hz), 3.70 (2H, t, J = 16 Hz), 4.08-4.16 (2H, m), 6.43 (2H, s), 6.52 (1H, s) mp: 163-165 204 2 ESI+: 291 NMR: 1.20 (6H, s), 2.71-2.77 (2H, m), 2.78-2.84 (2H, m), 2.87-2.96 (4H, m), 3.05 (2H, s), 3.25 (3H, s), 3.39-3.45 (2H, m), 3.47-3.53 (2H, m), 6.37 (1H, s), 6.44 (1H, s), 6.50 (1H, s) mp: 194 (decomp.) 205 2 ESI+: 283 NMR-A: 1.81-2.00 (2H, m), 2.46-2.63 (3H, br), 2.75-2.90 (4H, m), 2.97-3.26 (8H, m), 6.48-6.59 (1H, br), 6.63 (1H, s), 6.98-7.13 (1H, br), 7.63-7.78 (1H, br), 7.82-7.94 (1H, br) mp: 203 (decomp.) 206 2 ESI+: 277 NMR: 1.07 (3H, d, J = 6.5 Hz), 2.79-2.91 (4H, m), 2.98-3.07 (4H, m), 3.25-3.34 (4H, m), 3.40-3.54 (4H, m), 3.86 (1H, dd, J = 10.4, 2.3 Hz), 3.93 (1H, dd, J = 10.4, 3.1 Hz), 6.43 (1.8H, s), 6.50 (1H, s), 6.53 (1H, s) mp: 133-136 207 2 ESI+: 277 NMR: 1.07 (3H, d, J = 6.5 Hz), 2.79-2.93 (4H, m), 2.98-3.07 (4H, m), 3.25-3.34 (4H, m), 3.39-3.54 (4H, m), 3.86 (1H, dd, J = 10.4, 2.3 Hz), 3.93 (1H, dd, J = 10.4, 3.0 Hz), 6.44 (1.8H, s), 6.50 (1H, s), 6.53 (1H, s) mp.131-134 208 2 ESI+: 429 NMR: 2.26 (2H, s), 2.49-2.53 (2H, m), 2.77-2.79 (4H, m), 2.89-2.91 (2H, m), 2.98 (2H, t, J = 6.5 Hz), 3.70-3.72 (2H, m), 4.01-4.03 (2H, m), 4.39 (2H, t, J = 6.5 Hz), 7.08-7.11 (2H, m), 7.22-7.35 (6H, m), 7.37-7.41 (3H, m) mp: 169-171 209 2 ESI+: 283 NMR: 1.68-1.83 (2H, m), 2.03 (3H, s), 2.33-2.42 (2H, m), 2.71 (2H, t, J = 6.4 Hz), 2.93-3.10 (6H, m), 3.11-3.24 (2H, m), 6.50 (1H, t, J = 2.1 Hz), 6.63 (1H, s), 7.00 (1H, s), 8.65-8.95 (2H, m) mp: 206 (decomp.)

TABLE 168 Ex Syn Dat 210 2 ESI+: 285 NMR: 2.33 (3H, s), 2.82-2.89 (2H, m), 2.95-3.12 (6H, m), 3.12-3.22 (2H, m), 4.07-4.13 (2H, m), 6.51-6.52 (1H, m), 6.64 (1H, s), 6.75 (1H, s), 7.63-7.65 (1H, m), 7.81 (1H, t, J = 1.7 Hz), 8.66-8.91 (2H, br) mp: 226 (decomp.) 211 2 ESI+: 327 NMR: 0.35-0.48 (2H, m), 0.97-1.08 (2H, m), 1.64-1.78 (1H, m), 2.84-2.94 (2H, m), 2.98-3.11 (4H, m), 3.17-3.30 (4H, m), 3.93 (2H, q, J = 10 Hz), 4.12 (2H, t, J = 4.5 Hz), 6.44 (2H, s), 6.55 (1H, s) mp: 174 (decomp.) 212 2 ESI+: 395 NMR: 0.90 (3H, t, J = 7.3 Hz), 1.30-1.39 (2H, m), 2.53-2.57 (2H, m), 2.80-2.82 (2H, m), 2.95-3.01 (8H, m), 3.71-3.73 (2H, m), 4.16-4.18 (2H, m), 4.37 (2H, t, J = 6.5 Hz), 6.45 (2H, s), 7.21-7.34 (6H, m) mp: 134-136 213 2 ESI+: 401 NMR: 0.87-0.97 (5H, m), 1.10-1.25 (3H, m), 1.31-1.41 (3H, m), 1.53 (2H, q, J = 6.6 Hz), 1.59-1.71 (5H, m), 2.55-2.59 (2H, m), 2.88-2.91 (2H, m), 2.95-3.02 (6H, m), 3.76-3.78 (2H, m), 4.16 (2H, t, J = 6.6 Hz), 4.20-4.22 (2H, m), 6.44 (2H, s), 7.46 (1H, brs) mp: 139-141 214 2 ESI+: 435 NMR: 2.63-2.66 (2H, m), 2.77-2.82 (4H, m), 2.88-2.91 (2H, m), 2.96-2.99 (2H, m), 3.71-3.73 (2H, m), 4.07-4.09 (2H, m), 4.39 (2H, t, J = 6.5 Hz), 6.40 (1H, s), 6.84 (1H, dd, J = 3.4, 1.1 Hz), 7.10 (1H, dd, J = 5.2, 3.4 Hz), 7.21-7.34 (5H, m), 7.40-7.47 (1H, br), 7.59 (1H, dd, J = 5.2, 1.1 Hz) mp: 215-216 215 2 ESI+: 329 NMR: 0.32-0.39 (1H, m), 0.54-0.62 (1H, m), 0.96-1.07 (2H, m), 1.33-1.44 (1H, m), 1.58-1.67 (1H, m), 1.69-1.85 (2H, m), 1.91-2.01 (1H, m), 2.86-3.38 (11H, m), 3.46-3.55 (1H, m), 3.60-3.69 (1H, m), 3.72-3.80 (1H, m), 3.94-4.18 (3H, m), 6.53 (1H, s), 9.18-9.44 (2H, br) mp: 154-156 216 2 ESI+: 317 NMR: 0.32-0.41 (1H, m), 0.48-0.57 (1H, m), 0.96-1.10 (5H, m), 1.55-1.65 (1H, m), 2.81-3.30 (14H, m), 3.34-3.42 (1H, m), 3.64-3.73 (1H, m), 3.96-4.08 (2H, m), 6.43 (2H, s), 6.50 (1H, s) mp: 135-138 217 2 ESI+: 305 NMR: 0.31-0.41 (1H, m), 0.46-0.57 (1H, m), 0.95-1.04 (2H, m), 1.27 (3H, dd, J = 23.9, 6.3 Hz), 1.55-1.65 (1H, m), 2.74-3.02 (6H, m), 3.04-3.31 (6H, m), 3.97-4.09 (2H, m), 4.96-5.22 (1H, m), 6.37 (1H, s), 6.49 (1H, s) mp: 171-173

TABLE 169 Ex Syn Dat 218 2 ESI+: 301 NMR-A: 2.24 (3H, s), 2.76-2.85 (2H, m), 2.93-3.11 (6H, m), 3.12-3.23 (2H, br), 4.03-4.11 (2H, m), 6.63 (1H, s), 6.79 (1H, s), 6.98 (1H, dd, J = 3.4, 1.1 Hz), 7.16 (1H, dd, J = 5.1, 3.5 Hz), 7.68 (1H, dd, J = 5.1, 1.1 Hz), 8.71-8.96 (2H, br) mp: 248-252 219 2 ESI+: 295 NMR-A: 2.09 (3H, s), 2.63-2.71 (2H, m), 2.95-3.09 (6H, m), 3.14-3.23 (2H, br), 4.04-4.11 (2H, m), 6.64 (1H, s), 6.76 (1H, s), 7.19-7.24 (2H, m), 7.34-7.40 (1H, m), 7.43-7.49 (2H, m), 6.80 (2H, s) mp: 250 (decomp.) 220 2 ESI+: 341, 343 NMR: 1.69-1.75 (2H, m), 2.04-2.17 (2H, m), 2.27 (2H, s), 2.70 (2H, t, J = 6.7 Hz), 2.85-2.91 (8H, m), 2.96-2.99 (2H, m), 3.20-3.22 (2H, m), 4.46 (1H, t, J = 5.9 Hz), 4.58 (1H, t, J = 5.9 Hz), 6.83 (1H, s) 221 2 ESI+: 317 NMR: 0.29-0.35 (2H, br), 0.98-1.05 (2H, br), 1.62-1.75 (2H, m), 1.86-1.93 (1H, m), 2.29 (4H, s), 2.36-2.39 (2H, m), 2.65-2.69 (2H, m), 2.90-2.94 (2H, br), 3.01-3.10 (4H, br), 3.21-3.28 (2H, br), 4.06-4.29 (2H, br), 4.23 (1H, t, J = 5.8 Hz), 4.34 (1H, t, J = 5.8 Hz), 6.94 (1H, s) mp: 182 (decomp.) 222 2 ESI+: 283 NMR-A: 1.76-1.88 (2H, m), 2.38 (3H, s), 2.61-2.68 (2H, m), 2.73 (2H, t, J = 6.4 Hz), 2.95-3.22 (8H, m), 6.44 (1H, d, J = 2.9 Hz), 6.60-6.65 (2H, m), 7.02 (1H, s), 7.78-7.84 (1H, m) mp: 180 (decomp.) 223 2 ESI+: 353, 355 NMR: 1.12 (3H, d, J = 6.3 Hz), 1.60-1.68 (1H, m), 1.76-1.86 (1H, m), 2.66-2.70 (2H, m), 2.81 (1H, dd, J = 14.1, 3.4 Hz), 2.86-2.96 (7H, m), 3.22-3.25 (2H, m), 3.27 (3H, s), 3.36-3.41 (2H, m), 3.81-3.89 (1H, m), 6.41 (2H, s), 6.82 (1H, s) mp: 161 (decomp.) 224 2 ESI+: 315 NMR: 0.28-0.35 (1H, m), 0.38-0.44 (1H, m), 0.95-1.00 (5H, m), 1.55-1.62 (1H, m), 1.65-1.76 (2H, m), 2.57-2.60 (2H, m), 2.83-2.85 (2H, m), 2.99-3.13 (8H, m), 3.17 (3H, s), 3.19-3.23 (2H, m), 3.52-3.59 (1H, m), 6.41 (2H, s), 6.63 (1H, s) 225 2 ESI+: 261 NMR: 1.00 (3H, t, J = 7.2 Hz), 1.33-1.47 (2H, m), 2.62-2.73 (2H, m), 2.81 (3H, s), 2.94-3.15 (8H, m), 3.16-3.31 (2H, br), 4.21-4.35 (2H, br), 6.64 (1H, s), 9.42 (2H, s) mp: 151-152 226 2 ESI+: 247 NMR: 1.09 (3H, t, J = 7.4 Hz), 2.70-2.95 (5H, m), 2.97-3.17 (8H, m), 3.18-3.39 (2H, br), 4.23-4.39 (2H, m), 6.67 (1H, s), 9.48 (2H, s) mp: 184-185

TABLE 170 Ex Syn Dat 227 2 ESI+: 329 NMR: 0.30-0.40 (1H, m), 0.54-0.64 (1H, m), 0.96-1.06 (2H, m), 1.33-1.45 (1H, m), 1.58-1.67 (1H, m), 1.70-1.85 (2H, m), 1.92-2.01 (1H, m), 2.85-3.37 (11H, m), 3.46-3.55 (1H, m), 3.61-3.69 (1H, m), 3.72-3.80 (1H, m), 3.95-4.03 (1H, m), 4.05-4.18 (2H, m), 6.53 (1H, s), 9.19-9.37 (2H, br) mp: 156-158 228 2 ESI+: 305 NMR: 0.32-0.41 (1H, m), 0.48-0.55 (1H, m), 0.95-1.04 (2H, m), 1.27 (3H, dd, J = 23.9, 6.3 Hz), 1.56-1.65 (1H, m), 2.72-3.01 (6H, m), 3.04-3.31 (6H, m), 3.97-4.09 (2H, m), 4.97-5.01 (1H, m), 6.38 (1H, s), 6.48 (1H, s) mp: 117 (decomp.) 229 2 ESI+: 331 NMR: 0.41-0.48 (2H, m), 0.97-1.04 (2H, m), 1.07 (6H, d, J = 6.1 Hz), 1.58-1.66 (1H, m), 2.85-2.92 (2H, m), 2.99-3.18 (8H, m), 3.18-3.27 (2H, m), 3.47-3.57 (1H, m), 3.63 (2H, t, J = 5.9 Hz), 3.99-4.05 (2H, m), 6.43 (2H, s), 6.51 (1H, s) mp: 117 (decomp.) 230 2 ESI+: 331 NMR: 0.37-0.44 (2H, m), 0.96-1.03 (2H, m), 1.11 (6H, s), 1.63-1.72 (1H, m), 2.87-2.94 (2H, m), 3.04-3.16 (9H, m), 3.21-3.33 (4H, m), 4.10-4.17 (2H, m), 6.51 (1H, s), 8.99-9.17 (2H, br) mp: 155-156 231 2 ESI+: 345 NMR: 0.33-0.41 (2H, m), 0.90 (6H, s), 0.96-1.03 (2H, m), 1.65-1.74 (1H, m), 2.88-2.95 (2H, m), 3.00 (2H, s), 3.03-3.17 (9H, m), 3.22-3.30 (4H, m), 4.09-4.16 (2H, m), 6.50 (1H, s), 9.22-9.35 (2H, br) mp: 141-145 232 2 ESI+: 371 NMR: 0.39-0.46 (2H, m), 0.97-1.04 (2H, m), 1.57-1.66 (1H, m), 2.76-2.82 (2H, m), 2.84-2.97 (4H, m), 3.07-3.19 (6H, m), 3.88 (2H, t, J = 6.0 Hz), 3.99-4.12 (4H, m), 6.37 (1H, s), 6.48 (1H, s) mp: 187 (decomp.) 233 2 ESI+: 345 NMR: 0.29-0.38 (1H, m), 0.51-0.60 (1H, m), 0.93-1.05 (2H, m), 1.57-1.66 (1H, m), 2.72-3.25 (12H, m), 3.32-3.47 (2H, m), 3.55-3.74 (4H, m), 3.85-3.93 (1H, m), 3.95-4.08 (2H, m), 6.38 (1H, s), 6.47 (1H, s) mp: 204 (decomp.) 234 2 ESI+: 233 NMR: 0.96 (3H, t, J = 7.6 Hz), 1.48-1.66 (2H, m), 2.76-2.86 (4H, m), 2.89 (1H, dd, J = 11.8, 7.7 Hz), 2.94-3.09 (4H, m), 3.27 (1H, dd, J = 11.8, 2.4 Hz), 3.77-3.86 (1H, m), 5.32-5.87 (1H, br), 6.37 (1H, s), 6.43 (2H, s), 6.48 (1H, s) mp: 193 (decomp.)

TABLE 171 Ex Syn Dat 235 2 ESI+: 249 NMR: 2.76-2.87 (4H, m), 2.94-3.07 (5H, m), 3.25 (1H, dd, J = 11.9, 2.6 Hz), 3.30 (3H, s), 3.41-3.52 (2H, m), 4.07-4.14 (1H, m), 5.40-5.83 (1H, br), 6.38 (1H, s), 6.43 (2H, s), 6.50 (1H, s) 236 2 ESI+: 247 NMR: 0.87-0.97 (3H, m), 1.32-1.63 (4H, m), 2.75-2.86 (4H, m), 2.90 (1H, dd, J = 11.8, 7.7 Hz), 2.94-3.09 (4H, m), 3.26 (1H, dd, J = 11.8, 2.4 Hz), 3.86-3.94 (1H, m), 5.31-5.86 (1H, br), 6.36 (1H, s), 6.43 (2H, s), 6.47 (1H, s) mp: 191 (decomp.) 237 2 ESI+: 347 NMR: 0.33-0.41 (1H, m), 0.46-0.54 (1H, m), 0.97-1.08 (2H, m), 1.54-1.62 (1H, m), 2.84-2.98 (3H, m), 2.98-3.12 (5H, m), 3.14-3.25 (6H, m), 3.27-3.41 (6H, m), 3.61-3.70 (1H, m), 3.96-4.08 (2H, m), 6.43 (2H, s), 6.51 (1H, s) mp: 150-154 238 2 ESI+: 291 NMR: 0.96 (3H, t, J = 7.5 Hz), 1.48-1.64 (2H, m), 2.79-2.93 (4H, m), 2.97-3.10 (5H, m), 3.25 (3H, s), 3.27-3.39 (2H, m), 3.40-3.55 (3H, m), 3.80-3.89 (1H, m), 6.44 (2H, s), 6.52 (1H, s), 6.53 (1H, s) mp: 147 (decomp.) 239 2 ESI+: 305 NMR: 0.88-0.96 (3H, m), 1.34-1.60 (4H, m), 2.79-2.93 (4H, m), 2.95-3.10 (5H, m), 3.25 (3H, s), 3.29-3.38 (2H, m), 3.39-3.55 (3H, m), 3.89-3.97 (1H, m), 6.44 (2H, s), 6.51 (1H, s), 6.53 (1H, s) mp: 151 (decomp.) 240 2 ESI+: 247 NMR: 0.97 (3H, t, J = 7.5 Hz), 1.50-1.67 (2H, m), 2.78 (3H, s), 2.80-2.92 (5H, m), 2.97-3.07 (4H, m), 3.22 (1H, dd, J = 11.6, 2.4 Hz), 3.97-4.05 (1H, m), 6.43 (2H, s), 6.51 (1H, s), 6.53 (1H, s) mp: 166 (decomp.) 241 2 ESI+: 261 NMR: 0.88-0.97 (3H, m), 1.33-1.63 (4H, m), 2.78 (3H, s), 2.80-2.93 (5H, m), 2.96-3.09 (4H, m), 3.21 (1H, dd, J = 11.6, 2.3 Hz), 4.04-4.14 (1H, m), 6.44 (2H, s), 6.50 (1H, s), 6.53 (1H, s) mp: 152-153 242 2 ESI+: 347 NMR: 0.31-0.42 (1H, m), 0.44-0.57 (1H, m), 0.95-1.11 (2H, m), 1.53-1.64 (1H, m), 2.80-2.97 (3H, m), 2.98-3.13 (5H, m), 3.13-3.26 (6H, m), 3.27-3.42 (6H, m), 3.62-3.70 (1H, m), 3.96-4.09 (2H, m), 6.43 (2H, s), 6.51 (1H, s) mp: 156-158

TABLE 172 Ex Syn Dat 243 2 ESI+: 317 NMR: 0.30-0.42 (1H, m), 0.46-0.59 (1H, m), 0.95-1.09 (5H, m), 1.55-1.67 (1H, m), 2.80-3.30 (14H, m), 3.33-3.43 (1H, m), 3.62-3.75 (1H, m), 3.95-4.09 (2H, m), 6.42 (2H, s), 6.50 (1H, s) mp: 133-136 244 2 ESI+: 247 NMR: 1.17 (3H, t, J = 7.3 Hz), 2.16 (3H, s), 2.66 (2H, q, J = 7.3 Hz), 2.87-3.09 (10H, m), 3.98-4.04 (2H, m), 6.44 (2H, s), 6.50 (1H, s) mp: 200 (decomp.) 245 2 ESI+: 291 NMR: 1.82-1.92 (2H, m), 2.15 (3H, s), 2.63-2.71 (2H, m), 2.79-3.03 (10H, m), 3.23 (3H, s), 3.40 (2H, t, J = 5.2 Hz), 3.99-4.06 (2H, m), 6.37 (1H, s), 6.46 (1H, s) mp: 160-163 246 2 ESI+: 291 NMR: 1.13 (3H, t, J = 6.9 Hz), 2.19 (3H, s), 2.83 (2H, t, J = 6.2 Hz), 2.87-3.12 (10H, m), 3.48 (2H, q, J = 6.9 Hz), 3.65 (2H, t, J = 6.2 Hz), 3.99-4.09 (2H, m), 6.44 (2H, s), 6.50 (1H, s) mp: 152-155 247 2 ESI+: 279 NMR: 1.94-2.11 (2H, m), 2.16 (3H, s), 2.69-2.79 (2H, m), 2.88-3.10 (10H, m), 4.01-4.08 (2H, m), 4.55 (2H, dt, J = 48.1, 6.9 Hz), 6.44 (2H, s), 6.51 (1H, s) mp: 187-190 248 2 ESI+: 327 NMR: 0.28-0.32 (1H, m), 0.44-0.48 (1H, m), 0.97-0.99 (2H, m), 1.30-1.39 (1H, m), 1.56-1.79 (5H, m), 1.87-1.94 (1H, m), 2.58-2.61 (2H, m), 2.85-2.86 (2H, m), 2.99-3.08 (6H, m), 3.17-3.47 (4H, m), 3.58-3.64 (1H, m), 3.70-3.76 (1H, m), 4.02-4.09 (1H, m), 6.42 (2H, s), 6.64 (1H, s) 249 2 ESI+: 327 NMR: 0.28-0.32 (1H, m), 0.44-0.48 (1H, m), 0.97-0.99 (2H, m), 1.30-1.39 (1H, m), 1.56-1.79 (5H, m), 1.87-1.94 (1H, m), 2.58-2.61 (2H, m), 2.85-2.86 (2H, m), 2.99-3.08 (6H, m), 3.17-3.47 (4H, m), 3.58-3.64 (1H, m), 3.70-3.76 (1H, m), 4.02-4.09 (1H, m), 6.42 (2H, s), 6.64 (1H, s) 250 2 ESI+: 343 NMR: 0.36-0.50 (2H, m), 0.97-1.06 (2H, m), 1.13-1.29 (2H, m), 1.56-1.74 (3H, m), 1.90-2.06 (1H, m), 2.84 (2H, d, J = 7.3 Hz), 2.89-2.98 (2H, m), 3.03-3.18 (6H, m), 3.23-3.35 (4H, m), 3.79-3.87 (2H, m), 4.00-4.08 (2H, m), 6.53 (1H, s), 9.13-9.41 (2H, br) mp: 153-155

TABLE 173 Ex Syn Dat 251 2 ESI+: 343 NMR: 0.28-0.40 (1H, m), 0.50-0.62 (1H, m), 0.94-1.03 (2H, m), 1.10-1.25 (1H, m), 1.33-1.62 (5H, m), 1.71-1.80 (1H, m), 2.24 (2H, s), 2.70-3.10 (10H, m), 3.10-3.21 (1H, m), 3.30-3.48 (2H, m), 3.63-3.70 (1H, m), 3.82-3.89 (1H, m), 3.93-4.07 (2H, m), 6.46 (1H, s) mp: 171 (decomp.) 252 2 ESI+: 303 NMR: 1.43-1.54 (1H, m), 1.73-1.90 (2H, m), 2.00-2.06 (1H, m), 2.25 (3H, s), 2.83-3.23 (11H, m), 3.35-3.45 (1H, m), 3.66-3.84 (2H, m), 4.10-4.30 (3H, m), 6.57 (1H, s), 9.57 (2H, br) 253 2 ESI+: 303 NMR: 1.41-1.53 (1H, m), 1.70-1.88 (2H, m), 1.94-2.05 (1H, m), 2.23 (3H, s), 1.77-2.85 (2H, m), 2.93-3.16 (9H, m), 3.31-3.42 (1H, m), 3.65-3.89 (2H, m), 4.06-4.25 (3H, m), 6.54 (1H, s), 9.40 (2H, s) 254 2 ESI+: 331 NMR: 0.34-0.49 (2H, m), 0.92 (3H, d, J = 6.7 Hz), 0.96-1.03 (2H, m), 1.57-1.69 (1H, m), 2.08-2.23 (1H, m), 2.80 (1H, dd, J = 13.4, 7.8 Hz), 2.86-2.99 (3H, m), 3.02-3.14 (6H, m), 3.14-3.21 (4H, m), 3.21-3.26 (2H, m), 3.30 (1H, dd, J = 9.2, 5.0 Hz), 3.95-4.08 (2H, m), 6.48 (3H, s), 6.52 (1H, s) 255 2 ESI+: 329 NMR: 0.37-0.50 (2H, m), 0.93-1.05 (2H, m), 1.50-1.68 (2H, m), 1.92-2.04 (1H, m), 2.53-2.65 (1H, m), 2.76-2.85 (2H, m), 2.86-3.22 (10H, m), 3.37-3.47 (1H, m), 3.57-3.79 (3H, m), 3.97-4.09 (2H, m), 6.37 (1H, s), 6.48 (1H, s) mp: 117-118 256 2 ESI+: 279 NMR: 1.31 (3H, dd, J = 5.87, 24.2 Hz), 2.19 (3H, s), 2.70-3.17 (12H, m), 4.03-4.12 (2H, m), 4.96-5.19 (1H, m), 6.44 (2H, s), 6.51 (1H, s) mp: 165-168 257 2 ESI+: 335 NMR: 0.46-0.62 (2H, m), 0.89-1.01 (2H, m), 1.64-1.76 (1H, m), 2.25 (2H, s), 2.75-2.85 (2H, m), 2.88-3.02 (6H, m), 3.11-3.22 (2H, m), 3.86-3.98 (2H, m), 4.19 (2H, s), 6.54 (1H, s), 7.24-7.31 (1H, m), 7.33-7.40 (2H, m), 7.42-7.49 (2H, m) mp: 107-110 258 2 ESI+: 369, 371 NMR: 0.47-0.62 (2H, m), 0.87-1.00 (2H, m), 1.65-1.78 (1H, m), 2.28 (4H, s), 2.82-2.92 (2H, m), 2.94-3.13 (6H, m), 3.17-3.29 (2H, m), 3.90-4.01 (2H, m), 4.20 (2H, s), 6.58 (1H, s), 7.32-7.45 (3H, m), 7.50-7.54 (1H, m) mp: 139-141

TABLE 174 Ex Syn Dat 259 2 ESI+: 369, 371 0.41-0.56 (2H, m), 0.72-0.85 (2H, m), 1.52-1.63 (1H, m), 2.28 (4H, s), 2.81-2.93 (2H, m), 2.98-3.12 (6H, m), 3.16-3.27 (2H, m), 3.94-4.04 (2H, m), 4.23 (2H, s), 6.60 (1H, s), 7.33 (1H, dt, J = 1.61, 7.48 Hz), 7.40-7.49 (2H, m), 7.80-7.88 (1H, m) mp: 106-109 260 2 ESI+: 353 0.47-0.63 (2H, m), 0.83-1.00 (2H, m), 1.60-1.74 (1H, m), 2.25 (4H, s), 2.76-2.85 (2H, m), 2.88-3.05 (6H, m), 3.11-3.26 (2H, m), 3.87-3.99 (2H, m), 4.21 (2H, s), 6.55 (1H, s), 7.07-7.14 (1H, m), 7.24-7.32 (2H, m), 7.38-7.45 (1H, m) mp: 102-105 261 2 ESI+: 301 NMR: 1.85-2.01 (1H, m), 2.80 (3H, s), 2.94-3.26 (11H, m), 3.74-3.92 (2H, m), 4.10-4.31 (4H, m), 5.66 (1H, s), 6.69 (1H, s), 9.38-9.62 (2H, br) 262 2 ESI+: 301 NMR: 0.37-0.51 (2H, m), 0.91 (6H, d, J = 6.6 Hz), 0.96-1.04 (2H, m), 1.58-1.71 (1H, m), 1.92-2.08 (1H, m), 2.72-2.83 (2H, m), 2.89-2.99 (2H, m), 3.03-3.19 (6H, m), 3.23-3.34 (2H, m), 3.99-4.07 (2H, m), 6.53 (1H, s), 9.24-9.42 (2H, br) mp: 160-162 263 2 ESI+: 343 NMR: 0.30-0.49 (2H, m), 0.90-1.05 (2H, m), 1.12-1.27 (1H, m), 1.41-1.67 (3H, m), 1.73-1.85 (1H, m), 1.91-2.05 (1H, m), 2.66-2.99 (8H, m), 3.00-3.21 (5H, m), 3.22-3.32 (1H, m), 3.71-3.78 (1H, m), 3.82-3.90 (1H, m), 3.96-4.08 (2H, m), 6.37 (1H, s), 6.47 (1H, s) mp: 186-189 264 2 ESI+: 293 NMR: 1.07 (3H, t, J = 7.3 Hz), 1.95-2.15 (2H, m), 2.68 (2H, q, J = 7.3 Hz), 2.80-2.92 (2H, m), 2.93-3.18 (10H, m), 4.07-4.19 (2H, m), 4.56 (2H, dt, J = 47.4, 5.7 Hz), 6.55 (1H, s), 9.24-9.52 (2H, br) mp: 153-154 265 2 ESI+: 353 NMR: 0.46-0.57 (2H, m), 0.84-0.96 (2H, m), 1.64-1.74 (1H, m), 2.80-3.07 (8H, m), 3.14-3.25 (2H, m), 3.88-3.97 (2H, m), 4.24 (2H, s), 6.38 (1H, s), 6.54 (1H, s), 7.13-7.28 (2H, m), 7.30-7.39 (1H, m), 7.66 (1H, dt, J = 1.66, 7.68 Hz) mp: 133-136 266 2 ESI+: 331 NMR: 0.37-0.52 (2H, m), 0.95-1.06 (2H, m), 1.43-1.55 (2H, m), 1.58-1.74 (3H, m), 2.82-2.95 (4H, m), 2.98-3.12 (6H, m), 3.16-3.27 (5H, m), 3.33 (2H, t, J = 6.4 Hz), 3.94-4.02 (2H, m), 6.43 (2H, s), 6.51 (1H, s)

TABLE 175 Ex Syn Dat 267 2 ESI+: 393 NMR: 0.28-0.43 (1H, m), 0.44-0.58 (1H, m), 0.94-1.10 (2H, m), 1.52-1.64 (1H, m), 2.81-3.09 (6H, m), 3.09-3.25 (3H, m), 3.25-3.34 (2H, m), 3.34-3.46 (1H, m), 3.94-4.17 (3H, m), 4.29 (1H, dd, J = 11.5, 2.4 Hz), 4.53-4.63 (1H, m), 6.42 (1.5H, s), 6.52 (1H, s), 6.69-6.76 (1H, m), 6.77-6.87 (3H, m) mp: 179-182 268 2 ESI+: 365 NMR: 0.40-0.52 (2H, m), 0.98-1.10 (2H, m), 1.61-1.71 (1H, m), 2.85-2.93 (2H, m), 2.98-3.12 (4H, m), 3.17-3.29 (4H, m), 3.33-3.41 (2H, m), 4.02-4.10 (2H, m), 4.25 (2H, t, J = 5.9 Hz), 6.44 (2H, s), 6.53 (1H, s), 6.90-6.97 (3H, m), 7.24-7.32 (2H, m) 269 2 ESI+: 305 NMR: 1.04 (3H, t, J = 7.4 Hz), 1.14 (3H, t, J = 7.0 Hz), 2.71 (2H, q, J = 7.4 Hz), 2.76-2.95 (10H, m), 2.98-3.07 (2H, m), 3.49 (2H, q, J = 7.0 Hz), 3.64 (2H, t, J = 5.9 Hz), 4.04-4.11 (2H, m), 6.38 (1H, s), 6.45 (1H, s) mp: 179-181 270 2 ESI+: 379 NMR: 0.46-0.57 (2H, m), 0.84-0.97 (2H, m), 1.25 (3H, t, J = 7.09 Hz), 1.60-1.72 (1H, m), 2.87-2.95 (2H, m), 2.97-3.15 (6H, m), 3.20-3.33 (2H, m), 3.85-3.93 (2H, m), 3.97 (2H, q, J = 7.09 Hz), 4.16 (2H, s), 6.45 (2H, s), 6.56 (1H, s), 6.93-6.00 (2H, m), 7.24 (1H, dt, J = 1.42, 7.34 Hz), 7.55 (1H, dd, J = 1.42.8.22 Hz) mp: 215 (decomp.) 271 2 ESI+: 309 NMR: 0.38-0.49 (2H, m), 1.01-1.15 (2H, m), 1.62-1.75 (1H, m), 2.87-2.94 (2H, m), 2.99-3.10 (4H, m), 3.11-3.17 (2H, m), 3.20-3.27 (2H, m), 3.35 (2H, dt, J = 4.3, 15.2 Hz), 4.04-4.12 (2H, m), 6.22-6.40 (1H, m), 6.44 (2H, s), 6.55 (1H, s) mp: 198-201 272 2 ESI+: 415 NMR: 0.48-0.59 (2H, m), 0.88-0.98 (2H, m), 1.69-1.80 (1H, m), 2.89-2.97 (2H, m), 3.01-3.17 (6H, m), 3.23-3.32 (2H, m), 3.91-4.00 (2H, m), 4.30 (2H, s), 6.48 (2H, s), 6.58 (1H, s), 7.22-7.27 (1H, m), 7.30-7.35 (1H, m), 7.38-7.42 (1H, m) mp: 200 (decomp.) 273 2 ESI+: 415 NMR: 0.48-0.64 (2H, m), 0.91-1.01 (2H, m), 1.64-1.80 (1H, m), 2.86-3.17 (8H, m), 3.21-3.33 (2H, m), 3.88-3.99 (2H, m), 4.21 (2H, s), 6.45 (2H, s), 6.59 (1H, s), 7.28 (1H, dd, J = 1.22, 8.36 Hz), 7.41 (1H, d, J = 8.36 Hz), 7.46 (1H, d, J = 1.22 Hz) mp: 161-164 274 2 ESI+: 377 NMR: 0.46-0.64 (2H, m), 0.93-1.10 (2H, m), 1.67-1.81 (1H, m), 2.87-3.00 (4H, m), 3.01-3.35 (8H, m), 3.88-3.99 (2H, m), 4.09 (2H, s), 4.46-4.59 (2H, m), 6.45 (2H, s), 6.57 (1H, s), 6.73 (1H, d, J = 8.17 Hz), 7.11-7.16 (1H, m), 7.29 (1H, s) mp: 215 (decomp.)

TABLE 176 Ex Syn Dat 275 2 ESI+: 393 NMR: 0.40-0.63 (2H, m), 0.78-1.00 (2H, m), 1.56-1.77 (1H, m), 2.83-2.96 (2H, m), 2.99-3.17 (6H, m), 3.20-3.34 (2H, m), 3.84-3.93 (2H, m), 4.14 (2H, s), 4.17-4.25 (4H, m), 6.44 (2H, s), 6.56 (1H, s), 6.76 (1H, dd, J = 1.37, 8.27 Hz), 6.84 (1H, t, J = 8.27 Hz), 7.10 (1H, dd, J = 1.37, 8.27 Hz) mp: 184-187 276 2 ESI+: 349 NMR: 0.45-0.58 (2H, m), 0.75-0.88 (2H, m), 1.55-1.66 (1H, m), 2.17 (3H, s), 2.84-2.96 (2H, m), 2.99-3.14 (6H, m), 3.19-3.29 (2H, m), 3.93-4.01 (2H, m), 4.14 (2H, s), 6.42 (2H, s), 6.59 (1H, s), 7.14-7.17 (2H, m), 7.21-7.28 (1H, m), 7.68-7.75 (1H, m) mp: 163-166 277 2 ESI+: 349 NMR: 0.50-0.63 (2H, m), 0.92-1.03 (2H, m), 1.67-1.78 (1H, m), 2.31 (3H, s), 2.88-2.99 (4H, m), 3.03-3.15 (4H, m), 3.24-3.33 (2H, m), 3.91-3.99 (2H, m), 4.16 (2H, s), 6.45 (2H, s), 6.58 (1H, s), 7.05-7.11 (1H, m), 7.22-7.29 (3H, m) mp: 192-195 278 4 ESI+: 245 NMR: 1.20 (6H, s), 2.31 (2H, s), 2.95-3.18 (8H, m), 6.69 (1H, s), 7.12 (1H, s), 9.24-9.38 (1.8H, br), 10.12 (1H, s) mp: 270-272 279 4 ESI+: 231 NMR: 1.32 (6H, s), 1.78-1.89 (2H, m), 2.72-2.81 (2H, m), 3.00-3.21 (8H, m), 6.90-7.16 (2H, m), 9.29-9.48 (2H, br) mp: 270-273 280 282 ESI+: 353, 355 NMR: 1.27 (3H, d, J = 7.2 Hz), 1.69-1.79 (2H, m), 2.61-2.77 (4H, m), 2.93-3.46 (9H, m), 3.28 (3H, s), 3.72 (2H, t, J = 6.5 Hz), 6.47 (2H, s), 6.85 (1H, s) mp: 188 (decomp.) 281 282 ESI+: 315 NMR: 0.32-0.43 (2H, m), 0.97-1.01 (2H, m), 1.27 (3H, d, J = 7.2 Hz), 1.59-1.77 (3H, m), 2.62-2.70 (2H, m), 2.77-2.84 (1H, br), 3.03-3.28 (8H, m), 3.23 (3H, s), 3.43-3.58 (2H, m), 3.56 (2H, t, J = 6.3 Hz), 6.43 (2H, s), 6.67 (1H, s) mp: 195 (decomp.) 282 282 ESI+: 353, 355 NMR: 1.24 (3H, d, J = 7.4 Hz), 1.69-1.76 (2H, m), 2.62-2.75 (4H, m), 2.90-3.31 (8H, m), 3.28 (3H, s), 3.72 (2H, t, J = 6.5 Hz), 3.84-3.89 (1H, m), 6.49 (2H, s), 6.79 (1H, s) mp: 184 (decomp.) 283 2 ESI+: 371 NMR: 0.46-0.60 (2H, m), 0.81-0.95 (2H, m), 1.61-1.75 (1H, m), 2.78-2.89 (2H, m), 2.91-3.01 (4H, m), 3.01-3.08 (2H, m), 3.14-3.25 (2H, m), 3.91-3.99 (2H, m), 4.22 (2H, s), 6.40 (1H, s), 6.55 (1H, s), 7.12-7.30 (2H, m), 7.41-7.52 (1H, m) mp: 195 (decomp.)

TABLE 177 Ex Syn Dat 284 2 ESI+: 371 NMR: 0.46-0.55 (2H, m), 0.84-0.94 (2H, m), 1.64-1.75 (1H, m), 2.81-3.09 (8H, m), 3.14-3.25 (2H, m), 3.88-3.99 (2H, m), 4.28 (2H, s), 6.38 (1H, s), 6.55 (1H, s), 7.20-7.29 (1H, m), 7.30-7.40 (1H, m), 7.44-7.52 (1H, m) mp: 157-159 285 2 ESI+: 387, 389 NMR: 0.41-0.56 (2H, m), 0.79-0.93 (2H, m), 1.61-1.75 (1H, m), 2.78-3.09 (8H, m), 3.15-3.24 (2H, m), 3.92-3.98 (2H, m), 4.27 (2H, s), 6.39 (1H, s), 6.55 (1H, s), 7.25-7.32 (1H, m), 7.47-7.55 (1H, m), 7.62-7.70 (1H, m) mp: 181-184 286 2 ESI+: 377 NMR: 0.44-0.62 (2H, m), 0.85-1.02 (2H, m), 1.62-1.79 (1H, m), 2.83-3.38 (12H, m), 3.83-3.99 (2H, m), 4.10 (2H, s), 4.49 (2H, t, J = 8.51 Hz), 6.47 (2H, s), 6.57 (1H, s), 6.81-6.90 (1H, m), 7.14 (1H, d, J = 6.8 Hz), 7.30 (1H, d, J = 8.1 Hz) mp: 190 (decomp.) 287 2 ESI+: 335 NMR: 0.29-0.43 (1H, m), 0.43-0.57 (1H, m), 0.92-1.10 (2H, m), 1.56-1.68 (1H, m), 2.82-2.92 (2H, m), 2.95-3.39 (13H, m), 3.69-3.86 (1H, m), 3.96-4.11 (2H, m), 4.32-4.65 (2H, m), 6.43 (2H, s), 6.52 (1H, s) 288 2 ESI+: 379 NMR: 0.54-0.62 (2H, m), 0.94-1.04 (2H, m), 1.68-1.79 (1H, m), 2.90-3.17 (8H, m), 3.24-3.34 (5H, m), 3.90-3.98 (2H, m), 4.20 (2H, s), 4.41 (2H, s), 6.44 (2H, s), 6.58 (1H, s), 7.15-7.24 (1H, m), 7.29-7.42 (3H, m) mp: 190-193 289 2 ESI+: 371 NMR: 0.44-0.56 (2H, m), 0.85-0.96 (2H, m), 1.65-1.75 (1H, m), 2.80-3.08 (8H, m), 3.14-3.26 (2H, m), 3.88-3.98 (2H, m), 4.20 (2H, s), 6.38 (1H, s), 6.54 (1H, s), 7.13 (1H, dt, J = 2.5, 8.5 Hz), 7.18-7.26 (1H, m), 7.64-7.72 (1H, m) mp: 220 (decomp.) 290 2 ESI+: 387, 389 NMR: 0.44-0.58 (2H, m), 0.82-0.96 (2H, m), 1.64-1.75 (1H, m), 2.89-2.97 (2H, m), 3.00-3.16 (6H, m), 3.21-3.32 (2H, m), 3.90-4.01 (2H, m), 4.22 (2H, s), 6.45 (2H, s), 6.58 (1H, s), 7.22-7.29 (1H, m), 7.38-7.44 (1H, m), 7.69 (1H, dd, J = 6.7, 3.0 Hz) mp: 165-168 291 2 ESI+: 393 NMR: 0.47-0.60 (2H, m), 0.92-1.02 (2H, m), 1.65-1.76 (1H, m), 2.81-3.04 (8H, m), 3.17-3.27 (2H, m), 3.86-3.95 (2H, m), 4.06 (2H, s), 4.22 (4H, s), 6.38 (1H, s), 6.54 (1H, s), 6.79-6.89 (2H, m), 6.91-6.95 (1H, m) mp: 165-168

TABLE 178 Ex Syn Dat 292 2 ESI+: 317 NMR: 0.14-0.25 (1H, m), 0.58-0.68 (1H, m), 0.91 (3H, d, J = 6.9 Hz), 0.97-1.09 (2H, m), 1.55-1.68 (1H, m), 2.75-3.19 (8H, m), 3.25 (3H, s), 3.28-3.48 (3H, m), 3.61 (2H, t, J = 6.1 Hz), 3.86 (1H, dd, J = 10.5, 1.6 Hz), 3.92 (1H, dd, J = 10.6, 2.3 Hz), 6.43 (2H, s), 6.52 (1H, s) mp: 183 (decomp.) 293 2 ESI+: 379 NMR: 0.43-0.55 (2H, m), 0.76-0.87 (2H, m), 1.53-1.65 (1H, m), 2.86-3.12 (8H, m), 3.18-3.29 (5H, m), 3.88-3.97 (2H, m), 4.23 (2H, s), 4.36 (2H, s), 6.44 (2H, s), 6.60 (1H, s), 7.20-7.29 (1H, m), 7.31-7.43 (2H, m), 7.82 (1H, d, J = 7.8 Hz) mp: 180 (decomp.) 294 2 ESI+: 335 NMR: 0.31-0.43 (1H, m), 0.44-0.54 (1H, m), 0.94-1.10 (2H, m), 1.55-1.67 (1H, m), 2.82-2.93 (2H, m), 2.95-3.40 (13H, m), 3.68-3.86 (1H, m), 3.97-4.12 (2H, m), 4.33-4.65 (2H, m), 6.43 (2H, s), 6.52 (1H, s) 295 2 ESI+: 367 NMR: 0.43-0.46 (2H, m), 1.00-1.06 (2H, m), 1.60-1.67 (1H, m), 2.82-2.85 (2H, m), 2.98-3.03 (4H, m), 3.15-3.17 (2H, m), 3.20-3.23 (2H, m), 3.38-3.41 (2H, m), 4.05-4.07 (2H, m), 4.60 (2H, t, J = 6.1 Hz), 6.42 (2H, s), 6.51 (1H, s), 8.20 (2H, s), 8.22 (1H, s) mp: 170 (decomp.) 296 2 ESI+: 438 NMR: 0.44-0.48 (2H, m), 1.05-1.10 (2H, m), 1.63-1.70 (1H, m), 2.84-2.86 (2H, m), 2.98-3.04 (4H, m), 3.18-3.23 (4H, m), 3.41-3.44 (2H, m), 3.94 (3H, s), 4.06-4.09 (2H, m), 4.46-4.49 (2H, m), 6.42 (2H, s), 6.52 (1H, s), 6.99 (1H, d, J = 7.1 Hz), 7.71 (1H, d, J = 10.9 Hz) mp: 125-128 297 2 ESI+: 426 NMR: 0.42-0.46 (2H, m), 0.97-1.02 (2H, m), 1.57-1.64 (1H, m), 2.83-2.85 (2H, m), 2.98-3.03 (4H, m), 3.16-3.21 (4H, m), 3.34-3.37 (2H, m), 4.05-4.07 (2H, m), 4.56-4.59 (2H, m), 6.41 (2H, s), 6.52 (1H, s), 7.82-7.90 (2H, m) mp: 178 (decomp.) 298 2 ESI+: 365 NMR: 0.42-0.56 (2H, m), 0.78-0.91 (2H, m), 1.57-1.68 (1H, m), 2.83-3.14 (8H, m), 3.21-3.33 (2H, m), 3.72 (3H, s), 3.85-3.96 (2H, m), 4.15 (2H, s), 6.45 (2H, s), 6.57 (1H, s), 6.93-7.04 (2H, m), 7.22-7.30 (1H, m), 7.53-7.61 (1H, m) mp: 195 (decomp.) 299 2 ESI+: 365 NMR: 0.51-0.64 (2H, m), 0.93-1.03 (2H, m), 1.68-1.78 (1H, m), 2.84-3.15 (8H, m), 3.22-3.33 (2H, m), 3.74 (3H, s), 3.86-3.97 (2H, m), 4.18 (2H, s), 6.44 (2H, s), 6.57 (1H, s), 6.81-6.88 (1H, m), 6.96-7.04 (2H, m), 7.24-7.31 (1H, m) mp: 220 (decomp.)

TABLE 179 Ex Syn Dat 300 2 ESI+: 419 NMR: 0.44-0.58 (2H, m), 0.78-0.91 (2H, m), 1.55-1.67 (1H, m), 2.87-3.15 (8H, m), 3.21-3.33 (2H, m), 3.87-3.98 (2H, m), 4.27 (2H, s), 6.45 (2H, s), 6.66 (1H, s), 7.33-7.39 (1H, m), 7.41-7.52 (2H, m), 7.84-7.91 (1H, m) mp: 210 (decomp.) 301 2 ESI+: 379 NMR: 0.45-0.56 (2H, m), 0.82-0.95 (2H, m), 1.58-1.69 (1H, m), 2.27 (3H, s), 2.86-3.15 (8H, m), 3.22-3.32 (2H, m), 3.68 (3H, s), 3.78-3.96 (2H, m), 4.10 (2H, s), 6.45 (2H, s), 6.56 (1H, s), 6.86 (1H, d, J = 8.3 Hz), 7.05 (1H, dd, J = 1.8, 8.3 Hz), 7.38 (1H, d, J = 1.8 Hz) mp: 205 (decomp.) 302 2 ESI+: 383 NMR: 0.44-0.60 (2H, m), 0.76-0.89 (2H, m), 1.55-1.66 (1H, m), 2.89-2.96 (2H, m), 3.00-3.12 (6H, m), 3.21-3.30 (2H, m), 3.72 (3H, s), 3.91-3.97 (2H, m), 4.11 (2H, s), 6.45 (2H, s), 6.58 (1H, s), 6.95-7.01 (1H, m), 7.04-7.11 (1H, m), 7.35-7.42 (1H, m) mp: 189-192 303 2 ESI+: 399, 401 NMR: 0.39-0.57 (2H, m), 0.74-0.89 (2H, m), 1.53-1.68 (1H, m), 2.81-3.15 (8H, m), 3.20-3.32 (2H, m), 3.73 (3H, s), 3.88-3.99 (2H, m), 4.10 (2H, s), 6.45 (2H, s), 6.58 (1H, s), 7.01 (1H, d, J = 8.7 Hz), 7.31 (1H, dd, J = 2.6, 8.7 Hz), 7.59 (1H, d, J = 2.59 Hz) mp: 193-196 304 2 ESI+: 427 NMR: 0.34-0.50 (2H, m), 0.97-1.07 (2H, m), 1.60-1.67 (1H, m), 2.82-2.85 (2H, m), 2.96-3.05 (4H, m), 3.09-3.46 (6H, m), 3.22 (3H, s), 3.46-3.53 (2H, m), 4.03-4.05 (2H, m), 4.83-4.86 (1H, m), 6.42 (2H, s), 6.47 (1H, s), 6.92-6.97 (1H, m), 7.08-7.22 (3H, m) mp: 132-133 305 2 ESI+: 427 NMR: 0.34-0.49 (2H, m), 0.99-1.11 (2H, m), 1.61-1.68 (1H, m), 2.82-2.86 (2H, m), 2.89-3.43 (10H, m), 3.22 (3H, s), 3.44-3.52 (2H, m), 3.97-4.06 (2H, m), 4.81-4.87 (1H, m), 6.42 (2H, s), 6.45 (1H, s), 6.73-6.78 (3H, m), 7.25-7.31 (1H, m) mp: 174 (decomp.) 306 2 ESI+: 427 NMR: 0.35-0.51 (2H, m), 0.97-1.09 (2H, m), 1.60-1.67 (1H, m), 2.80-3.51 (14H, m), 3.21 (3H, s), 3.97-4.06 (2H, m), 4.71-4.76 (1H, m), 6.43 (2H, s), 6.47 (1H, s), 6.91-6.95 (2H, m), 7.07-7.11 (2H, m) mp: 138-140 307 2 ESI+: 445 NMR: 0.35-0.50 (2H, m), 0.97-1.08 (2H, m), 1.59-1.66 (1H, m), 2.79-2.86 (2H, m), 2.89-3.43 (10H, m), 3.21 (3H, s), 3.44-3.52 (2H, m), 4.03-4.05 (2H, m), 4.75-4.80 (1H, m), 6.43 (2H, s), 6.47 (1H, s), 6.95-7.00 (1H, m), 7.17 (1H, td, J = 9.3, 5.6 Hz), 7.26 (1H, ddd, J = 11.5, 8.7, 2.9 Hz) mp: 150-151

TABLE 180 Ex Syn Dat 308 2 ESI+: 463 NMR: 0.35-0.46 (2H, m), 0.97-1.12 (2H, m), 1.61-1.68 (1H, m), 2.78-3.58 (14H, m), 3.21 (3H, s), 3.96-4.05 (2H, m), 4.77-4.82 (1H, m), 6.43 (3H, s), 6.84-6.88 (2H, m) mp: 155 (decomp.) 309 2 ESI+: 461, 463 NMR: 0.34-0.39 (1H, m), 0.46-0.51 (1H, m), 0.98-1.10 (2H, m), 1.61-1.68 (1H, m), 2.80-3.42 (12H, m), 3.21 (3H, s), 3.45-3.53 (2H, m), 4.02-4.07 (2H, m), 4.83-4.88 (1H, m), 6.43 (2H, s), 6.48 (1H, s), 7.12-7.21 (2H, m), 7.41 (1H, dd, J = 8.3, 3.0 Hz) mp: 149 (decomp.) 310 2 ESI+: 367 NMR: 0.43-0.47 (2H, m), 1.03-1.07 (2H, m), 1.63-1.70 (1H, m), 2.83-2.86 (2H, m), 2.99-3.05 (4H, m), 3.18-3.22 (4H, m), 3.35-3.38 (2H, m), 4.05-4.07 (2H, m), 4.58 (2H, t, J = 6.1 Hz), 6.42 (2H, s), 6.52 (1H, s), 7.14 (1H, t, J = 4.8 Hz), 8.60 (2H, d, J = 4.8 Hz) mp: 188 (decomp.) 311 2 ESI+: 386 NMR: 0.42-0.46 (2H, m), 1.01 (6H, d, J = 6.3 Hz), 1.60-1.69 (3H, m), 2.57-2.61 (2H, m), 2.71-2.74 (2H, m), 2.88-2.90 (2H, m), 3.03-3.11 (8H, m), 3.23-3.24 (2H, m), 3.41-3.50 (4H, m), 4.01-4.03 (2H, m), 6.48 (3H, s), 6.52 (1H, s) mp: 129 (decomp.) 312 2 ESI+: 371 NMR: 0.49-0.60 (2H, m), 0.85-1.00 (2H, m), 1.61-1.74 (1H, m), 2.78-3.07 (8H, m), 3.13-3.27 (2H, m), 3.87-4.00 (2H, m), 4.17 (2H, s), 6.38 (1H, s), 6.55 (1H, s), 7.25-7.51 (3H, m) mp: 230 (decomp.) 313 2 ESI+: 371 NMR: 0.49-0.60 (2H, m), 0.85-0.95 (2H, m), 1.62-1.72 (1H, m), 2.81-3.06 (8H, m), 3.17-3.25 (2H, m), 3.92-4.01 (2H, m), 4.21 (2H, s), 6.38 (1H, s), 6.56 (1H, s), 7.09-7.22 (3H, m) mp: 191-194 314 2 ESI+: 459 NMR: 0.43-0.47 (2H, m), 0.95-1.00 (2H, m), 1.15 (3H, t, J = 7.0 Hz), 1.53-1.60 (1H, m), 2.85-2.87 (2H, m), 3.00-3.05 (4H, m), 3.17-3.22 (4H, m), 3.31-3.34 (2H, m), 3.47 (2H, q, J = 7.0 Hz), 4.05-4.07 (2H, m), 4.38-4.40 (4H, m), 6.42 (2H, s), 6.53 (1H, s), 7.06-7.12 (2H, m) mp: 138-139 315 2 ESI+: 331 NMR: 0.30-0.42 (1H, m), 0.46-0.59 (1H, m), 0.93-1.12 (8H, m), 1.53-1.65 (1H, m), 2.79-3.58 (14H, m), 3.71-3.83 (1H, m), 3.94-4.12 (2H, m), 6.42 (2H, s), 6.50 (1H, s) mp: 157-160 316 2 ESI+: 317 NMR: 0.14-0.27 (1H, m), 0.57-0.68 (1H, m), 0.91 (3H, d, J = 6.9 Hz), 0.96-1.09 (2H, m), 1.55-1.68 (1H, m), 2.76-3.19 (9H, m), 3.25 (3H, s), 3.28-3.48 (2H, m), 3.61 (2H, t, J = 6.1 Hz), 3.80-3.97 (2H, m), 6.43 (2H, s), 6.52 (1H, s) mp: 186 (decomp)

TABLE 181 Ex Syn Dat 317 2 ESI+: 349 NMR: 0.32-0.43 (1H, m), 0.44-0.55 (1H, m), 0.93-1.15 (5H, m), 1.55-1.67 (1H, m), 2.82-2.92 (2H, m), 2.94-3.30 (9H, m), 3.33-3.48 (2H, m), 3.57-3.67 (1H, m), 3.79-3.94 (1H, m), 3.98-4.13 (2H, m), 4.31-4.60 (2H, m), 6.43 (2H, s), 6.52 (1H, s) 318 2 ESI+: 291 NMR: 0.91 (3H, d, J = 6.8 Hz), 2.01-2.15 (1H, m), 2.83-3.31 (17H, m), 4.05-4.14 (2H, m), 6.51 (1H, s), 6.52 (1H, s), 9.24-9.50 (2H, br) mp: 129-132 319 2 ESI+: 277 NMR: 1.1 (3H, t, J = 6.2 Hz), 2.85-2.93 (2H, m), 2.93-3.00 (2H, m), 3.01-3.12 (4H, m), 3.12-3.46 (7H, m), 3.53-3.64 (1H, m), 4.02-4.13 (2H, m), 6.52 (1H, s), 6.54 (1H, s), 9.32-9.48 (2H, br)

TABLE 182

TABLE 183

TABLE 184

TABLE 185

TABLE 186

TABLE 187

TABLE 188

TABLE 189

TABLE 190

INDUSTRIAL APPLICABILITY

The compound of the formula (I) or a salt thereof, or the compound of the formula (II) or a salt thereof has a 5-HT_(2C) receptor agonist activity and can be used as an agent for preventing or treating 5-HT_(2C) receptor-related diseases.

Here, examples of the 5-HT_(2C) receptor-related diseases include incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile dysfunction syndrome and the like, obesity, and the like. 

1. A pharmaceutical composition comprising a compound of the formula (I) or a salt thereof and a pharmaceutically acceptable excipient:

(wherein R^(1a) and R^(1b) are the same or different and each represents —H or C₁₋₆ alkyl, or are combined to form oxo, R^(2a) and, R^(2b) are the same or different and each represents —H or C₁₋₆ alkyl which may be substituted with —O—C₁₋₆ alkyl, R³ represents —H, C₁₋₆ alkyl which may be substituted, C₃₋₈ cycloalkyl, aryl which may be substituted, —SO₂—C₁₋₆ alkyl, or a hetero ring which may be substituted, R⁴ represents —H, halogen, cyano, C₁₋₆ alkyl which may be substituted, C₂₋₆ alkenyl, aryl which may be substituted, C₃₋₈ cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring, R⁵ represents —H, halogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or an aromatic hetero ring, R⁶ and R⁷ are the same or different and each represents —H or C₁₋₆ alkyl, X represents —C(R^(A))(R^(B))— or —O—, and R^(A) and R^(B) are the same or different and each represents —H or C₁₋₆ alkyl).
 2. A pharmaceutical composition as described in claim 1, wherein R^(1a) and R^(1b) are respectively —H or are combined to form oxo, R^(2a) is —H or C₁₋₆ alkyl, R^(2b) is —H R³ is —H, C₁₋₆ alkyl, halogeno-C₁₋₆ alkyl, C₁₋₆ alkylene-OH, (C₁₋₆ alkylene which may be substituted)-O—C₁₋₆ alkyl, C₁₋₆ alkylene-cycloalkyl which may be substituted, C₁₋₆ alkylene-aryl which may be substituted, C₁₋₆ alkylene-hetero ring group which may be substituted, —CO—C₁₋₆ alkyl, —CO—C₁₋₆ alkylene-O—C₁₋₆ alkyl, —CO-cycloalkyl which may be substituted, —CO-aryl which may be substituted, —CO—NR⁸R⁹, —CO—O—C₁₋₆ alkyl, —CO—O—C₁₋₆ alkylene-aryl which may be substituted, —SO₂—C₁₋₆ alkyl, aryl which may be substituted, or a hetero ring which may be substituted, R⁸ and R⁹ are the same or different and each is —H or C₁₋₆ alkyl, R⁴ is —H, C₁₋₆ alkyl, halogen, halogeno-C₁₋₆ alkyl, cycloalkyl which may be substituted, or aryl which may be substituted, and R⁵ are the same as or different from each other and are —H or C₁₋₆ alkyl.
 3. A pharmaceutical composition as described in claim 1, wherein R³ is —H, C₁₋₆ alkyl which may be substituted, C₃₋₈ cycloalkyl, aryl which may be substituted, —SO₂—C₁₋₆ alkyl, or an oxygen-containing hetero ring, and R⁴ is —H, halogen, cyano, C₁₋₆ alkyl which may be substituted, C₂₋₆ alkenyl, aryl which may be substituted, C₃₋₈ cycloalkyl, an aromatic hetero ring, or an oxygen-containing hetero ring.
 4. A compound of the formula (II) or a salt thereof:

(wherein R^(11a) and R^(11b) are respectively the same or different and each represents —H or C₁₋₆ alkyl, or are combined to form oxo, R^(21a) and R^(21b) are respectively the same or different and each represents —H or C₁₋₆ alkyl which may be substituted with —O—C₁₋₆ alkyl, R³¹ represents —H, C₁₋₆ alkyl which may be substituted, C₃₋₈ cycloalkyl, aryl which may be substituted, —SO₂—C₁₋₆ alkyl, or a hetero ring which may be substituted, R⁴¹ represents —H, halogen, cyano, C₁₋₆ alkyl which may be substituted, C₂₋₆ alkenyl, aryl which may be substituted, C₃₋₈ cycloalkyl which may be substituted, an aromatic hetero ring, or an oxygen-containing hetero ring, R⁵¹ represents —H, halogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, aryl, or an aromatic hetero ring, R⁶¹ and R⁷¹ are the same or different and each represents —H or C₁₋₆ alkyl, X¹ represents —C(R^(A1))(R^(B1))— or —O—, and R^(A1) and R^(B1) are the same or different and each represents —H or C₁₋₆ alkyl, provided that (i) in the case where R^(11a), R^(11b), R^(21a), R^(21b), R⁴¹, R⁵¹, R⁶¹, and R⁷¹ are respectively —H and X¹ is —O—, R³¹ is a group other than —H, —CO-methyl, or —SO₂-methyl, and (ii) in the case where R^(11a) and R^(11b) are combined to form oxo, R^(21a), R^(21b), R⁴¹, R⁵¹, R⁶¹, and R⁷¹ are respectively —H, and X¹ is —O—, R³¹ is a group other than —H or methyl).
 5. A compound or a salt thereof as described in claim 4, wherein R^(11a) and R^(11b) are respectively —H or are combined to form oxo, R^(21a) is —H or C₁₋₆ alkyl, R^(21b) is —H, R³¹ is —H, C₁₋₆ alkyl, halogeno-C₁₋₆ alkyl, C₁₋₆ alkylene-OH, (C₁₋₆ alkylene which may be substituted)-O—C₁₋₆ alkyl, C₁₋₆ alkylene-cycloalkyl which may be substituted, C₁₋₆ alkylene-aryl which may be substituted, C₁₋₆ alkylene-hetero ring group which may be substituted, —CO—C₁₋₆ alkyl, —CO—C₁₋₆ alkylene-O—C₁₋₆ alkyl, —CO-cycloalkyl which may be substituted, —CO-aryl which may be substituted, —CO—NR⁸¹R⁹¹, —CO—O—C₁₋₆ alkyl, —CO—O—C₁₋₆ alkylene-aryl which may be substituted, —SO₂—C₁₋₆ alkyl, aryl which may be substituted, or a hetero ring which may be substituted, R⁸¹ and R⁹¹ are the same or different and each is —H or C₁₋₆ alkyl, R⁴¹ is —H, C₁₋₆ alkyl, halogen, halogeno-C₁₋₆ alkyl, cycloalkyl which may be substituted, or aryl which may be substituted, and R⁵¹ are the same as or different from each other and are —H or C₁₋₆ alkyl.
 6. A compound or a salt thereof as described in claim 4, wherein R³¹ is —H, C₁₋₆ alkyl which may be substituted, C₃₋₈ cycloalkyl, aryl which may be substituted, —SO₂—C₁₋₆ alkyl, or an oxygen-containing hetero ring, and R⁴¹ is —H, halogen, cyano, C₁₋₆ alkyl which may be substituted, C₂₋₆ alkenyl, aryl which may be substituted, C₃₋₈ cycloalkyl, an aromatic hetero ring, or an oxygen-containing hetero ring.
 7. A compound or a salt thereof as described in claim 6, wherein R³¹ is a group other than —H, methyl, —CO-methyl, or —SO₂-methyl.
 8. A compound or a salt thereof as described in claim 7, wherein R^(11a) is —H or methyl, and R^(11b), R^(21a), R^(21b), R⁵¹, R⁶¹, and R⁷¹ are respectively —H.
 9. A compound or a salt thereof as described in claim 8, wherein R⁴¹ is —H, halogen, or C₃₋₈ cycloalkyl.
 10. A compound or a salt thereof as described in claim 9, wherein R⁴¹ is cyclopropyl.
 11. A compound or a salt thereof as described in claim 10, wherein R³¹ is C₁₋₆ alkyl which may be substituted with one or more groups selected from the group consisting of (a) halogen, (b) —O—C₁₋₆ alkyl, (c) phenoxy which may be substituted with one or more groups selected from the group consisting of halogen and cyano, (d) an oxygen-containing hetero ring, and (e) phenyl which may be substituted with one or more groups selected from the group consisting of C₁₋₆ alkyl which may be substituted with —O—C₁₋₆ alkyl, halogen, and —O—C₁₋₆ alkyl.
 12. A compound or a salt thereof as described in claim 4, which is 11-cyclopropyl-1-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline, 4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(2-ethoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(3-methoxypropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(3-fluoropropyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 1-isobutyl-2,3,4,6,7,8,9,10-octahydro-1H-azepino[4,5-g]quinoline, 5-bromo-4-(2-methoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-[(2S)-tetrahydrofuran-2-ylmethyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-[(2R)-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(2-fluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-[(2S)-3-fluoro-2-methoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 4-(3-chlorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(tetrahydro-2H-pyran-3-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(2-phenoxyethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(2-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(3-methylbenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(2,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-[3-(methoxymethyl)benzyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 4-(5-chloro-2-fluorobenzyl)-5-cyclopropyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, (3S)-5-cyclopropyl-4-(2-methoxyethyl)-3-methyl-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 4-[2-(5-cyclopropyl-2,3,7,8,9,10-hexahydro[1,4]oxazino[2,3-h][3]benzazepin-4(6H)-yl)ethoxy]-3,5-difluorobenzonitrile, 5-cyclopropyl-4-(3-methoxybenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, 5-cyclopropyl-4-(3,5-difluorobenzyl)-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine, or 5-cyclopropyl-4-[(2R)-2-ethoxypropyl]-2,3,4,6,7,8,9,10-octahydro[1,4]oxazino[2,3-h][3]benzazepine or a salt thereof.
 13. A pharmaceutical composition comprising a compound or a salt thereof as described in claim 4 and a pharmaceutically acceptable excipient.
 14. A pharmaceutical composition for preventing or treating 5-HT_(2C) receptor-related diseases, comprising a compound or a salt thereof as described in claim
 4. 15. A pharmaceutical composition as described in claim 14, which is a pharmaceutical composition for preventing or treating incontinence.
 16. Use of a compound or a salt thereof as described in claim 4 for preparation of a pharmaceutical composition for preventing or treating incontinence.
 17. A compound or a salt thereof as described in claim 4 for use in the prevention or treatment of incontinence.
 18. A method for preventing or treating incontinence, comprising administering to a subject an effective amount of a compound or a salt thereof as described in claim
 4. 